,Covidence #,Study ID,Title,Short Title,Year,Organization(s)/Association(s),Country,Topic/Category,Grading Method,Overall guideline assessment: Rate the overall quality of this guideline.,Number of LoE levels,Number of SoR levels,Recommendation,LoE (Text),LoE (Number),SoR (Text),SoR (Number),Specific target group?,LoE (scaled),Source,AI Clustering
0,16,McDonagh 2021,2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.,Diagnosis and treatment of acute and chronic heart failure,2021,European Society of Cardiology,Other: Europe,Heart Failure,Other: custom,5,3,3,Long-term treatment with an oral anticoagulant should be considered for stroke prevention in artrial fibrillation patients with a CHA2DS2-VASc score of 1 in men or 2 in women.,B,2,IIa,2,,0.666666666666667,"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021 Sep 21;42(36):3599–726.",15
1,16,McDonagh 2021,2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.,Diagnosis and treatment of acute and chronic heart failure,2021,European Society of Cardiology,Other: Europe,Heart Failure,Other: custom,5,3,3,"Long-term treatment with an oral anticoagulant is recommended in all patients with atrial fibrillation, heart failure, and CHA2DS2-VASc score ≥ 2 in men or ≥ 3 in women.",A,3,I,3,,1,"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021 Sep 21;42(36):3599–726.",15
2,81,Ewig 2021,"[Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Me",Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie,2021,"Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin, Paul-Ehrlich-Gesellschaft für Chemotherapie, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin, Gesellschaft für Virologie, Kompetenznetzwerk CAPNETZ, Deutsche Gesellschaft für Allgemeinmedizin, Deutsche Gesellschaft für Geriatrie, Deutsche Gesellschaft für Palliativmedizin, Österreichische Gesellschaft für Pneumologie, Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin, Schweizerische Gesellschaft für Pneumologie, Schweizerische Gesellschaft für Infektiologie",Germany,Pneumonia & COPD,Other: modified Grade,5,3,3,"Im Zentrum der initialen Risikostratifizierung (ambulant und in der Notaufnahme) zur Entscheidung über das Behandlungssetting steht die ärztliche Einschätzung des Patienten. Zur Identifikation von Patienten mit einem minimalen Letalitätsrisiko soll zur Ergänzung der klinischen Einschätzung die Verwendung des CRB-65 Scores erfolgen. Dieser Score soll ergänzt werden durch:
- die Evaluation des funktionellen Status
- die klinische Evaluation potenziell instabiler Komorbiditäten
- die Messung der Oxygenierung",B,2,Stark,3,,0.666666666666667,Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. (DGP). S3-Leitlinie Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie. 2021 Apr 24 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/020-020,5
3,81,Ewig 2021,"[Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Me",Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie,2021,"Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin, Paul-Ehrlich-Gesellschaft für Chemotherapie, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin, Gesellschaft für Virologie, Kompetenznetzwerk CAPNETZ, Deutsche Gesellschaft für Allgemeinmedizin, Deutsche Gesellschaft für Geriatrie, Deutsche Gesellschaft für Palliativmedizin, Österreichische Gesellschaft für Pneumologie, Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin, Schweizerische Gesellschaft für Pneumologie, Schweizerische Gesellschaft für Infektiologie",Germany,Pneumonia & COPD,Other: modified Grade,5,3,3,Bei Verordnung einer antimikrobiellen Substanz sollten relevante Interaktionen mit der Ko-Medikation berücksichtigt werden. Dies gilt insbesondere für die Interaktion zwischen Clarithromycin und Statinen bzw. Antikoagulatien sowie für die Interaktion von Makroliden bzw. Fluorochinolonen mit anderen QT-Zeit verlängernden Substanzen. Unter den Makroliden weist Azithromycin deutliche Vorteile gegenüber Clarithromycin hinsichtlich des Interaktionspotentials auf. Es sollte daher insbesondere bei älteren Patienten bzw. interaktions-relevanter Ko-Medikation bevorzugt eingesetzt werden.,B,2,Stark,3,,0.666666666666667,Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. (DGP). S3-Leitlinie Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie. 2021 Apr 24 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/020-020,5
4,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Discuss with the person the purpose of the approach to care, that is, to improve quality of life. This might include reducing treatment burden and optimising care and support by identifying:
- ways of maximising benefit from existing treatments
- treatments that could be stopped because of limited benefit
- treatments and follow-up arrangements with a high burden
- medicines with a higher risk of adverse events (for example, falls, gastrointestinal bleeding, acute kidney injury)
- non-pharmacological treatments as possible alternatives to some medicines
- alternative arrangements for follow-up to coordinate or optimise the number of appointments",Low,2,Strong,2,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
5,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Tell a person who has been taking bisphosphonate for osteoporosis for at least 3 years that there is no consistent evidence of:
- further benefit from continuing bisphosphonate for another 3 years
- harms from stopping bisphosphonate after 3 years of treatment. Discuss stopping bisphosphonate after 3 years and include patient choice, fracture risk and life expectancy in the discussion",Very Low,1,Strong,2,,0.25,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,7
6,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Establish disease burden by talking to people about how their health problems affect their day-to-day life. Include a discussion of:
- mental health
- how disease burden affects their wellbeing
- how their health problems interact and how this affects quality of life",Low,2,Strong,2,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
7,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Consider using a validated tool such as eFI, PEONY or QAdmissions, if available in primary care electronic health records, to identify adults with multimorbidity who are at risk of adverse events such as unplanned hospital admission or admission to care homes.",Low,2,Weak,1,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
8,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Follow these steps when delivering an approach to care that takes account of multimorbidity:
- Discuss the purpose of an approach to care that takes account of multimorbidity
- Establish disease and treatment burden
- Establish patient goals, values and priorities
- Review medicines and other treatments taking into account evidence of likely benefits and harms for the individual patient and outcomes important to the person
- Agree an individualised management plan with the person, including:
   - goals and plans for future care (including advance care planning)
   - who is responsible for coordination of care
   - how the individualised management plan and the responsibility for coordination of care is communicated to all professionals and services involved
   - timing of follow-up and how to access urgent care",Low,2,Strong,2,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
9,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Use an approach to care that takes account of multimorbidity for adults of any age who are prescribed 15 or more regular medicines, because they are likely to be at higher risk of adverse events and drug interactions.",Very Low,1,Strong,2,,0.25,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
10,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,Consider using primary care electronic health records to identify markers of increased treatment burden such as number of regular medicines a person is prescribed.,Low,2,Weak,1,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
11,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Encourage people with multimorbidity to clarify what is important to them, including their personal goals, values and priorities. These may include:
- maintaining their independence
- undertaking paid or voluntary work, taking part in social activities and playing an active part in family life
- preventing specific adverse outcomes (for example, stroke)
- reducing harms from medicines
- reducing treatment burden
- lengthening life",Low,2,Strong,2,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
12,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Identify adults with multimorbidity who may benefit from an approach to care that takes account of multimorbidity (as outlined in Chapter 6):
- opportunistically during routine care
- proactively using electronic health records. Use the criteria in recommendation 5 to guide this",Low,2,Strong,2,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
13,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Consider an approach to care that takes account of multimorbidity for adults of any age who:
- are prescribed 10 to 14 regular medicines
- are prescribed fewer than 10 regular medicines but are at particular risk of adverse events",Very Low,1,Weak,1,,0.25,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
14,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Be alert to the possibility of:
- depression and anxiety
- chronic pain and the need to assess this and the adequacy of pain management",Low,2,Strong,2,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,2
15,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"After a discussion of disease and treatment burden and the person’s personal goals, values and priorities, develop and agree an individualised management plan with the person. Agree what will be recorded and what actions will be taken. These could include:
- starting, stopping or changing medicines and nonpharmacological treatments
- prioritising healthcare appointments
- anticipating possible changes to health and wellbeing
- assigning responsibility for coordination of care and ensuring this is communicated to other healthcare professionals and services
- other areas the person considers important to them arranging a follow-up and review of decisions made. Share copies of the management plan in an accessible format with the person and (with the person's permission) other people involved in care (including healthcare professionals, a partner, family members and/or carers)",Low,2,Strong,2,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
16,1429,NationalGuidelineCentre(UK) 2016,,Multimorbidity: clinical assessment and management,2016,National Institute for Health and Care Excellence,UK,Multimorbidity,GRADE,6,4,3,"Establish treatment burden by talking to people about how treatments for their health problems affect their day-to-day life. Include in the discussion:
- the number and type of healthcare appointments a person has and where these take place
- the number and type of medicines a person is taking and how often
- any harms from medicines
- non-pharmacological treatments such as diets, exercise programmes and psychological treatments
- any effects of treatment on their mental health or wellbeing",Low,2,Strong,2,,0.5,National Institute for Health and Care Excellence. Multimorbidity: Clinical Assessment and Management [Internet]. London: National Institutefor Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng56,20
17,1432,NationalClinicalGuidelineCentre(UK) 2016,,Fractures (non-complex): assessment and management,2018,National Institute for Health and Care Excellence,UK,Fractures & Osteoporosis,GRADE,6,4,3,Use intravenous opioids with caution in frail or older adults.,Very low,1,Should,2,,0.25,National Institute for Health and Care Excellence. Fractures (non-complex): assessment and management [Internet]. London: National Institute for Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng38,20
18,1432,NationalClinicalGuidelineCentre(UK) 2016,,Fractures (non-complex): assessment and management,2018,National Institute for Health and Care Excellence,UK,Fractures & Osteoporosis,GRADE,6,4,3,Do not offer non-steroidal anti-inflammatory drugs (NSAIDs) to frail or older adults with fractures.,Very low,1,Should,2,,0.25,National Institute for Health and Care Excellence. Fractures (non-complex): assessment and management [Internet]. London: National Institute for Health and Care Excellence; 2016 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng38,9
19,1504,Anonymous 2021,"Osteoporosis Prevention, Screening, and Diagnosis: ACOG Clinical Practice Guideline No. 1.","Osteoporosis Prevention, Screening, and Diagnosis",2021,American College of Obstetricians and Gynecologists,United States,Fractures & Osteoporosis,GRADE,4,4,2,The American College of Obstetricians and Gynecologists (ACOG) recommends screening for osteoporosis in postmenopausal patients 65 years and older with bone mineral density testing to prevent osteoporotic fractures.,High,4,Strong,2,Women,1,"Osteoporosis Prevention, Screening, and Diagnosis: ACOG Clinical Practice Guideline No. 1. Obstetrics & Gynecology. 2021 Sep;138(3):494–506.",7
20,2010,Klijn 2019,Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.,"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients
with stroke or transient ischemic attack and non-valvular atrial fibrillation",2019,European Stroke Organisation,Other: Europe,Atrial Fibrillation,GRADE,5,4,2,"In elderly patients with nonvalvular artrial fibrillation and a history of ischemic stroke or transient ischaemic attack, we suggest oral anticoagulant treatment over antiplatelet treatment or no oral anticoagulant treatment for secondary prevention of all events.",Low,2,Weak,1,,0.5,"Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. European Stroke Journal. 2019 Sep;4(3):198–223.",15
21,2010,Klijn 2019,Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.,"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients
with stroke or transient ischemic attack and non-valvular atrial fibrillation",2019,European Stroke Organisation,Other: Europe,Atrial Fibrillation,GRADE,5,4,2,"In patients with cognitive deficits, non-valvular artrial fibrillation and previous ischemic stroke or transient ischaemic attack, we suggest oral anticoagulant treatment over antiplatelet treatment or no oral anticoagulant treatment for secondary prevention of all events.",Low,2,Weak,1,,0.5,"Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. European Stroke Journal. 2019 Sep;4(3):198–223.",15
22,2010,Klijn 2019,Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.,"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients
with stroke or transient ischemic attack and non-valvular atrial fibrillation",2019,European Stroke Organisation,Other: Europe,Atrial Fibrillation,GRADE,5,4,2,"In patients with cognitive decline, non-valvular artrial fibrillation and previous ischemic stroke or transient ischaemic attack, we suggest non Vitamin K antagonist oral anticoagulants treatment over Vitamin K antagonist treatment for secondary prevention of all events.",Low,2,Weak,1,,0.5,"Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. European Stroke Journal. 2019 Sep;4(3):198–223.",15
23,2010,Klijn 2019,Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.,"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients
with stroke or transient ischemic attack and non-valvular atrial fibrillation",2019,European Stroke Organisation,Other: Europe,Atrial Fibrillation,GRADE,5,4,2,"In elderly patients with nonvalvular artrial fibrillation and previous ischemic stroke or transient ischaemic attack, we suggest non-Vitamin K antagonist oral anticoagulants treatment over Vitamin K antagonist treatment for secondary prevention of all events.",Low,2,Weak,1,,0.5,"Klijn CJ, Paciaroni M, Berge E, Korompoki E, Kõrv J, Lal A, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. European Stroke Journal. 2019 Sep;4(3):198–223.",15
24,2048,Smith 2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.,Management of vascular cognitive impairment,2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia,Canada,Delirium & Dementia,Other: Modified GRADE,4,3,2,The use of aspirin is not recommended for patients with mild cognitive impairment (MCI) or dementia who have brain imaging evidence of covert white matter lesions of presumed vascular origin without history of stroke or brain infarcts.,C,1,2,1,,0.333333333333333,"Smith EE, Barber P, Field TS, Ganesh A, Hachinski V, Hogan DB, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. A&D Transl Res & Clin Interv. 2020 Jan;6(1):e12056.",9
25,2048,Smith 2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.,Management of vascular cognitive impairment,2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia,Canada,Delirium & Dementia,Other: Modified GRADE,4,3,2,"Because treatment of hypertension may reduce risk of dementia, clinicians should assess, diagnose, and treat hypertension according to guidelines from Hypertension Canada.",B,2,1,2,,0.666666666666667,"Smith EE, Barber P, Field TS, Ganesh A, Hachinski V, Hogan DB, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. A&D Transl Res & Clin Interv. 2020 Jan;6(1):e12056.",6
26,2048,Smith 2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.,Management of vascular cognitive impairment,2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia,Canada,Delirium & Dementia,Other: Modified GRADE,4,3,2,"Use of standardized criteria (one of: the Vascular Behavioral and Cognitive Disorders [VAS-COG] Society criteria, Diagnostic and Statistical Manual of Mental Disorders [DSM5], Vascular Impairment of Cognition Classification Consensus Study, or the American Heart Association consensus statement) are recommended for the diagnosis of vascular mild cognitive impairment and vascular dementia.",C,1,1,2,,0.333333333333333,"Smith EE, Barber P, Field TS, Ganesh A, Hachinski V, Hogan DB, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. A&D Transl Res & Clin Interv. 2020 Jan;6(1):e12056.",19
27,2048,Smith 2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.,Management of vascular cognitive impairment,2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia,Canada,Delirium & Dementia,Other: Modified GRADE,4,3,2,"The effects of aspirin on cognitive decline in patients with mild cognitive impairment (MCI) or dementia who have covert brain infarcts detected on neuroimaging without history of stroke has not been defined. The use of aspirin in this setting is reasonable, but the benefit is unclear.",C,1,2,1,,0.333333333333333,"Smith EE, Barber P, Field TS, Ganesh A, Hachinski V, Hogan DB, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. A&D Transl Res & Clin Interv. 2020 Jan;6(1):e12056.",9
28,2048,Smith 2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.,Management of vascular cognitive impairment,2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia,Canada,Delirium & Dementia,Other: Modified GRADE,4,3,2,"All patients with cognitive symptoms or impairment should receive guideline-recommended treatments to prevent first-ever or recurrent stroke, as appropriate.",B,2,1,2,,0.666666666666667,"Smith EE, Barber P, Field TS, Ganesh A, Hachinski V, Hogan DB, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. A&D Transl Res & Clin Interv. 2020 Jan;6(1):e12056.",15
29,2048,Smith 2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.,Management of vascular cognitive impairment,2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia,Canada,Delirium & Dementia,Other: Modified GRADE,4,3,2,"Cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and the N-methyl-D-aspartate (NMDA) receptor antagonist memantine may be considered for the treatment of vascular cognitive impairment in selected patients.",B,2,2,1,,0.666666666666667,"Smith EE, Barber P, Field TS, Ganesh A, Hachinski V, Hogan DB, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. A&D Transl Res & Clin Interv. 2020 Jan;6(1):e12056.",25
30,2048,Smith 2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.,Management of vascular cognitive impairment,2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia,Canada,Delirium & Dementia,Other: Modified GRADE,4,3,2,"For patients with cognitive disorders in which a vascular contribution is known or suspected, antihypertensivet herapy should be strongly considered for average diastolic blood pressure readings ≥ 90 mmHg and for average systolic blood pressure readings ≥ 140 mmHg.",B,2,1,2,,0.666666666666667,"Smith EE, Barber P, Field TS, Ganesh A, Hachinski V, Hogan DB, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. A&D Transl Res & Clin Interv. 2020 Jan;6(1):e12056.",6
31,2048,Smith 2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.,Management of vascular cognitive impairment,2020,Canadian Consensus Conference on Diagnosis and Treatment of Dementia,Canada,Delirium & Dementia,Other: Modified GRADE,4,3,2,In middle-aged and older persons being treated for hypertension who have associated vascular risk factors a systolic blood pressure treatment target of < 120 mmHg may be associated with a decreased risk of developing mild cognitive impairment (MCI) and should be considered when deciding on the intensity of their therapy.,C,1,2,1,,0.333333333333333,"Smith EE, Barber P, Field TS, Ganesh A, Hachinski V, Hogan DB, et al. Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. A&D Transl Res & Clin Interv. 2020 Jan;6(1):e12056.",6
32,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should advise patients, caregivers, and families that it is dangerous to ride as a passenger with a driver who has used cannabis within the previous 24 hours.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
33,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Cannabis should generally be avoided by older adults who have: Cognitive impairment, cardiovascular disease, cardiac arrhythmias, coronary artery disease, unstable blood pressure, or impaired balance.",Moderate,2,Strong,2,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
34,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should educate patients to avoid illegal synthetic cannabinoids (e.g., K2 and SPICE,) because of the potential to cause serious harm.",Low,1,Strong,2,,0.333333333333333,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
35,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should be aware of the following: The common signs and symptoms associated with cannabis use, cannabis-induced impairment, cannabis withdrawal, CUD, and common consequences of problematic cannabis use.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
36,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should be aware of the following: Mental health disorders which are commonly comorbid withcannabis use disorder such as depression, anxiety, and schizophrenia/psychosis.",Moderate,2,Strong,2,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
37,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Patients, caregivers, and families should be provided with information about the signs, symptoms, and risks of cannabis withdrawal.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
38,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should advise patients, care-givers, and families of risks associated with different modes of use of cannabis and cannabis products (e.g., smoking, aporizing, oils, sprays, etc.) and counsel patients on these risks.",Moderate,2,Strong,2,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
39,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"The Screening, Brief Intervention, and Referral to Treatment (SBIRT) approach should be considered for assessing and managingcannabis use disorder similarly to othersubstance use disorders.",Low,1,Strong,2,,0.333333333333333,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
40,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should advise patients, care-givers, and families about potentially increased risks associated with higher potency tetrahydrocannabinol (THC) extracts, or higher potency strains of cannabis when compared to those with lower tetrahydrocannabinol (THC) content.",Low,1,Strong,2,,0.333333333333333,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
41,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Cannabis should generally be avoided by older adults who have: A history of, or are currently experiencing, mental health disorders, problematic substance use, or Substance Use Disorder.",Moderate,2,Strong,2,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
42,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"It is recommended that a variety of psychosocial approaches be considered for harm reduction or relapse prevention including: Cognitive Behavioural Therapy (CBT), Motivational Interviewing (MI), Mindfulness Based Relapse Prevention (MBRP), Motivational Enhancement Therapy (MET), and Contingency Management (CM).",Moderate,2,Strong,2,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",8
43,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should be aware of the following: The current evidence base on the medical use of cannabis is relatively limited, and cannabis and most derivative products have not been approved as therapeutic agents by Health Canada, with the exception of two pharmaceutical grade cannabinoid products. Clinicians should keep informed about new evidence regarding possible indications and contraindications for cannabis and cannabinoid use.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
44,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should initiate non-judgmental discussions related to cannabis and cannabinoid use. Careful histories should be obtained from patients, caregivers, and families about signs and symptoms ofcannabis use disorder that may be similar to those of age-related nervous system changes, such as drowsiness, dizziness, memory impairment, and falls.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
45,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should counsel patients, care-givers, and families to be aware that older adults can be more susceptible than younger adults to some dose-related adverse events associated with cannabis use.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
46,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Peer support programs should be considered for individuals withcannabis use disorder.,Moderate,2,Strong,2,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
47,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Accredited residential treatment should be considered as appropriate for treatingcannabis use disorder if the individual is unable to effectively reduce or cease their cannabis use.,Low,1,Strong,2,,0.333333333333333,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
48,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"All patients regardless of age should be screened for: The use of non-medical and medically authorized cannabis and cannabinoids, and illicit synthetic cannabinoids as well as tobacco, alcohol, and other drugs.",Low,1,Strong,2,,0.333333333333333,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
49,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinical assessment ofcannabis use disorder in older adults should evaluate the signs and symptoms of cannabis withdrawal, with consideration that the rapid reduction or abrupt discontinuation of cannabis use may also be associated with withdrawal symptoms.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
50,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"When assessing patients, clinicians should be aware of the risk of cannabis hyperemesis syndrome in association with chronic cannabis use, especially with higher potency preparations.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
51,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Clinicians should be aware that the diagnostic accuracy of some screening tools may be variable given that some of the symptoms of aging may overlap with those ofcannabis use disorder.,Moderate,2,Weak,1,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
52,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should advise patients, caregivers, and families that Cannabis may impair the ability to safely drive a motor vehicle for up to 24 hours.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
53,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should counsel patients on the potential long-term effects of frequent cannabis use including respiratory problems, precancerous epithelial changes, and cognitive impairment. Patients should also be counselled on the risk of exacerbation of mental health conditions with CUD, especially when high tetrahydrocannabinol (THC) strains are used.",Moderate,2,Strong,2,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
54,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should be aware of the following: The potential adverse effects of cannabis use in older adults, such as changes in depth perception risking balance instability and falls, changes in appetite, cognitive impairment, cardiac arrhythmia, anxiety, panic, psychosis, and depression.",Moderate,2,Strong,2,,0.666666666666667,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
55,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Clinicians should educate patients on the risk of cannabis-induced impairment especially if the patient is cannabis-naive or titrating to a new dose. It is recommended that the starting dose should be as low as possible and gradu-ally increased over time if needed.,High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
56,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Clinicians should advise patients, caregivers, and families that the use of both cannabis and alcohol together results in synergistic impairment, increases risks for driving, and should be avoided.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
57,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"All patients regardless of age should be screened for: The amount and type of cannabis or cannabinoid used, and its frequency, by those who acknowledge any use. Those who acknowledge any recent use (any in the past month) should then go on to targeted screening using the Cannabis Use Disorder Identification Test (CUDIT).",Low,1,Strong,2,,0.333333333333333,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
58,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Assessment ofcannabis use disorder in older adults should evaluate: Modes of use: i.e., ingesting, smoking, vaping, use of extracts, topicals, nabilone, and nabiximols, etc., and consider the risks/benefits/harms of all that apply to the patient.",High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
59,2163,Bertram 2020,Canadian Guidelines on Cannabis Use Disorder Among Older Adults.,Cannabis Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Assessment ofcannabis use disorder in older adults should evaluate: Frequency and dosage.,High,3,Strong,2,,1,"Bertram JR, Porath A, Seitz D, Kalant H, Krishnamoorthy A, Nickerson J, et al. Canadian guidelines on cannabis use disorder among older adults. Canadian geriatrics journal. 2020;23(1):135.",0
60,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"For women 65 years of age or older, no more than 1 standard drink per day, with no more than 5 alcoholic drinks per week, is recommended; for men 65 years of age or older, no more than 1-2 standard drinks per day, with no more than 7 per week in total, is recommended. Non-drinking days are recommended every week.",Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
61,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Assess older adults with alcohol use disorder for cognitive impairment using a validated tool every 12 months or as indicated. In cases of cognitive impairment, repeat the cognitive evaluation at 6 and 12 months after a reduction or discontinuation of alcohol, to assess for evidence of improvement. The treatment plan should specify the timeline and procedure for ongoing evaluation of clinical outcomes and treatment effectiveness.",Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
62,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"To prevent the development of Wernicke’s encephalopathy during withdrawal, at least 200 mg of parenteral thiamine (IM or IV) should be administered daily for 3-5 days.",Low,1,Strong,2,,0.333333333333333,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
63,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"In the management of alcohol withdrawal in older adults, it is best to use the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) symptom score with protocols using a shorter-acting benzodiazepine such as lorazepam. One should also pay close attention to comorbidities to avoid complications.",High,3,Strong,2,,1,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
64,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Older adults who choose to drink alcohol should be advised to slow their pace of consumption and lower their total alcohol intake at each sitting in order to decrease the risk of harm. Alcoholic drinks are best taken with food and not on an empty stomach, and should be alternated with caffeine-free, non-alcoholic beverages. They should be completely avoided in potentially risky situations or activities.",Low,1,Strong,2,,0.333333333333333,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
65,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"All older adults with alcohol use disorder, and their caregivers and support persons, should be offered psychosocial treatment and support, as indicated, as part of a treatment plan.",Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
66,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Increase awareness of the risk of alcohol use through labeling that indicates:
- Standard drink content of the product
- National Low Risk Drinking Guidelines for both adults and older adults
- A warning of alcohol related risks and harms",Low,1,Strong,2,,0.333333333333333,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
67,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Older adults should be asked about alcohol use in all care settings including: hospitals, rehabilitation facilities, home health care, community services, assisted living and long-term care facilities, and specialized programs.",High,3,Strong,2,,1,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
68,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Use the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) to screen for those requiring medical withdrawal management (prior delirium, seizures, or protracted withdrawal). Patients who are in poor general health, acutely suicidal, have dementia, are medically unstable, or who need constant one-on-one monitoring should receive 24-hour medical, psychiatric, and/or nursing inpatient care in medically-managed and monitored intensive treatment or hospital settings.",High,3,Strong,2,,1,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
69,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"As the older adult ages, especially those with comorbidities (as above), alcohol should be further reduced to 1 drink or less per day, consumed on fewer occasions, and consideration should be given to abstaining from alcohol.",Low,1,Strong,2,,0.333333333333333,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
70,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Routinely offer pharmacological treatment (e.g., anti-craving medication) with alcohol behavioural intervention and case management in moderate and severe alcohol use disorder, as it may improve the efficacy of primary care treatment.",Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
71,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Older adults who screen positive for an alcohol use disorder should be assessed by an appropriately trained health-care provider.,Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
72,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"All patients (including older adults) should be screened for alcohol use at least annually (i.e., as part of his or her regular physical examination) and at transitions of care (e.g., admission to hospital). Screening should be conducted more frequently if: consumption levels exceed the low-risk drinking guidelines; there are symptoms of an alcohol use disorder; there is a family history of alcohol use disorder; the patient currently experiences anxiety and/or depression; caregivers express concern; or the older adult is undergoing major life changes or transitions.",Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
73,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Naltrexone and acamprosate pharmacotherapy can be used to treat alcohol use disorder in older adults, as indicated, with attention to contraindications and side effects. Naltrexone may be used for both alcohol reduction and abstinence, while acamprosate is used to support abstinence. In general, start at low doses and titrate slowly, with attention to open communication with the patient. Initiation may be done in the home, hospital, during withdrawal management, or in long-term care with subsequent transition to an appropriate placement.",High,3,Strong,2,,1,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
74,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Peri-operative elective surgical management should include medically supported withdrawal or alcohol use taper pre-operatively, with post-operative treatment and consideration of anti-craving medication.",Low,1,Strong,2,,0.333333333333333,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",11
75,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Request consent to discuss the patient’s alcohol use and its impact with family, friends, and other caregivers.",Low,1,Strong,2,,0.333333333333333,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
76,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"It is recommended that older adults do not drink when operating any kind of vehicle, tools or machinery; using medications or other drugs that interact with alcohol; engaging in sports or potentially dangerous physical activity; preparing for bed or having to arise at night; making important decisions; while responsible for the care of others; if living with serious physical or mental illness or a substance use disorder.",Low,1,Strong,2,,0.333333333333333,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
77,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"The least intrusive or invasive treatment options, such as behavioural interventions, should be explored initially with older adults who present with a mild alcohol use disorder. These initial approaches can function either as an initial treatment strategy or as treatment itself.",High,3,Strong,2,,1,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
78,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"The severity and management of concurrent physical and mental health conditions (including co-occurring psychiatric disorders, suicide risk, and cognitive disorders), as well as significant social transitions in the individual or family, should continue to be reviewed and monitored regardless of continuance, reduction, or cessation of alcohol use.",Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
79,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Ensure that screening for alcohol use disorder in older adults is age-appropriate and employs active listening, is supportive, accounts for memory impairment or cognitive decline, is non-threatening, non-judgmental, and non-stigmatizing, and recognizes that DSM-5 criteria will under-identify due to potentially reduced occupational or social obligations.",Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
80,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Treatment response for alcohol use disorder should be monitored though laboratory measures such as gamma-glutamyl transferase (GGT) and mean corpuscular volume (MCV).,Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
81,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Depending upon health (i.e., dementia; Parkinson’s disease; hemorrhagic stroke; epilepsy; cardiac dysrhythmias; hypertension; sleep apnea; COPD; liver disease; pancreatitis; gastrointestinal and breast cancers; compromised balance or mobility), frailty, and medication use (i.e., benzodiazepines, opioids, Gabapentinoids, sedating antidepressants), some adults should adhere to these recommended lower levels of alcohol consumption before they reach the age of 65.",High,3,Strong,2,,1,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
82,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"As a harm reduction strategy for chronic heavy drinkers, it is recommended that at least 50 mg of thiamine supplementation daily be used to prevent Wernicke-Korsakoff syndrome, progressive cognitive decline, and increased frailty.",Low,1,Strong,2,,0.333333333333333,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
83,2164,Butt 2020,Canadian Guidelines on Alcohol Use Disorder Among Older Adults.,Alcohol Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"A comprehensive assessment is indicated for all older adults who have an alcohol use disorder, have signs of harmful use, or who present with acute intoxication. The assessment should include: the use of a standardized alcohol use questionnaire to determine quantity and frequency of alcohol use and potential harms; a comprehensive assessment of medication and other substance use; determination of the presence of another substance use disorder; evaluation of physical, mental, and cognitive capacity, nutrition, chronic pain, social conditions, family/social supports, and overall functioning; collateral history. The assessment should be performed regardless of physical, mental, or cognitive co-morbidities, with modifications as deemed appropriate.",Moderate,2,Strong,2,,0.666666666666667,"Butt PR, White-Campbell M, Canham S, Dowsett Johnston A, Indome EO, Purcell B, et al. Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):143–8.",13
84,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,The combination of a benzodiazepine receptor agonist with alcohol should be avoided.,Low,1,Weak,1,,0.333333333333333,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",10
85,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Health-care practitioners, older adults, and their families should advocate for adequate access and funding of effective non-pharmacological alternatives for the management of insomnia, anxiety disorders, and behavioral and psychological symptoms of dementia.",Low,1,Strong,2,,0.333333333333333,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",8
86,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Health-care practitioners should avoid prescribing benzodiazepine receptor agonists concurrently with opioids whenever possible.,Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",10
87,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Management of acute benzodiazepine receptor agonist withdrawal symptoms should be monitored carefully and can be guided by a validated tool [e.g. Benzodiazepine Withdrawal Symptom Questionnaire, Clinical Institute Withdrawal Assessment-Benzodiazepine (CIWA-B)] and managed with symptom-driven judicious use of an appropriate benzodiazepine receptor agonists.",Low,1,Weak,1,,0.333333333333333,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
88,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,A benzodiazepine receptor agonist should only be considered in the management of insomnia or anxiety after failing adequate trials of non-pharmacological interventions or safer pharmacological alternatives OR for short-term bridging until more appropriate treatment becomes effective.,Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
89,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Older adults who are receiving a benzodiazepine receptor agonist should be educated and provided the opportunity to discuss the ongoing risks of taking BZRAs.,Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
90,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Older adults who are receiving a benzodiazepine receptor agonist should be supported in stopping the drug, which may require a gradual reduction until discontinued.",Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
91,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Psychological interventions such as cognitive behavioral therapy should be considered during efforts to withdraw benzodiazepine receptor agonists as they can improve the older adult’s experiences and increase the likelihood of stopping the benzodiazepine receptor agonists.,High,3,Strong,2,,1,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
92,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"A person-centred, stepped-care approach to enable the gradual withdrawal and discontinuation of benzodiazepine receptor agonists should be used. Clinicians and patients should share in: a) planning and applying a gradual dose reduction scheme supported by appropriate education of the patient; b) identifying and optimizing alternatives to manage the underlying health issue(s) that initiated or perpetuated the use of BZRAs; c) developing strategies to minimize acute withdrawal and managing rebound symptoms as needed; and d) establishing a schedule of visits for reviewing progress.",Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
93,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Abrupt discontinuation of a benzodiazepine receptor agonist after intermediate to long-term use (> 4 weeks) in individuals with benzodiazepine receptor agonist use disorder should be avoided due to the risk of withdrawal symptoms, substance dependence reinforcement, rebound phenomena, and/or higher likelihood of relapse with resumption of benzodiazepine receptor agonist use.",Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
94,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"The routine switching of a short half-life benzodiazepine receptor agonist with one having a long half-life to aid in withdrawing benzodiazepine receptor agonists is not generally recommended in older adults. Switching may have a role in certain situations, such as when withdrawal is being hindered by a limited number of available benzodiazepine receptor agonist pill strengths or when alprazolam is the agent of dependence or misuse.",Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
95,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Older adults who are receiving a benzodiazepine receptor agonist should be encouraged to only take the benzodiazepine receptor agonist for a short period of time (2 to 4 weeks or less) at the minimally effective dose.,Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
96,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Appropriate first-line non-pharmacological options for the treatment of insomnia and anxiety disorders include cognitive behaviour therapies (CBTs) provided in various formats.,Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",11
97,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Multiple substance use is common and should be considered and inquired about in all older adults with a benzodiazepine receptor agonist use disorder.,Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
98,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Substituting a pharmacologically different drug as a specific intervention to mitigate benzodiazepine receptor agonist withdrawal symptoms during gradual dose reduction is not routinely recommended.,Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
99,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Long-term use of benzodiazepine receptor agonists (> 4 weeks) in older adults should be avoided for most indications because of their minimal efficacy and risk of harm. Older adults have increased sensitivity to benzodiazepine receptor agonists and decreased ability to metabolize some longer-acting agents, such as diazepam. All benzodiazepine receptor agonists increase the risk of cognitive impairment, delirium, falls, fractures, hospitalizations, and motor vehicle crashes. Alternative management strategies for insomnia, anxiety disorders, and the behavioural and psychological symptoms of dementia are recommended.",Moderate,2,Strong,2,,0.666666666666667,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
100,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Health-care providers and organizations should consider implementing interventions to decrease inappropriate use of benzodiazepine receptor agonists in their practice settings. These include medication reviews, prescribing feedback, audits and alerts, multidisciplinary case conferences, and brief educational sessions. Regulators, health authorities, and professional organizations should consult with clinical leaders and older adults to develop and implement policies that aim to minimize inappropriate use of BZRAs.",Low,1,Strong,2,,0.333333333333333,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
101,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,"Health-care institutions, including acute care hospitals and long-term care facilities, should implement protocols that minimize new prescriptions for benzodiazepine receptor agonists because of the potential for harm and the risk of this leading to long-term use following discharge to the community or other transitions in care.",Low,1,Strong,2,,0.333333333333333,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
102,2165,Conn 2020,Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults Title.,Benzodiazepine Receptor Agonist Use Disorder Among Older Adults,2020,Canadian Coalition for Seniors’ Mental Health,Canada,Alcohol & Drug Abuse,Other: modified GRADE,4,3,2,Clinicians should be aware that benzodiazepine receptor agonists are prescribed more frequently to women and the potential implicit bias that may lead to inappropriate use.,Low,1,Weak,1,women,0.333333333333333,"Conn DK, Hogan DB, Amdam L, Cassidy KL, Cordell P, Frank C, et al. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. Can Geri J. 2020 Mar 13;23(1):116–22.",17
103,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,Treatment of hypertension to individualized target levels is indicated in most older adults.,C,2,,,,0.5,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,6
104,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,Screening for early detection of mild cognitive impairment or dementia should be performed for adults 65 years of age or older at the initial visit and annually as appropriate.,B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,2
105,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,Screening for diabetes complications should be individualized in older adults. Particular attention should be paid to complications that would lead to functional impairment.,C,2,,,,0.5,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
106,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,"Glycemic goals for some older adults might reasonably be relaxed as part of individualized care, but hyperglycemia leading to symptoms or risk of acute hyperglycemia complications should be avoided in all patients.",C,2,,,,0.5,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
107,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,"Deintensification (or simplification) of complex regimens is recommended to reduce the risk of hypoglycemia and polypharmacy, if it can be achieved within the individualized A1C target.",B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
108,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,"In older adults with type 2 diabetes at increased risk of hypoglycemia, medication classes with low risk of hypoglycemia are preferred.",B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
109,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,Consider costs of care and insurance coverage rules when developing treatment plans in order to reduce risk of cost-related nonadherence.,B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,20
110,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,"Consider the assessment of medical, psychological, functional (self-management abilities), and social geriatric domains in older adults to provide a framework to determine targets and therapeutic approaches for diabetes management.",B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
111,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,"Screen for geriatric syndromes (i.e., polypharmacy, cognitive impairment, depression, urinary incontinence, falls, and persistent pain) in older adults as they may affect diabetes self-management and diminish quality of life.",B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
112,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,Overtreatment of diabetes is common in older adults and should be avoided.,B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
113,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,Hypoglycemia should be avoided in older adults with diabetes. It should be assessed and managed by adjusting glycemic targets and pharmacologic regimens.,B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
114,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,"Optimal nutrition and protein intake is recommended for older adults; regular exercise, including aerobic activity and resistance training, should be encouraged in all older adults who can safely engage in such activities.",B,3,,,,0.75,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,24
115,2393,AmericanDiabetesAssociation 2020,12. Older Adults: Standards of Medical Care in Diabetes-2020.,Older Adults: Standards of Medical Care in Diabetes,2020,American Diabetes Association,United States,Diabetes Mellitus,Other: ADA,4,4,1,"Older adults who are otherwise healthy with few coexisting chronic illnesses and intact cognitive function and functional status should have lower glycemic goals (such as A1C < 7.5 % [58 mmol/mol]), while those with multiple coexisting chronic illnesses, cognitive impairment, or functional dependence should have less-stringent glycemic goals (such as A1C < 8.0-8.5 % [64-69 mmol/mol]).",C,2,,,,0.5,American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020 Jan 1;43(Supplement_1):S152–62.,16
116,2626,Hachimi-Idrissi 2020,Approaching acute pain in emergency settings: European Society for Emergency Medicine (EUSEM) guidelines-part 1: assessment.,Approaching acute pain in emergency settings,2020,European Society for Emergency Medicine ,Other: Europe,Pain Management,Other: custom,4,6,1,"In children, and non-verbal adults or those with cognitive impairment the FACES or FLACC scale is of particular use where patients can rate their scale using a series of representative facial images; for children with cognitive impairment, the FLACC-R may also be appropriate.",IB,5,Recommendation,1,,0.833333333333333,"Hachimi-Idrissi S, Coffey F, Hautz WE, Leach R, Sauter TC, Sforzi I, et al. Approaching acute pain in emergency settings: European Society for Emergency Medicine (EUSEM) guidelines—part 1: assessment. Internal and emergency medicine. 2020;15:1125–39.",19
117,2626,Hachimi-Idrissi 2020,Approaching acute pain in emergency settings: European Society for Emergency Medicine (EUSEM) guidelines-part 1: assessment.,Approaching acute pain in emergency settings,2020,European Society for Emergency Medicine ,Other: Europe,Pain Management,Other: custom,4,6,1,"Consider a numerical scale for adults, elderly patients without cognitive impairment and adolescents who can verbalise their pain as these may be more discriminating in evaluating pain than categorical scales and are quick and simple to implement
- NRS rating pain from 0-10 (no pain to worst pain possible) where a score of 0-3 suggests mild pain, 4-6 moderate pain and > 7 severe pain
- VAS rating the severity of pain on a line from 0 to 10 or 0 to 100 with pain scores 0-3 or 0-30 suggesting mild pain, 4-6 or 40-60 suggesting moderate pain and scores greater than 7 or 70 indicating severe pain",IA,6,Recommendation,1,,1,"Hachimi-Idrissi S, Coffey F, Hautz WE, Leach R, Sauter TC, Sforzi I, et al. Approaching acute pain in emergency settings: European Society for Emergency Medicine (EUSEM) guidelines—part 1: assessment. Internal and emergency medicine. 2020;15:1125–39.",2
118,2626,Hachimi-Idrissi 2020,Approaching acute pain in emergency settings: European Society for Emergency Medicine (EUSEM) guidelines-part 1: assessment.,Approaching acute pain in emergency settings,2020,European Society for Emergency Medicine ,Other: Europe,Pain Management,Other: custom,4,6,1,"Consider the use of specialist scales for those patients with cognitive impairment such as advanced dementia. In these situations, scales such as Pain Assessment in Advanced Dementia Scale (PAINAD) can be particularly useful.",IB,5,Recommendation,1,,0.833333333333333,"Hachimi-Idrissi S, Coffey F, Hautz WE, Leach R, Sauter TC, Sforzi I, et al. Approaching acute pain in emergency settings: European Society for Emergency Medicine (EUSEM) guidelines—part 1: assessment. Internal and emergency medicine. 2020;15:1125–39.",2
119,2786,Frederiksen 2020,A European Academy of Neurology guideline on medical management issues in dementia.,Medical management issues in dementia,2020,European Academy of Neurology,Other: Europe,Delirium & Dementia,GRADE,5,4,2,"The authors conclude that there should be a weak recommendation for treatment of patients with dementia and agitation/aggressive behavior with modern (atypical) antipsychotics compared to haloperidol when pharmacological treatment of agitation/aggressive behavior is necessary. Among modern (atypical) antipsychotics, risperidone may be considered as firstline treatment when pharmacological treatment of agitation/aggressive behavior is necessary.",Very Low,1,Weak,1,,0.25,"Frederiksen KS, Cooper C, Frisoni GB, Frölich L, Georges J, Kramberger MG, et al. A European Academy of Neurology guideline on medical management issues in dementia. Euro J of Neurology. 2020 Oct;27(10):1805–20.",21
120,2786,Frederiksen 2020,A European Academy of Neurology guideline on medical management issues in dementia.,Medical management issues in dementia,2020,European Academy of Neurology,Other: Europe,Delirium & Dementia,GRADE,5,4,2,The authors conclude that there should be a weak recommendation against treatment of behavioral symptoms in persons with dementia with mild analgesics.,Very Low,1,Weak,1,,0.25,"Frederiksen KS, Cooper C, Frisoni GB, Frölich L, Georges J, Kramberger MG, et al. A European Academy of Neurology guideline on medical management issues in dementia. Euro J of Neurology. 2020 Oct;27(10):1805–20.",21
121,2786,Frederiksen 2020,A European Academy of Neurology guideline on medical management issues in dementia.,Medical management issues in dementia,2020,European Academy of Neurology,Other: Europe,Delirium & Dementia,GRADE,5,4,2,"The authors conclude that there should be a weak recommendation for discontinuation in patients currently treated with antipsychotics. Discontinuation of antipsychotics may be considered in patients for whom there is no obvious indication and in patients in whom there is suspicion of side effects, such as rapid cognitive decline, sedation, falls, or extrapyramidal symptoms.",Very Low,1,Weak,1,,0.25,"Frederiksen KS, Cooper C, Frisoni GB, Frölich L, Georges J, Kramberger MG, et al. A European Academy of Neurology guideline on medical management issues in dementia. Euro J of Neurology. 2020 Oct;27(10):1805–20.",21
122,2786,Frederiksen 2020,A European Academy of Neurology guideline on medical management issues in dementia.,Medical management issues in dementia,2020,European Academy of Neurology,Other: Europe,Delirium & Dementia,GRADE,5,4,2,The authors conclude that there should be a weak recommendation against treatment of patients with dementia and agitation/aggressive behavior with modern (atypical) antipsychotics compared to no pharmacological treatment.,Low,2,Weak,1,,0.5,"Frederiksen KS, Cooper C, Frisoni GB, Frölich L, Georges J, Kramberger MG, et al. A European Academy of Neurology guideline on medical management issues in dementia. Euro J of Neurology. 2020 Oct;27(10):1805–20.",21
123,2786,Frederiksen 2020,A European Academy of Neurology guideline on medical management issues in dementia.,Medical management issues in dementia,2020,European Academy of Neurology,Other: Europe,Delirium & Dementia,GRADE,5,4,2,The authors conclude that there should be a weak recommendation for treatment with anticoagulants in patients with dementia (without previous stroke) and atrial fibrillation.,Very Low,1,Weak,1,,0.25,"Frederiksen KS, Cooper C, Frisoni GB, Frölich L, Georges J, Kramberger MG, et al. A European Academy of Neurology guideline on medical management issues in dementia. Euro J of Neurology. 2020 Oct;27(10):1805–20.",9
124,3002,Hoshide 2020,Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients.,Management of Hypertension,2019,Japanese Society of Hypertension,Other: Japan,Hypertension,Other: Minds Handbook for Clinical Practice Guideline Development 2014,5,4,2,"In older patients with frailty or those requiring nursing care, the target of blood pressure control should be individually determined.",D,1,Weak,1,,0.25,"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019 Sep;42(9):1235–481.",6
125,3002,Hoshide 2020,Highlights of the 2019 Japanese Society of Hypertension Guidelines and perspectives on the management of Asian hypertensive patients.,Management of Hypertension,2019,Japanese Society of Hypertension,Other: Japan,Hypertension,Other: Minds Handbook for Clinical Practice Guideline Development 2014,5,4,2,"In hypertensive patients aged ≥ 75 years, blood pressure should be lowered to < 140 mmHg if tolerated.",A,4,Strong,2,,1,"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019 Sep;42(9):1235–481.",6
126,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,We recommend oral anticoagulation alone for patients with artrial fibrillation aged 65 years or older or with a CHADS2 score ≥1 and stable coronary or arterial vascular disease.,Moderate,3,Strong,2,,0.75,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
127,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"We suggest additional monitoring for artrial fibrillation detection (e.g., prolonged external loop recorder or implantable cardiac monitoring, where available) be performed for selected older patients with nonlacunar embolic stroke of undetermined source in whom artrial fibrillation is suspected but unproven.",Moderate,3,Weak,1,,0.75,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
128,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,We suggest that digoxin be considered as a monotherapy in older or sedentary individuals with permanent atrial fibrillation; or those with side effects or contraindications to first-line agents; or in addition to first-line agents in those who fail to achieve satisfactory symptom or heart rate control.,Low,2,Weak,1,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",12
129,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,We recommend that oral anticoagulation be prescribed for most frail elderly patients with artrial fibrillation.,Moderate,3,Strong,2,,0.75,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
130,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"For patients with atrial fibrillation aged 65 years or older or with a CHADS2 score ≥ 1 undergoing percutaneous coronary intervention (PCI) without acute coronary syndrome (ACS) or high-risk features, we recommend dual pathway therapy (Oral anticoagulation with P2Y12) for at least 1 month and up to 12 months after PCI.",Low,2,Weak,1,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
131,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"For patients with artrial fibrillation aged 65 years or older or with a CHADS2 score ≥ 1, we suggest that dual pathway therapy (Oral anticoagulation with P2Y12) be given without concomitant acetylsalicylic acid (ASA) for up to 12 months after medically managed type I ACS.",Low,2,Weak,1,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
132,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"We recommend that patients with artrial fibrillation should be assessed for multimorbidity, frailty, cognitive impairment, dementia, and depression.",Low,2,Strong,2,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",1
133,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,We recommend that opportunistic screening for artrial fibrillation should be conducted in people 65 years of age and older at the time of medical encounters.,Low,2,Strong,2,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
134,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"For patients with atrial fibrillation aged older than 65 years or with a CHADS2 score ≥ 1 undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) or elective PCI with high-risk features, we recommend an initial regimen of triple therapy (oral anticoagulation with P2Y12 and acetylsalicylic acid (ASA) 81 mg/d).",Low,2,Strong,2,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
135,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,We recommend that patients who present with artrial fibrillation in the acute care setting have their need for long-term antithrombotic therapy be determined using the Canadian Cardiovascular Society (CCS) algorithm (age > 65: antocoagulation).,Moderate,3,Strong,2,,0.75,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
136,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"When a decision to interrupt Vitamin K antagonist therapy for an invasive procedure has been made, we suggest that bridging therapy with LMWH or UFH should be started when the INR is below therapeutic level only in patients at high risk of thromboembolic events (mechanical heart valves, moderate-severe mitral valve stenosis, non-valvular artrial fibrillation with a CHADS2 score of 5-6, and those with a recent stroke or transient ischemic attack (TIA).",Low,2,Weak,1,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
137,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"For patients with atrial fibrillation aged 65 years or older or with a CHADS2 score ≥ 1 undergoing percutaneous coronary intervention (PCI) without acute coronary syndrome (ACS) or high-risk features, we recommend dual pathway therapy (Oral anticoagulation with P2Y12).",High,4,Strong,2,,1,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
138,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,We recommend that oral anticoagulation be prescribed for most patients with artrial fibrillation and age 65 years or older or CHADS2 score ≥ 1.,Moderate,3,Strong,2,,0.75,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
139,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"We suggest that, in the absence of a strong contraindication, all patients who undergo cardioversion of artrial fibirllation receive at least 4 weeks of therapeutic anticoagulation (adjusted-dose Vitamin K Antagonist or a direct oral anticoagulant (DOAC) after cardioversion. Thereafter, we recommend that the need for ongoing antithrombotic therapy should be on the basis of the risk of stroke as determined by the Canadian Cardiovascular Society (CCS) algorithm (CHADS-65).",Moderate,3,Strong,2,,0.75,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
140,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"We suggest oral anticoagulation for most patients with artrial fibrillation or intra-atrial reentrant tachycardia and age 65 years or older, CHADS2 score ≥1, or congenital heart disease of moderate or severe complexity.",Moderate,3,Weak,1,,0.75,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
141,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,We suggest that it is reasonable to prescribe oral anticoagulation for patients with artrial fibrillation who are aged 65 years or older or with a CHADS2 score ≥ 1 who have episodes of subclinical artrial fibrillation lasting > 24 continuous hours.,Low,2,Weak,1,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
142,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"We suggest that after successful catheter or surgical ablation of artrial fibrillation, the decision to continue oral anticoagulation beyond 2 months after ablation should be determined on the basis of the patient’s risk of stroke (“Canadian Cardiovascular Society (CCS) algorithm”; age > 65: anticoagulation) and not according to the apparent success of the procedure.",Low,2,Weak,2,,0.5,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
143,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,We recommend that the “CCS Algorithm” (age > 65: anticoagulation) be used to guide the choice of appropriate antithrombotic therapy for the purpose of stroke/systemic embolism prevention in patients with non-valvular artrial fibrillation.,High,4,Strong,2,,1,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
144,3051,Andrade 2020,The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.,Management of Atrial Fibrillation,2020,"Canadian Cardiovascular Society, Canadian Heart Rhythm Society",Canada,Atrial Fibrillation,GRADE,4,4,2,"After acetylsalicylic acid (ASA) discontinuation, which may occur as early as the day after percutaneous coronary intervention (PCI), we recommend that dual pathway therapy (oral anticoagulation with P2Y12) be continued for up to 12 months after PCI for patients with AF aged older than 65 years or with a CHADS2 score ≥ 1 undergoing PCI for acute coronary syndrome (ACS) or elective PCI with high-risk features.",High,4,Strong,2,,1,"Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Canadian Journal of Cardiology. 2020;36(12):1847–948.",15
145,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Physical therapists may provide upper-body aerobic training in addition to progressive resistive, balance, and mobility training in the early postacute period (inpatient setting) for older adults after hip fracture.",Level II,2,C,1,,0.666666666666667,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
146,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Patients should be offered high-frequency (daily) in-hospital physical therapy following surgery for a hip fracture, with duration as tolerated, including instruction in a home program.",Level II,2,B,2,,0.666666666666667,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",7
147,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists should use the timed up-and-go test in all settings to measure mobility and risk for falls when patients do not require human assistance. Documentation should include the features of test administration: comfortable or maximum speed and walking-aid use.,Level I,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
148,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Physical therapists may use the Short Physical Performance Battery in all settings, though completion may not be feasible in the early postoperative period, depending on ability.",Level III,1,C,1,,0.333333333333333,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
149,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Clinicians must provide assisted transfer out of bed and ambulation as soon as possible after hip fracture surgery and at least daily thereafter, unless contraindicated for medical or surgical reasons.",Level II,2,A,3,,0.666666666666667,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",7
150,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists may use electrical stimulation for pain if it is not sufficiently managed with usual strategies.,Level II,2,C,1,,0.666666666666667,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
151,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists should use the Cumulated Ambulation Score in the acute and postacute clinical settings to measure basic mobility until independent ambulation has been reached.,Level I,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
152,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Physical therapists should use the gait speed test in all settings when patients do not require human assistance to walk. Documentation should include the features of test administration: comfortable or maximum speed, walking aid, and rolling start or static start.",Level I,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
153,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Physical therapists should use the New Mobility Score in the early period/inpatient setting to assess prefracture status, and in the postacute and community settings to assess current status and recovery of prefracture status.",Level II,2,B,2,,0.666666666666667,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
154,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists may use electrical stimulation for quadriceps strengthening if other approaches have not been effective.,Level II,2,C,1,,0.666666666666667,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
155,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists must administer and document the verbal rating (ranking) scale for pain in all settings to monitor pain.,Level I,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
156,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Physical therapists must provide structured exercise, including progressive high-intensity resistive strength, balance, weight bearing, and functional mobility training, to older adults after hip fracture.",Level I,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
157,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Physical therapists should participate in multicomponent nonpharmacological intervention programs delivered by an interprofessional team (including physicians, nurses, and possibly other health care professionals) for the entire hospitalization for at-risk older adults undergoing surgery to prevent delirium.",High-quality,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",11
158,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists may use the 3-level version of the EuroQol-5 dimensions scale in all settings to measure health-related quality of life.,Level III,1,C,1,,0.333333333333333,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
159,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists may use the Activity Measure for Post-Acute Care in all settings.,Level II,2,C,1,,0.666666666666667,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
160,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Clinicians should provide physical therapy/rehabilitation to patients with mild to moderate dementia, using similar interventions and prescriptions as for those without dementia.",Level III,1,B,2,,0.333333333333333,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",8
161,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists may use the 10-item physical functioning scale of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) to measure physical functioning in all settings.,Level III,1,C,1,,0.333333333333333,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
162,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists must test and document knee extension strength across all settings.,Level I,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
163,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists must assess and document patient risk factors for falls and contribute to interprofessional management. Physical therapists should use published recommendations from the Academy of Geriatric Physical Therapy of the American Physical Therapy Association to guide fall-risk management in patients with hip fracture to assess and manage fall risk.,High-quality,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
164,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists may use the SF-36 in all settings to measure health-related quality of life.,Level III,1,C,1,,0.333333333333333,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
165,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,Physical therapists in all settings should use the Falls Efficacy Scale-International to measure concern about falling.,Level II,2,B,2,,0.666666666666667,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",26
166,3438,McDonough 2021,Physical Therapy Management of Older Adults With Hip Fracture.,Physical Therapy Management of Older Adults With Hip Fracture,2021,Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association,United States,Fractures & Osteoporosis,Other: Modified Oxford,5,3,3,"Older adults with hip fracture should be treated in a multidisciplinary orthogeriatric program, which includes physical therapy and early mobilization.",Level I,3,A,3,,1,"McDonough CM, Harris-Hayes M, Kristensen MT, Overgaard JA, Herring TB, Kenny AM, et al. Physical Therapy Management of Older Adults With Hip Fracture: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy and the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Feb;51(2):CPG1–81.",7
167,3983,Mukherjee 2020,Elderly adults with isolated hip fractures- orthogeriatric care versus standard care: A practice management guideline from the Eastern Association for the Surgery of Trauma.,Elderly adults with isolated hip fractures,2019,Eastern Association for the Surgery of Trauma,United States,Fractures & Osteoporosis,GRADE,5,4,2,"We conditionally recommend that for elderly adults (ages 65+) with isolated hip fracture after ground-level fall, orthogeriatric consultation be performed to reduce the rates of hospital-acquired pressure ulcers and improve short-term physical functioning, long-term cognitive functioning, and short- and long-term execution of activities of daily living (ADL).",III,2,Conditional,1,,0.5,"Mukherjee K, Brooks SE, Barraco RD, Como JJ, Hwang F, Robinson BRH, et al. Elderly adults with isolated hip fractures- orthogeriatric care versus standard care: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2020 Feb;88(2):266–78.",7
168,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Modified low vision rehabilitation that includes frequent and repetitive training sessions, simplified training experience, and involvement of a friend or family member to improve instrumental activities of daily living (IADL) performance for clients with cognitive deficits.",C,2,Recommendation,1,,0.5,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
169,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,Self-management training with vision assessment and multidisciplinary low vision rehabilitation to increase participation in life situations.,B,3,Recommendation,1,,0.75,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
170,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Multidisciplinary low vision rehabilitation, including occupational therapy, delivered over more service hours rather than less, to improve activities of daily living (ADL) and instrumental activities of daily living (IADL) performance.",C,2,Recommendation,1,,0.5,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
171,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,Portable artificial vision device (OrCam) to increase reading ability.,C,2,Recommendation,1,,0.5,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
172,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,Computer tablet (iPad) with larger text to increase reading speed.,B,3,Recommendation,1,,0.75,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
173,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Multicomponent intervention including five weekly 2-hour vision therapy sessions, a home visit, homework each week, and a low vision device prescription to improve reading and other visual function.",C,2,Recommendation,1,,0.5,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
174,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Multicomponent interventions that include education about low vision conditions, use of low vision devices, problem-solving skills, and low vision resources to promote performance of ADLs and IADLs.",A,4,Recommendation,1,,1,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
175,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Multidisciplinary intervention in a 20-week program including practical training, education, social interaction, counseling, and training in problem-solving skills to increase frequency of outdoor activities, improve satisfaction with partner relationships, and increase satisfaction with outdoor leisure pursuits.",C,2,Recommendation,1,,0.5,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
176,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Low vision rehabilitation therapy, including five weekly sessions, a home visit by a vision therapist, and 5 hours of homework each week, to improve visual ability and activities of daily living (ADL) and instrumental activities of daily living (IADL) performance.",B,3,Recommendation,1,,0.75,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
177,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Self-management therapy, provided over 8 weeks in a group format, that includes education and training on low vision aids and visual techniques to improve participation, reduce depression, and increase health and self-efficacy.",B,3,Recommendation,1,,0.75,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
178,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Low vision rehabilitation (low vision devices) for 3 months to improve perceived near tasks, social functioning, and reading ability.",C,2,Recommendation,1,,0.5,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
179,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,Eccentric viewing with controlled eye movements to improve reading speed and duration for older adults with central visual field impairment.,B,3,Recommendation,1,,0.75,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
180,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,Reading and visual exploration or audiovisual stimulation training to improve visual search and reading for older adults with hemianopsia.,B,3,Recommendation,1,,0.75,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
181,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,"Low vision rehabilitation, including prescription of and training with low vision aids, for 3 months to improve social functioning.",C,2,Recommendation,1,,0.5,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
182,4293,Kaldenberg 2020,Occupational Therapy Practice Guidelines for Older Adults With Low Vision.,Occupational Therapy for Older Adults With Low Vision,2020,American Occupational Therapy Association,United States,Sensory Impairment,Other: U.S. Preventive Services Task Force,4,4,1,Problem-solving training to improve social functioning and develop coping strategies for older adults with macular degeneration.,C,2,Recommendation,1,,0.5,"Kaldenberg J, Smallfield S. Occupational Therapy Practice Guidelines for Older Adults With Low Vision. The American Journal of Occupational Therapy. 2020 Mar 1;74(2):7402397010p1–23.",22
183,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and hypertension, we recommend that an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker should be the first-line therapy.",Moderate,3,1,2,,0.75,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",23
184,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes, we recommend assessing nutritional status to detect and manage malnutrition.",High,4,1,2,,1,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",24
185,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes who have not achieved glycemic targets with metformin and lifestyle, we recommend that other oral or injectable agents and/or insulin should be added to metformin.",High,4,1,2,,1,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
186,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes, we recommend annual comprehensive eye examinations to detect retinal disease.",High,4,1,2,,1,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
187,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes, we recommend an annual lipid profile.",Low,2,1,2,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
188,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes who are in group 3 (poor health, see Table 3) of the framework and have a previous albumin-to-creatinine ratio of, 30 mg/g, we suggest against additional annual albumin-to-creatinine ratio measurements.",Low,2,2,1,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
189,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 to 85 years with diabetes, we recommend a target blood pressure of 140/90 mmHg to decrease the risk of cardiovascular disease outcomes, stroke, and progressive chronic kidney disease.",Moderate,3,1,2,,0.75,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",6
190,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes who are not on dialysis, we recommend annual screening for chronic kidney disease with an estimated glomerular filtration rate and urine albumin-to-creatinine ratio.",High,4,1,2,,1,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",1
191,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and a history of atherosclerotic cardiovascular disease, we recommend low-dosage aspirin (75 to 162 mg/d) for secondary prevention of cardiovascular disease after careful assessment of bleeding risk and collaborative decision-making with the patient, family, and other caregivers.",Low,2,1,2,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",12
192,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and peripheral neuropathy with balance and gait problems, we suggest referral to physical therapy or a fall management program to reduce the risk of fractures and fracture-related complications.",Very Low,1,2,1,,0.25,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",26
193,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and peripheral neuropathy and/or peripheral vascular disease, we suggest referral to a podiatrist, orthopedist, or vascular specialist for preventive care to reduce the risk of foot ulceration and/or lower extremity amputation.",Low,2,2,1,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",7
194,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and fasting triglycerides > 500 mg/dL, we recommend the use of fish oil and/or fenofibrate to reduce the risk of pancreatitis.",Low,2,1,2,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
195,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes, we suggest that periodic cognitive screening should be performed to identify undiagnosed cognitive impairment.",Low,2,2,1,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
196,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and frailty, we suggest the use of diets rich in protein and energy to prevent malnutrition and weight loss.",Low,2,2,1,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",24
197,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and a diagnosis of cognitive impairment (i.e., mild cognitive impairment or dementia), we suggest that medication regimens should be simplified and glycemic targets tailored (i.e., be more lenient) to improve compliance and prevent treatment-related complications.",Low,2,2,1,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
198,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes, we recommend that outpatient diabetes regimens be designed specifically to minimize hypoglycemia.",Moderate,3,1,2,,0.75,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
199,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and advanced chronic sensorimotor distal polyneuropathy, we suggest treatment regimens that minimize fall risk, such as the minimized use of sedative drugs or drugs that promote orthostatic hypotension and/or hypoglycemia.",Very Low,1,2,1,,0.25,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
200,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes who cannot achieve glycemic targets with lifestyle modification, we suggest avoiding the use of restrictive diets and instead limiting consumption of simple sugars if patients are at risk for malnutrition.",Very Low,1,2,1,,0.25,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
201,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes, we recommend metformin as the initial oral medication chosen for glycemic management in addition to lifestyle management.",Moderate,3,1,2,,0.75,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
202,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older who have prediabetes, we recommend a lifestyle program similar to the Diabetes Prevention Program to delay progression to diabetes.",High,4,1,2,,1,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
203,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older without known diabetes, we recommend fasting plasma glucose and/or HbA1c screening to diagnose diabetes or prediabetes.",High,4,1,2,,1,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
204,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older without diagnosed diabetes, we suggest routine screening for HbA1c during admission to the hospital to ensure detection and treatment where needed.",Low,2,2,1,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
205,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and decreased estimated glomerular filtration rate, we recommend limiting the use or dosage of many classes of diabetes medications to minimize the side effects and complications associated with chronic kidney disease.",Low,2,1,2,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
206,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes who are treated with insulin, we recommend frequent fingerstick glucose monitoring and/or continuous glucose monitoring (to assess glycemia) in addition to HbA1c.",Low,2,1,2,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
207,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and over with diabetes in hospitals or nursing homes, we recommend establishing clear targets for glycemia at 100 to 140 mg/dL (5.55 to 7.77 mmol/L) fasting and 140 to 180 mg/dL (7.77 to 10 mmol/L) postprandial while avoiding hypoglycemia.",Low,2,1,2,,0.5,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
208,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes who are ambulatory, we recommend lifestyle modification as the first-line treatment of hyperglycemia.",High,4,1,2,,1,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
209,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes, we suggest that if statin therapy is inadequate for reaching the low-density lipoprotein cholesterol reduction goal, either because of side effects or because the low-density lipoprotein cholesterol target is elusive, then alternative or additional approaches (such as including ezetimibe or pro-protein convertase subtilisin/kexin type 9 inhibitors) should be initiated.",Very Low,1,2,1,,0.25,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",23
210,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes and a terminal illness or severe comorbidities, we recommend simplifying diabetes management strategies.",Very Low,1,2,1,,0.25,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
211,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older without known diabetes who meet the criteria for pre-diabetes by fasting plasma glucose or HbA1c, we suggest obtaining a 2-hour glucose post-oral glucose tolerance test measurement.",Moderate,3,2,1,,0.75,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",16
212,4584,LeRoith 2019,Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.,Treatment of Diabetes in Older Adults,2019,"European Society of Endocrinology, Gerontological Society of America, Obesity Society",Other: International,Diabetes Mellitus,GRADE,4,4,2,"In patients aged 65 years and older with diabetes, we recommend statin therapy and the use of an annual lipid profile to achieve the recommended levels for reducing absolute cardiovascular disease events and all-cause mortality.",High,4,1,2,,1,"LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(5):1520–74.",23
213,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"After discharge from the hospital, older persons with malnutrition or at risk of malnutrition shall be offered oral nutritional supplements in order to improve dietary intake and body weight, and to lower the risk of functional decline.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
214,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Older persons with malnutrition or at risk of malnutrition and with eating dependency in institutions shall be offered mealtime assistance in order to support adequate dietary intake.,1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
215,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,All older patients admitted to a medical ward at moderate to high risk of delirium shall receive a multi-component non-pharmacological intervention that includes hydration and nutrition management in order to prevent delirium.,1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",11
216,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"For older adults with measured serum or plasma osmolality > 300 mOsm/kg (or calculated osmolarity > 295 mmol/L) and unable to drink, intravenous fluids shall be considered.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",6
217,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"To prevent dehydration in older persons living in residential care, institutions should implement multicomponent strategies across their institutions for all residents.",1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",13
218,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Guiding value for energy intake in older persons is 30 kcal per kg body weight and day and should be individually adjusted with regard to nutritional status, physical activity level, disease status and tolerance.",1-,6,B,2,,0.75,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
219,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,A range of appropriate (i.e. hydrating) drinks should be offered to older people according to their preferences.,1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",13
220,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Nutritional and hydration care for older persons shall be individualized and comprehensive in order to ensure adequate nutritional intake, maintain or improve nutritional status and improve clinical course and quality of life.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
221,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Older persons with malnutrition or at risk of malnutrition should be offered nutritional information and education as part of a comprehensive intervention concept in order to improve awareness of and knowledge about nutritional problems and thus promote adequate dietary intake.,1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
222,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"These strategies should include high availability of drinks, varied choice of drinks, frequent offering of drinks, staff awareness of the need for adequate fluid intake, staff support for drinking and staff support in taking older adults to the toilet quickly and when they need it.",1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",13
223,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Older persons with malnutrition or at risk of malnutrition should be offered fortified food in order to support adequate dietary intake.,1+,7,B,2,,0.875,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
224,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Bioelectrical impedance shall NOT be used to assess hydration status in older adults as it has not been shown to be usefully diagnostic.,1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",9
225,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"For older adults with measured serum or plasma osmolality > 300 mOsm/kg (or calculated osmolarity > 295 mmol/L) who appear unwell, subcutaneous or intravenous fluids shall be offered in parallel with encouraging oral fluid intake.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",6
226,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Older patients with hip fracture shall be offered oral nutritional supplements postoperatively in order to improve dietary intake and reduce the risk of complications.,1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",7
227,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,All older patients hospitalized to have urgent surgery shall receive a multi-component non-pharmacological intervention that includes hydration and nutrition management in order to prevent delirium.,1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",11
228,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Older women should be offered at least 1.6 L of drinks each day, while older men should be offered at least 2.0 L of drinks each day unless there is a clinical condition that requires different approach.",2+,4,B,2,,0.5,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",13
229,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"If weight reduction is considered in obese older persons, dietary interventions shall be combined with physical exercise whenever possible in order to preserve muscle mass.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
230,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Hospitalized older persons with malnutrition or at risk of malnutrition shall be offered ONS, in order to improve dietary intake and body weight, and to lower the risk of complications and readmission.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
231,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Strategies to support adequate fluid intake should be developed including older persons themselves, staff, management and policymakers.",1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",13
232,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Simple signs and tests commonly used to assess for dehydration such as skin turgor, mouth dryness, weight change, urine color or specific gravity, shall NOT be used to assess hydration status in older adults.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",6
233,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Nutritional interventions should be offered to older patients at risk of pressure ulcers in order to prevent the development of pressure ulcers.,1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
234,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Nutritional interventions in geriatric patients after hip fracture and orthopedic surgery shall be part of an individually tailored, multidimensional and multidisciplinary team intervention in order to ensure adequate dietary intake, improve clinical outcomes and maintain quality of life.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",7
235,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"In older adults, volume depletion following fluid and salt loss with vomiting or diarrhea should be assessed by checking a set of signs. A person with at least four of the following seven signs is likely to have moderate to severe volume depletion: confusion, non-fluent speech, extremity weakness, dry mucous membranes, dry tongue, furrowed tongue, sunken eyes.",1-,6,B,2,,0.75,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",6
236,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,An action threshold of directly measured serum osmolality > 300 mOsm/kg should be used to identify low-intake dehydration in older adults.,2++,5,B,2,,0.625,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",6
237,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"In institutional settings, food intake of older persons with malnutrition or at risk of malnutrition shall be supported by a home-like, pleasant dining environment in order to support adequate dietary intake and maintain quality of life.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
238,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Nutritional interventions for older persons should be part of a multimodal and multidisciplinary team intervention in order to support adequate dietary intake, maintain or increase body weight and improve functional and clinical outcome.",1+,7,B,2,,0.875,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
239,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,For enteral nutrition fiber-containing products should be used.,1+,7,B,2,,0.875,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
240,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Protein intake in older persons should be at least 1 g protein per kg body weight and day. The amount should be individually adjusted with regard to nutritional status, physical activity level, disease status and tolerance.",1+,7,B,2,,0.875,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
241,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Older adults with mild/moderate/severe volume depletion should receive isotonic fluids orally, nasogastrically, subcutaneously or intravenously.",1+,7,B,2,,0.875,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",6
242,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"In older adults, volume depletion following excessive blood loss should be assessed using postural pulse change from lying to standing (≥ 30 beats per minute) or severe postural dizziness resulting in inability to stand.",1-,6,B,2,,0.75,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",6
243,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"Oral nutritional supplements offered to an older person with malnutrition or at risk of malnutrition, shall provide at least 400 kcal/day including 30 g or more of protein/day.",1++,8,A,3,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
244,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Nutritional interventions should be offered to malnourished older patients with pressure ulcers to improve healing.,1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
245,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Older persons with malnutrition or at risk of malnutrition and/or their caregivers should be offered individualized nutritional counselling in order to support adequate dietary intake and maintain nutritional status.,1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
246,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"In older patients with hip fracture, postoperative oral nutritional supplements may be combined with perioperative parenteral nutrition in order to improve nutritional intake and reduce the risk of complications.",1+,7,0,1,,0.875,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",7
247,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,"During periods of exercise interventions, adequate amounts of energy and protein should be provided to older persons with malnutrition or at risk of malnutrition in order to maintain body weight and to maintain or improve muscle mass.",1++,8,B,2,,1,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",24
248,4711,Volkert 2019,ESPEN guideline on clinical nutrition and hydration in geriatrics.,Clinical nutrition and hydration in geriatrics,2019,European Society for Clinical Nutrition and Metabolism,Other: Europe,"Hydration, Nutrition & Sarcopenia",SIGN,5,8,3,Where directly measured osmolality is not available then the osmolarity equation (osmolarity = 1.86 × (Na+ + K+) + 1.15 × glucose + urea + 14 (all measured in mmol/L) with an action threshold of > 295mmol/L) should be used to screen for low-intake dehydration in older persons.,1+,7,B,2,,0.875,"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019 Feb;38(1):10–47.",6
249,4716,Nicolle 2019,Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America.,Management of Asymptomatic Bacteriuria,2019,Infectious Diseases Society of America,United States,UTI & Asymptomatic Bacturia,GRADE,5,4,2,"In older persons resident in long-term care facilities, we recommend against screening for or treating asymptomatic bacteriuria.",Moderate,3,Strong,2,,0.75,"Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clinical Infectious Diseases [Internet]. 2019 Mar 21 [cited 2024 Feb 20]; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy1121/5407612",18
250,4716,Nicolle 2019,Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America.,Management of Asymptomatic Bacteriuria,2019,Infectious Diseases Society of America,United States,UTI & Asymptomatic Bacturia,GRADE,5,4,2,"In older patients with functional and/or cognitive impairment with bacteriuria and delirium (acute mental status change, confusion) and without local genitourinary symptoms or other systemic signs of infection (e.g., fever or hemodynamic instability), we recommend assessment for other causes and careful observation rather than antimicrobial treatment.",Very Low,1,Strong,2,,0.25,"Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clinical Infectious Diseases [Internet]. 2019 Mar 21 [cited 2024 Feb 20]; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy1121/5407612",11
251,4716,Nicolle 2019,Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America.,Management of Asymptomatic Bacteriuria,2019,Infectious Diseases Society of America,United States,UTI & Asymptomatic Bacturia,GRADE,5,4,2,"In older patients with functional and/or cognitive impairment with bacteriuria and without local genitourinary symptoms or other systemic signs of infection (fever, hemodynamic instability) who experience a fall, we recommend assessment for other causes and careful observation rather than antimicrobial treatment of bacteriuria.",Very Low,1,Strong,2,,0.25,"Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clinical Infectious Diseases [Internet]. 2019 Mar 21 [cited 2024 Feb 20]; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy1121/5407612",18
252,4716,Nicolle 2019,Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America.,Management of Asymptomatic Bacteriuria,2019,Infectious Diseases Society of America,United States,UTI & Asymptomatic Bacturia,GRADE,5,4,2,"In older, community-dwelling persons who are functionally impaired, we recommend against screening for or treating asymptomatic bacteriuria.",Low,2,Strong,2,,0.5,"Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clinical Infectious Diseases [Internet]. 2019 Mar 21 [cited 2024 Feb 20]; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy1121/5407612",18
253,4868,Marcucci 2019,"Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines.","Interventions to prevent, delay or reverse frailty in older people",2019,,Other: International,Frailty,GRADE,4,4,2,"We suggest implementing interventions basedon tailored care and/or Geriatric Evaluation andManagement (GEM), to prevent or delay the progression of frailty or to reverse frailty.",Low,2,Conditional,1,,0.5,"Marcucci M, Damanti S, Germini F, Apostolo J, Bobrowicz-Campos E, Gwyther H, et al. Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines. BMC Med. 2019 Dec;17(1):193.",14
254,4868,Marcucci 2019,"Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines.","Interventions to prevent, delay or reverse frailty in older people",2019,,Other: International,Frailty,GRADE,4,4,2,"We suggest implementing physical interventions, including physical activity/exercise, nutritional interventions, and a combination of exercise and nutritional interventions, to prevent or delay the progression of frailty or to reverse frailty.",Low,2,Conditional,1,,0.5,"Marcucci M, Damanti S, Germini F, Apostolo J, Bobrowicz-Campos E, Gwyther H, et al. Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines. BMC Med. 2019 Dec;17(1):193.",14
255,4868,Marcucci 2019,"Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines.","Interventions to prevent, delay or reverse frailty in older people",2019,,Other: International,Frailty,GRADE,4,4,2,"We suggest implementing interventions specifically intended to have an impact on frailty in older age, i.e. preventing or delaying the progression of frailty or reversing frailty.",Low,2,Conditional,1,,0.5,"Marcucci M, Damanti S, Germini F, Apostolo J, Bobrowicz-Campos E, Gwyther H, et al. Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines. BMC Med. 2019 Dec;17(1):193.",14
256,4868,Marcucci 2019,"Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines.","Interventions to prevent, delay or reverse frailty in older people",2019,,Other: International,Frailty,GRADE,4,4,2,"We suggest considering interventions to prevent or delay the progression of frailty or to revert frailty, based on cognitive training, alone or in combination with exercise and nutritional supplementation.",Very low,1,Conditional,1,,0.25,"Marcucci M, Damanti S, Germini F, Apostolo J, Bobrowicz-Campos E, Gwyther H, et al. Interventions to prevent, delay or reverse frailty in older people: a journey towards clinical guidelines. BMC Med. 2019 Dec;17(1):193.",14
257,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Older people with frailty should be offered a multi-component physical activity programme (or those with pre-frailty as a preventative component).,Moderate,3,Strong,3,,0.75,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",14
258,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,"A comprehensive care plan for frailty should systematically address polypharmacy, the management of sarcopenia, treatable causes of weight loss, and the causes of fatigue (depression, anaemia, hypotension, hypothyroidism, and Vitamin B12 deficiency).",Very Low,1,Strong,3,,0.25,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",14
259,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Hormone therapy is not recommended for the treatment of frailty.,Very Low,1,CBR,1,,0.25,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",9
260,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,"Health practitioners are strongly encouraged to refer older people with frailty to physical activity programmes with a progressive, resistance-training component.",Moderate,3,Strong,3,,0.75,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",14
261,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,All adults aged 65 years and over should be offered screening for frailty using a validated rapid frailty instrument suitable to the specific setting or context.,Low,2,Strong,3,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",14
262,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Health practitioners may offer nutritional/protein supplementation paired with physical activity prescription.,Low,2,Conditional,2,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",24
263,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Vitamin D supplementation is not recommended for the treatment of frailty unless Vitamin D deficiency is present.,Very Low,1,CBR,1,,0.25,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",9
264,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Protein/caloric supplementation can be considered for persons with frailty when weight loss or undernutrition has been diagnosed.,Very Low,1,Conditional,2,,0.25,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",24
265,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Cognitive or problem-solving therapy is not systematically recommended for the treatment of frailty.,Very Low,1,CBR,1,,0.25,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",9
266,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,All persons with frailty may be offered social support as needed to address unmet needs and encourage adherence to the Comprehensive Management Plan.,Very Low,1,Strong,3,,0.25,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",14
267,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Pharmacological treatment as presently available is not recommended therapy for the treatment of frailty.,Very Low,1,CBR,1,,0.25,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",9
268,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Clinical assessment of frailty should be performed for all older adults screening as positive for frailty or pre-frailty.,Low,2,Strong,3,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",14
269,4879,Dent 2019,Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management.,Identification and management of physical frailty,2019,International Conference of Frailty and Sarcopenia Research,Other: International,Frailty,Other: Modified GRADE,4,4,3,Persons with frailty can be referred to home-based training.,Low,2,Conditional,2,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Woodhouse L, Rodríguez-Mañas L, Fried LP, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. The Journal of nutrition, health and aging. 2019 Nov;23(9):771–87.",14
270,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,Statin treatment is recommended as the first drug of choice to reduce CVD risk in high-risk individuals with hypertriglyceridaemia (TG levels > 2.3 mmol/L (> 200 mg/dL)).,B,2,I,3,,0.666666666666667,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",23
271,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,"In secondary prevention for patients at very-high-risk, and LDL-C reduction of ≥ 50 % from baseline and an LDL-C goal of < 1.4 mmol/L (< 55 mg/dL) are recommended.",A,3,I,3,,1,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",23
272,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,Treatment with statins is recommended for older people with atherosclerotic cardiovascular disease in the same way as for younger patients.,A,3,I,3,,1,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",23
273,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,"For secondary prevention, patients at very-high-risk not achieving their goal on a maximum tolerated dose of a statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended.",A,3,I,3,,1,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",23
274,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,"In patients at high risk, an LDL-C reduction of ≥ 50 % from baseline and an LDL-C goal of < 1.8 mmol/L (< 70 mg/dL) are recommended.",A,3,I,3,,1,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",23
275,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,"Initiation of stating treatment for primary prevention in older people aged > 75 years may be considered, if at high-risk or above.",B,2,IIb,1,,0.666666666666667,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",20
276,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,"Treatment with statins is recommended for primary prevention, according to the level of risk, in older people aged  > 65 and ≤ 75 years.",A,3,I,3,,1,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",23
277,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,"In individuals at moderate risk, an LDL-C goal of < 2.6 mmol/L (< 100 mg/dL) should be considered.",A,3,IIa,2,,1,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",23
278,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,"In high-risk (or above) patients withtriglyceride levels between 1.5-5.6 mmol/L (135-499 mg/dL) despite statin treatment, n-3 PUFAs (icosapent ethyl 2x2 g/day) should be considered in combination with a statin.",B,2,IIa,2,,0.666666666666667,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",23
279,4917,Authors/TaskForceMembers 2019,2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.,Management of dyslipidaemias: Lipidmodification to reduce cardiovascular risk,2019,"European Society of Cardiology, European Atherosclerosis Society",Other: Europe,Dyslipidemia,Other: European Society of Cardiology,4,3,3,Arterial (carotid and/or femoral) plaque burden on arterial ultrasonography should be considered as a risk modifier in individuals at low or moderate risk.,B,2,IIa,2,,0.666666666666667,"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.",15
280,5197,Bannuru 2019,"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.","Non-surgical management of knee, hip, and polyarticular osteoarthritis",2019,Osteoarthritis Research Society International,Other: International,Osteoarthritis,GRADE,4,4,2,NSAIDs were not recommended in knee osteoarthritis patients with frailty.,Moderate,3,Conditional,1,,0.75,"Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019 Nov;27(11):1578–89.",9
281,5197,Bannuru 2019,"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.","Non-surgical management of knee, hip, and polyarticular osteoarthritis",2019,Osteoarthritis Research Society International,Other: International,Osteoarthritis,GRADE,4,4,2,Aquatic exercise was not recommended for knee osteoarthritis patients who suffered from frailty due to potential risk of accidental injury.,Low,2,Conditional,1,,0.5,"Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019 Nov;27(11):1578–89.",9
282,5197,Bannuru 2019,"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.","Non-surgical management of knee, hip, and polyarticular osteoarthritis",2019,Osteoarthritis Research Society International,Other: International,Osteoarthritis,GRADE,4,4,2,Topical NSAIDs were also strongly recommended for Knee osteoarthritis patients with gastrointestinal or cardiovascular comorbidities and for patients with frailty.,Moderate,3,Strong,2,,0.75,"Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019 Nov;27(11):1578–89.",7
283,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,"A Computed tomography (CT) brain scan should not be used routinely but should be considered in patients presenting to hospital with delirium in the presence of:
- new focal neurological signs
- a reduced level of consciousness (not adequately explained by another cause)
- a history of recent falls
- a head injury (patients of any age)
- anticoagulation therapy",3,2,Should,2,,0.25,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
284,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,"Healthcare professionals should be aware that older people may have pre-existing cognitive impairment which may have been undetected, or exacerbated in the context of delirium. Appropriate cognitive and functional assessment should be considered. Timing of this assessment must take into account persistent delirium.",2++,5,Should,2,,0.625,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
285,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,The use of earplugs should be considered as part of a sleep-promotion strategy in intensive care.,2++,5,Should,2,,0.625,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
286,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,"For intensive care unit settings, CAM-ICU or ICDSC should be considered to help identify patients with probable delirium.",2+,4,Could,1,,0.5,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
287,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,"The following components should be considered as part of a package of care for patients at risk of developing delirium:
- orientation and ensuring patients have their glasses and hearing aids
- promoting sleep hygiene
- early mobilisation•pain control
- prevention, early identification and treatment of postoperative complications
- maintaining optimal hydration and nutrition
- regulation of bladder and bowel function
- provision of supplementary oxygen, if appropriate",1++,8,Should,2,,1,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
288,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,All patients at risk of delirium should have a medication review conducted by an experienced healthcare professional.,1++,8,Should,2,,1,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
289,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,"Depth of anaesthesia should be monitored in all patients aged over 60 years under general anaesthesia for surgery expected to last for more than one hour, with the aim of avoiding excessively deep anaesthesia.",1++,8,Should,2,,1,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
290,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,In patients who have experienced delirium in the intensive care unit (ICU) consideration should be given to follow up for psychological sequelae including cognitive impairment.,2+,4,Should,2,,0.5,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
291,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,The 4AT tool should be used for identifying patients with probable delirium in emergency department and acute hospital settings.,2++,5,Should,2,,0.625,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
292,5578,Davis 2019,The Scottish Intercollegiate Guidelines Network: risk reduction and management of delirium.,Risk reduction and management of delirium,2019,Scottish Intercollegiate Guidelines Network,UK,Delirium & Dementia,SIGN,5,8,2,Electroencephalogram should be considered when there is a suspicion of epileptic activity or non convulsive status epilepticus as a cause of a patient’s delirium.,3,2,Should,2,,0.25,Risk reduction and management of delirium: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2019.,11
293,5758,Reeve 2019,Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.,Deprescribing cholinesterase inhibitors and memantine in dementia,2019,National Health and Medical Research Council,Australia,ADR & Deprescribing,GRADE,6,4,2,"For individuals taking a Cholinesterase Inhibitors for an indication other than Alzheimer disease, dementia of Parkinson disease, Lewy body dementia or vascular dementia, we recommend trial discontinuation.",Low,2,Strong,2,,0.5,"Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. Vol. 210. Sydney: : The University of Sydney; 2018.",25
294,5758,Reeve 2019,Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.,Deprescribing cholinesterase inhibitors and memantine in dementia,2019,National Health and Medical Research Council,Australia,ADR & Deprescribing,GRADE,6,4,2,"For individuals taking memantine for Alzheimer disease, dementia of Parkinson disease or Lewy body dementia for > 12 months, we recommend trial discontinuation if:
- cognition and/or function has significantly worsened over the past 6 months (or less, as per the individual)
- no benefit (improvement, stabilisation or decreased rate of decline) was seen at any time during treatment
- the individual has severe/end-stage dementia (characteristics of this stage include dependence in most activities of daily living, inability to respond to their environment and/or limited life expectancy)",Very Low,1,Strong,2,,0.25,"Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. Vol. 210. Sydney: : The University of Sydney; 2018.",25
295,5758,Reeve 2019,Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.,Deprescribing cholinesterase inhibitors and memantine in dementia,2019,National Health and Medical Research Council,Australia,ADR & Deprescribing,GRADE,6,4,2,"For individuals taking a Cholinesterase Inhibitors for Alzheimer disease, dementia of Parkinson disease, Lewy body dementia or vascular dementia for > 12 months, we recommend trial discontinuation if:
- cognition and/or function has significantly worsened over the past 6 months (or less, as per the individual);
- no benefit (improvement, stabilisation or decreased rate of decline) was seen at any time during treatment; or
- the individual has severe or end-stage dementia (characteristics include dependence in most activities of daily living, inability to respond to environment and/or limited life expectancy)",Low,2,Strong,2,,0.5,"Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. Vol. 210. Sydney: : The University of Sydney; 2018.",25
296,5758,Reeve 2019,Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.,Deprescribing cholinesterase inhibitors and memantine in dementia,2019,National Health and Medical Research Council,Australia,ADR & Deprescribing,GRADE,6,4,2,"For individuals taking memantine for indications other than Alzheimer disease, dementia of Parkinson disease or Lewy body dementia, we recommend trial discontinuation.",Very Low,1,Strong,2,,0.25,"Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin PJ, et al. Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine. Vol. 210. Sydney: : The University of Sydney; 2018.",25
297,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Barbiturates: Amobarbital, Butabarbital, Butalbital, Mephobarbital, Pentobarbital, Phenobarbital, Secobarbital.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
298,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Amiodarone as first-line therapy for atrial fibrillation unless patient has heart failure or substantial left ventricular hypertrophy.,High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
299,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Colchicine dose in creatinine clearance < 30 mL/min; monitor for adverse effects.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
300,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Disopyramide.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
301,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Digoxin as first-line therapy for heart failure.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
302,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Benzodiazepines that are short and intermediate acting (Alprazolam, Estazolam, Lorazepam, Oxazepam, Temazepam, Triazolam) and long acting (Chlordiazepoxide (alone or in combination with amitriptyline or clidinium), Clonazepam, Clorazepate, Diazepam, Flurazepam, Quazepam).",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
303,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"If used for atrial fibrillation or heart failure, avoid Digoxin dosages > 0.125 mg/day.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
304,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Dronedarone in individuals with permanent atrial fibrillation or severe or recently decompensated heart failure.,High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
305,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Nifedipine, immediate release.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
306,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Peripheral alpha-1 blockers for treatment of hypertension: Doxazosin, Prazosin, Terazosin.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
307,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Antidepressants, alone or in combination: Amitriptyline, Amoxapine ,Clomipramine, Desipramine, Doxepin > 6 mg/day, Imipramine, Nortriptyline, Paroxetine, Protriptyline, Trimipramine.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
308,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid antipsychotics, first (conventional) and second (atypical) generation, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",3
309,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid other central nervous system (CNS) alpha-agonists: Guanabenz, Guanfacine, Methyldopa, Reserpine (> 0.1 mg/day).",Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
310,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Central alpha-agonist as first-line antihypertensive: Clonidin.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
311,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Digoxin as firstline therapy for atrial fibrillation.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
312,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Probenecid in creatinine clearance < 30 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
313,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Dronedarone in heart failure.,High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
314,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid proton-pump inhibitors scheduled use for > 8 weeks unless for high-risk patients (e.g., oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (e.g., because of failure of drug discontinuation trial or H2-receptor antagonists).",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
315,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Mineral oil, given orally.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
316,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid strongly anticholinergic drugs, except, antimuscarinics for urinary incontinence in Lower urinary tract, symptoms, benign prostatic hyperplasia in men.",Moderate,2,Strong,2,men,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",18
317,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Use Aspirin for primary prevention of cardiovascular disease and colorectal cancer with caution in adults ≥ 70 years.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
318,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Use Dabigatran, Rivaroxaban with caution for treatment of venous thromboembolism or atrial fibrillation in adults ≥ 75 years.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
319,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Use Prasugrel with caution in adults ≥ 75 years.,Moderate,2,Weak,1,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",20
320,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Use Antipsychotics, Carbamazepine, Diuretics, Mirtazapine, Oxcarbazepine, serotonin and norepinephrine reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), Tricyclic antidepressants (TCA) and Tramadol with caution.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
321,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Use Dextromethorphan/ quinidine with caution.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
322,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Use Trimethoprim-sulfamethoxazole with caution in patients on angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and decreased creatinine clearance.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
323,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid routine use of renin–angiotensin system (RAS) inhibitors (Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), aliskiren) or potassium-sparing diuretics (amiloride, triamterene) combined with another RAS inhibitor (ACEIs, ARBs, aliskiren) in those with chronic kidney disease stage 3a or higher.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
324,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Opioids in combination with Benzodiazepines.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
325,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid opioids in combination with gabapentin, pregabalin; exceptions are when transitioning from opioid therapy to gabapentin or pregabalin, or when using gabapentinoids to reduce opioid dose, although caution should be used in all circumstances.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
326,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid anticholinergic in combination with anticholinergic drugs; minimize number of anticholinergic drugs.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
327,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Minimize the number of CNS-active drugs and avoid any combination of three or more of these CNS-active drugs: Antidepressants (Tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), and serotonin and norepinephrine reuptake inhibitors (SNRI)), Antipsychotics, Antiepileptics, Benzodiazepines and nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”), Opioids.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
328,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Minimize the number of CNS-active drugs and avoid any combination of three or more CNS-active drugs, Combinations including benzodiazepines and nonbenzodiazepine benzodiazepine receptor agonist hypnotics or opioids.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
329,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Antiparkinsonian agents: Benztropine (oral) and Trihexyphenidyl.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
330,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Metoclopramid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
331,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Corticosteroids, oral or parenteral in combination with NSAID; if not possible, provide gastrointestinal protection.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
332,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Lithium in combination with loop diuretics; monitor lithium concentrations.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
333,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid long acting Sulfonylureas: Chlorpropamide, Glimepiride, Glyburide (also known as glibenclamide).",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
334,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Peripheral α-1 blockers in combination with loop diuretics in older women, unless conditions warrant both drugs.",Moderate,2,Strong,2,women,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",18
335,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Megestrol.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
336,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid phenytoin in combination with Trimethoprim-sulfamethoxazole.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
337,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Meperidine.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
338,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid chronic use of oral non-cyclooxygenase-selective NSAIDs (unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)): Aspirin > 325 mg/day, Diclofenac, Diflunisal, Etodolac, Fenoprofen, Ibuprofen, Ketoprofen, Meclofenamate, Mefenamic acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Piroxicam, Sulindac, Tolmetin.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
339,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Indomethacin, Ketorolac (includes parenteral).",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
340,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Skeletal muscle relaxants: Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
341,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Estrogen oral and transdermal (excludes intravaginal estrogen) in Urinary incontinence (all types) in women.,High,3,Strong,2,women,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",18
342,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid NSAIDs (non-COX and COX selective, oral and parenteral, nonacetylated Salicylates) in Chronic kidney disease stage 4 or higher (creatinine clearance < 30 mL/min).",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
343,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Aspirin > 325 mg/day and Non-COX-2-selective NSAIDs unless other alternatives are not effective and patient can take gastroprotective agent (ie, proton-pump inhibitor or misoprostol) in history of gastric or duodenal ulcers.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
344,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Antiemetics (Metoclopramide, Prochlorperazine, Promethazine) and all antipsychotics (except quetiapine, clozapine, pimavanserin) in Parkinson‘s Disease.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
345,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Antidepressants unless safer alternatives are not avaiable: Tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI).",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
346,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Antipsychotics, Benzodiazepines, Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (Eszopiclone Zaleplon Zolpidem), Antidepressants (Tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI)) unless safer alternatives are not available in people with a history of falls or fractures.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
347,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid opioids, except for pain management in the setting of severe acute pain (e.g., recent fractures or joint replacement) in people with a history of falls or fractures.",Moderate,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
348,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid antiepileptics unless safer alternatives are not available and except for seizure and mood disorders in people with a history of falls or fractures.,High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",3
349,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Anticholinergics in Dementia or Cognitive Impairment: Benzodiazepines Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (Eszopiclone Zaleplon Zolpidem), Antipsychotics (chronic and as-needed use).",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",3
350,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid H2-receptor antagonists in Delirium: Cimetidine, Famotidine, Nizatidine, Ranitidine.",Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",3
351,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid anticholinergics in Delirium: Antipsychotics, Benzodiazepines, Corticosteroids (oral and parenteral), Meperidine, Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (eszopiclone, zaleplon, zolpidem).",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",3
352,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin).",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",16
353,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Antipsychotics: Chlorpromazine, Thioridazine, Olanzapine in Syncope.",High,3,Weak,1,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
354,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Nonselective peripheral alpha-1 blockers (i.e. doxazosin, prazosin, terazosin) in Syncope.",High,3,Weak,1,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
355,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Acetylcholine-Esterase Inhibitors in Syncope.,High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
356,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Meprobamate.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
357,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Thiazolidinediones (pioglitazone, Rosiglitazone) in heart failure.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
358,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Use COX-2-Inhibitors with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
359,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Use NSAIDs with caution in patients with heart failure who are asymptomatic; avoid in patients with symptomatic heart failure.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
360,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Nondihydropyridine calcium channel blockers (CCB) (diltiazem, verapamil) in heart failure with reduced ejection fraction.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
361,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Peripheral alpha-1 blockers (Doxazosin, Prazosin, Terazosin) in Urinary incontinence (all types) in women.",Moderate,2,Strong,2,women,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",18
362,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid First-generation antihistamines: Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyproheptadine, Dexbrompheniramine, Dexchlorpheniramine, Dimenhydrinate, Diphenhydramine (oral), Doxylamine, Hydroxyzine, Meclizine, Promethazine, Pyrilamine and Triprolidine.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
363,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Cilostazol in Heart Failure.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
364,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid desmopressin for treatment of nocturia or nocturnal polyuria.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
365,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid tertiary tricyclic antidepressants in Syncope.,High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
366,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Theophylline in combination with Cimetidine.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
367,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Lithium in combination with angiotensin-converting enzyme inhibitor; monitor lithium concentrations.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
368,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Theophylline in combination with Ciprofloxacin.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
369,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Dabigatran in creatinine clearance < 30 mL/min; dose adjustment advised when creatinine clearance > 30 mL/min in the presence of drug-drug interactions.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
370,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Desiccated thyroid.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
371,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Dofetilide dose if creatinine clearance 20-59 mL/min. Avoid if creatinine clearance < 20 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
372,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Edoxaban dose if creatinine clearance 15-50 mL/min. Avoid if creatinine clearance < 15 or > 95 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
373,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”): Eszopiclone, Zaleplon, Zolpidem.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
374,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Enoxaparin dose in creatinine clearance < 30 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
375,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Fondaparinux in creatinine clearance < 30 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
376,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid growth hormone, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deficiency due to an established etiology.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
377,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Cimetidine dose in creatinine clearance < 50 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
378,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid systemic estrogen (e.g., oral and topical patch) with or without progestins.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",18
379,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce rivaroxaban dose in nonvalvular atrial fibrillation if creatinine clearance 15-50 mL/min and avoid if creatinine clearance < 15 mL/min. Avoid rivaroxaban in venous thromboembolism (VTE) treatment and for VTE prophylaxis with hip or knee replacement if creatinine clearance < 30 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",12
380,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Spironolactone in creatinine clearance < 30 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
381,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Androgens, unless indicated for confirmed hypogonadism with clinical symptoms: Methyltestosterone, Testosterone.",Moderate,2,Weak,1,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
382,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Triamterene in creatinine clearance < 30 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
383,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid  Ergoloid mesylates (dehydrogenated ergot alkaloids): Isoxsuprine.,High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
384,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Duloxetine in creatinine clearance < 30 mL/min.,Moderate,2,Weak,1,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
385,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Gabapentine dose in creatinine clearance < 60 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
386,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Levetiracetam dose in creatinine clearance ≤ 80 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
387,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Pregabalin dose in creatinine clearance < 60 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
388,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Nitrofurantoin in individuals with creatinine clearance < 30 mL/min or for long-term suppression.,Low,1,Strong,2,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
389,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin).",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
390,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Apixaban in creatinine clearance < 25 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
391,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Famotidine dose in creatinine clearance < 50 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
392,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Avoid Amilorid in creatinine clearance < 30 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
393,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Warfarin in combination with amiodarone when possible; if used together, monitor INR closely.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
394,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Warfarin in combination with ciprofloxcin when possible; if used together, monitor INR closely.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
395,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Warfarin in combination with Macrolides (excluding azithromycin) when possible; if used together, monitor INR closely.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
396,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Warfarin in combination with Trimethoprim-sulfamethoxazole when possible; if used together, monitor INR closely.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
397,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Ranitidine dose in creatinine clearance < 50 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
398,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Warfarin in combination with NSAIDs when possible; if used together, monitor monitor closely for bleeding.",High,3,Strong,2,,1,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
399,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Nizatidine dose in creatinine clearance < 50 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
400,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Vaginal cream or vaginal tablets are acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms.",Moderate,2,Weak,1,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",18
401,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce immediate release Tramadol dose and avoid extended release Tramadol in creatinine clearance < 30 mL/min.,Low,1,Weak,1,,0.333333333333333,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
402,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Reduce Trimethoprimsulfamethoxazole dose if creatinine clearance 15-29 mL/min Avoid if creatinine clearance < 15 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
403,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,Ciprofloxacine doses used to treat common infections typically require reduction when creatinine clearance < 30 mL/min.,Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",4
404,5840,Bythe2019AmericanGeriatricsSocietyBeersCriteriaRUpdateExpertPanel 2019,American Geriatrics Society 2019 Updated AGS Beers Criteria R for Potentially Inappropriate Medication Use in Older Adults.,AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults,2019,American Geriatrics Society,United States,ADR & Deprescribing,Other: modified GRADE,4,3,2,"Avoid Antispasmodics: Atropine (excludes ophthalmic), Belladonna alkaloids, Clidinium-chlordiazepoxide, Dicyclomine Homatropine (excludes opthalmic), Hyoscyamine, Methscopolamine, Propantheline and Scopolamine.",Moderate,2,Strong,2,,0.666666666666667,"2019 American Geriatrics Society Beers Criteria® Update Expert Panel, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2019;67(4):674–94.",10
405,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,"Older adults aged 65 years and older should be screened for sarcopenia annually, or after the occurrence of major health events.",Low,2,Weak,1,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",14
406,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,"Screening for sarcopenia can be performed using gait speed, or with the SARC-F questionnaire.",Low,2,Weak,1,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",14
407,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,Individuals screened as positive for sarcopenia should be referred for further assessment to confirm the presence of the disease.,Low,2,Weak,1,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",14
408,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,Walking speed or grip strength should be used to determine low levels of muscle strength and physical performance respectively when diagnosing sarcopenia.,Moderate,3,Strong,2,,0.75,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",14
409,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,Dual-energy x-ray absorptiometry should be used to determine low lean mass when diagnosing sarcopenia.,Low,2,Weak,1,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",14
410,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,"It is recommended that health practitioners use an objective measurement tool for the diagnosis of Sarcopenia, utilising any of the published consensus definitions.",Moderate,3,Weak,1,,0.75,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",14
411,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,"In patients with sarcopenia, prescription of resistance-based training may be effective to improve lean mass, strength and physical function.",Moderate,3,Strong,2,,0.75,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",14
412,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,We recommend clinicians consider protein supplementation/a protein rich diet for older adults with sarcopenia.,Low,2,Weak,1,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",24
413,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,Clinicians may also consider discussing with patients the importance of adequate calorie and protein intake.,Very Low,1,Weak,1,,0.25,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",24
414,6456,Dent 2018,"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management.","Sarcopenia: Screening, Diagnosis and Management",2018,International Conference on Sarcopenia and Frailty Research,Other: International,"Hydration, Nutrition & Sarcopenia",GRADE,4,4,2,Nutritional (protein) intervention should be combined with a physical activity intervention.,Low,2,Weak,1,,0.5,"Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. The Journal of nutrition, health and aging. 2018 Dec;22(10):1148–61.",24
415,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"In atrial fibrillation patients requiring oral anticoagulation presenting with an acute coronary syndrome (ACS), undergoing percutaneous coronary intervention (PCI)/stenting, where bleeding risk is low (HAS-BLED 0-2) relative to risk for ACS or stent thrombosis, we suggest triple therapy for 6 months, followed by dual therapy with oral anticoagulation plus single antiplatelet (preferably clopidogrel) until 12 months, following which oral anticoagulation monotherapy can be used.",Low,2,Weak,1,,0.5,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",15
416,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"In atrial fibrillation patients requiring oral anticoagulation undergoing elective percutaneous coronary intervention (PCI)/stenting, where bleeding risk is high (HAS-BLED ≥ 3), we suggest triple therapy for 1 month, followed by dual therapy with oral anticoagulation plus single antiplatelet (preferably clopidogrel) for 6 months, following which oral anticoagulation monotherapy can be used.",Low,2,Weak,1,,0.5,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",15
417,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"In patients in whom sinus rhythm has been restored, we suggest that long-term anticoagulation should be based on the patient’s CHA2DS2-VASc thromboembolic risk profile, regardless of whether sinus rhythm has been restored via ablation, cardioversion (even spontaneous), or other means.",Low,2,Weak,1,,0.5,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",15
418,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"Subsequent to this initial step, for patients with atrial fibrillation, including those with paroxysmal atrial fibrillation, we recommend stroke prevention should be offered to those atrial fibrillation patients with one or more non-sex CHA2DS2-VASc stroke risk factors (score of ≥ 1 in a male or ≥ 2 in a female).",Moderate,3,Strong,2,,0.75,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",15
419,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"For moderate chronic kidney disease (Stage III, creatinine clearance 30-59 mL/min), we suggest oral anticoagulation in patients with a CHA2DS2-VASc ≥ 2 with label-adjusted novel oral anticoagulant (NOAC) or dose-adjusted Vitamin K antagonists.",Very Low,1,Weak,1,,0.25,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",4
420,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"For patients with atrial fibrillation, we recommend use of the HAS-BLED score to address modifiable bleeding risk factors in all atrial fibrillation patients. Those potentially at high risk (HAS-BLED score ≥ 3) warrant more frequent and regular reviews or follow-up.",Moderate,3,Strong,2,,0.75,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",15
421,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"In atrial fibrillation patients requiring oral anticoagulation undergoing elective percutaneous coronary intervention (PCI)/stenting, where bleeding risk is low (HAS-BLED 0-2) relative to risk for recurrent acute coronary syndrome (ACS) and/or stent thrombosis, we suggest triple therapy for 1-3 months, followed by dual therapy with oral anticoagulation plus single antiplatelet (preferably clopidogrel) until 12 months, following which oral anticoagulation monotherapy can be used.",Low,2,Weak,1,,0.5,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",15
422,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"For patients with atrial fibrillation, including those with paroxysmal atrial fibrillation, stroke risk should be assessed using a risk factor based approach, rather than an categorization into low, moderate/high risk strata. We recommend use of the CHA2DS2-VASc as a simple clinical based stroke risk score to initially identify ‘low stroke risk’ patients who should not be offered antithrombotic therapy to prevent stroke and reduce mortality.",Moderate,3,Strong,2,,0.75,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",15
423,6692,Lip 2018,Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.,Antithrombotic Therapy for Atrial Fibrillation,2018,American College of Chest Physicians,United States,Atrial Fibrillation,GRADE,6,4,2,"In atrial fibrillation patients requiring oral anticoagulation presenting with an acute coronary syndrome (ACS), undergoing percutaneous coronary intervention (PCI)/stenting, where bleeding risk is high (HAS-BLED ≥ 3), we suggest triple therapy for 1-3 months, followed by dual therapy with oral anticoagulation plus single antiplatelet (preferably clopidogrel) up to 12 months, following which oral anticoagulation monotherapy can be used.",Low,2,Weak,1,,0.5,"Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.",15
424,6736,Devlin 2018,"Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.","Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU",2018,"American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Clinical Pharmacy, American Delirium Society, Australian College of Criti-cal Care Nurses, Canadian Critical Care Society, Eastern Association for the Surgery of Trauma, European Delirium Association, European Federation of Critical Care Nursing Associations, Neurocritical Care Society, and Society of Critical Care Anesthesiologists.",Other: International,Perioperative Management,GRADE,6,4,2,We suggest not using haloperidol or an atypical antipsychotic to treat subsyndromal delirium in critically ill adults.,Low,2,Conditional,1,,0.5,"Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical Care Medicine. 2018 Sep;46(9):e825–73.",3
425,6736,Devlin 2018,"Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.","Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU",2018,"American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Clinical Pharmacy, American Delirium Society, Australian College of Criti-cal Care Nurses, Canadian Critical Care Society, Eastern Association for the Surgery of Trauma, European Delirium Association, European Federation of Critical Care Nursing Associations, Neurocritical Care Society, and Society of Critical Care Anesthesiologists.",Other: International,Perioperative Management,GRADE,6,4,2,"We suggest using a multicomponent, nonpharmacologic intervention that is focused on (but not limited to) reducing modifiable risk factors for delirium, improving cognition, and optimizing sleep, mobility, hearing, and vision in critically ill adults.
Remarks: These multicomponent interventions include (but are not limited to) strategies to reduce or shorten delirium (e.g., reorientation, cognitive stimulation, use of clocks), improve sleep (e.g., minimizing light and noise), improve wakefulness (i.e., reduced sedation), reduce immobility (e.g., early rehabilitation/mobilization), and reduce hearing and/or visual impairment (e.g., enable use of devices such as hearing aids or eye glasses).",Low,2,Conditional,1,,0.5,"Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical Care Medicine. 2018 Sep;46(9):e825–73.",11
426,6736,Devlin 2018,"Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.","Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU",2018,"American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Clinical Pharmacy, American Delirium Society, Australian College of Criti-cal Care Nurses, Canadian Critical Care Society, Eastern Association for the Surgery of Trauma, European Delirium Association, European Federation of Critical Care Nursing Associations, Neurocritical Care Society, and Society of Critical Care Anesthesiologists.",Other: International,Perioperative Management,GRADE,6,4,2,We suggest not using bright light therapy to reduce delirium in critically ill adults.,Moderate,3,Conditional,1,,0.75,"Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical Care Medicine. 2018 Sep;46(9):e825–73.",3
427,6736,Devlin 2018,"Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.","Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU",2018,"American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Clinical Pharmacy, American Delirium Society, Australian College of Criti-cal Care Nurses, Canadian Critical Care Society, Eastern Association for the Surgery of Trauma, European Delirium Association, European Federation of Critical Care Nursing Associations, Neurocritical Care Society, and Society of Critical Care Anesthesiologists.",Other: International,Perioperative Management,GRADE,6,4,2,We suggest using dexmedetomidine for delirium in mechanically ventilated adults where agitation is precluding weaning/extubation.,Low,2,Conditional,1,,0.5,"Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical Care Medicine. 2018 Sep;46(9):e825–73.",3
428,6736,Devlin 2018,"Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.","Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU",2018,"American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Clinical Pharmacy, American Delirium Society, Australian College of Criti-cal Care Nurses, Canadian Critical Care Society, Eastern Association for the Surgery of Trauma, European Delirium Association, European Federation of Critical Care Nursing Associations, Neurocritical Care Society, and Society of Critical Care Anesthesiologists.",Other: International,Perioperative Management,GRADE,6,4,2,"We suggest not using haloperidol, an atypical antipsychotic, dexmedetomidine, a HMG-CoA reductase inhibitor (i.e., statin), or ketamine to prevent delirium in all critically ill adults.",Low,2,Conditional,1,,0.5,"Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical Care Medicine. 2018 Sep;46(9):e825–73.",3
429,6736,Devlin 2018,"Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.","Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU",2018,"American Association of Critical-Care Nurses, American College of Chest Physicians, American College of Clinical Pharmacy, American Delirium Society, Australian College of Criti-cal Care Nurses, Canadian Critical Care Society, Eastern Association for the Surgery of Trauma, European Delirium Association, European Federation of Critical Care Nursing Associations, Neurocritical Care Society, and Society of Critical Care Anesthesiologists.",Other: International,Perioperative Management,GRADE,6,4,2,"We suggest not routinely using haloperidol, an atypical antipsychotic, or a HMG-CoA reductase inhibitor (i.e., a statin) to treat delirium.",Low,2,Conditional,1,,0.5,"Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical Care Medicine. 2018 Sep;46(9):e825–73.",3
430,6887,USPreventiveServicesTaskForce 2018,Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.,Screening for Osteoporosis to Prevent Fractures,2018,US Preventive Services Task Force,United States,Fractures & Osteoporosis,Other: custom,5,3,3,The US Preventive Services Task Force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.,Moderate,2,B,2,women,0.666666666666667,"US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Jun 26;319(24):2521.",7
431,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Offer a cholinesterase inhibitor and consider adding memantine for people with moderate Alzheimer’s disease.,High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",25
432,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"If dementia is still suspected after initial assessment:
- Conduct a physical examination
- Undertake appropriate blood and urine tests to exclude reversible causes of cognitive decline
- Use cognitive testing: use a validated brief structured cognitive instrument such as the 10-point cognitive screener (10-CS), the 6-item cognitive impairment test (6CIT), the 6-item screener, the Memory Impairment Screen (MIS), the Mini-Cog, or the Test Your Memory (TYM)",High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",2
433,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Do not offer acupuncture to treat dementia.,Low,2,Should,2,,0.5,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",9
434,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Offer a cholinesterase inhibitor and memantine for people with severe Alzheimer’s disease.,High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",25
435,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"Do not offer ginseng, Vitamin E supplements, or herbal formulations to treat dementia.",Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",9
436,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Do not offer cognitive training to treat mild to moderate Alzheimer’s disease.,Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",9
437,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Consider cognitive rehabilitation or occupational therapy to support functional ability in people living with mild to moderate dementia.,Moderate,3,Consider,1,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",8
438,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Do not offer cholinesterase inhibitors or memantine to people with frontotemporal dementia.,Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",25
439,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"When using antipsychotics:
- Use the lowest effective dose and for the shortest possible time
- Reassess the person at least every six weeks to check whether they still need medication",High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",21
440,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"For people who are in hospital and have cognitive impairment with an unknown cause, consider using one of the following to find out whether they have delirium or delirium superimposed on dementia, compared with dementia alone:
- The long Confusion Assessment Method (CAM)
- The Observational Scale of Level of Arousal (OSLA)",Moderate,3,Consider,1,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",11
441,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"At each care review, offer people the chance to review and change any advance statements and decisions they have made.",High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",20
442,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"Before starting antipsychotics, discuss the benefits and harms with the person and their family members or carers (as appropriate).",High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",21
443,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Offer group cognitive stimulation therapy to people living with mild to moderate dementia.,Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",8
444,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Do not rule out dementia solely because the person has a normal score on a cognitive instrument.,High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",2
445,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"Consider cholinesterase inhibitors or memantine for people with vascular dementia only if they have suspected comorbid Alzheimer’s disease, Parkinson’s disease dementia, or dementia with Lewy bodies.",High,4,Consider,1,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",25
446,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"For people living with dementia who are in pain, consider using a stepwise treatment protocol that balances pain management and potential adverse events.",Moderate,3,Consider,1,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",2
447,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"Consider using a structured observational pain assessment tool:
- Alongside self reported pain and standard clinical assessment for people living with moderate to severe dementia
- Alongside standard clinical assessment for people living with dementia who are unable to self report pain",Moderate,3,Consider,1,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",2
448,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"For people living with dementia who have sleep problems, consider a personalised multicomponent sleep management approach that includes sleep hygiene education, exposure to daylight, exercise, and personalised activities.",High,4,Consider,1,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",8
449,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Do not offer melatonin to manage insomnia in people living with Alzheimer’s disease.,Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",9
450,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"Offer antipsychotics for people living with dementia only if they are:
- At risk of harming themselves or others
- Experiencing agitation, hallucinations, or delusions that are causing them severe distress",High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",21
451,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Do not offer valproate to manage agitation or aggression in people living with dementia unless it is indicated for another condition.,High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",9
452,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Provide people living with dementia with a single named health or social care professional who is responsible for coordinating their care.,High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",8
453,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"When taking a history from someone who knows the person with suspected dementia, consider supplementing this with a structured instrument such as the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) or the Functional Activities Questionnaire (FAQ).",Moderate,3,Consider,1,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",2
454,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Offer a range of activities to promote wellbeing that are tailored to the person’s preferences to all people living with dementia.,High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",8
455,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Do not use standardised instruments (including cognitive instruments) alone to distinguish delirium from delirium superimposed on dementia.,Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",11
456,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"Stop treatment with antipsychotics:
- If the person is not getting a clear ongoing benefit from taking them
- After discussion with the person taking them and their family members or carers (as appropriate)",High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",21
457,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Do not stop cholinesterase inhibitors in people with Alzheimer’s disease because of disease severity alone.,Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",25
458,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Consider group reminiscence therapy for people living with mild to moderate dementia.,Moderate,3,Consider,1,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",8
459,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"As initial and ongoing management, offer psychosocial and environmental interventions to reduce distress in people living with dementia.",Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",8
460,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,"For people living with dementia who experience agitation or aggression, offer personalised activities to promote engagement, pleasure, and interest.",Moderate,3,Should,2,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",8
461,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Offer donepezil or rivastigmine to people with mild to moderate dementia with Lewy bodies.,High,4,Should,2,,1,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",25
462,6914,Pink 2018,"Dementia: assessment, management and support: summary of updated NICE guidance.","Dementia: assessment, management and support for people living with dementia and their carers",2018,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,2,Consider memantine for people with dementia with Lewy bodies if cholinesterase inhibitors are not tolerated or are contraindicated.,Moderate,3,Consider,1,,0.75,"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers [Internet]. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng97",25
463,7113,Cesareo 2018,Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults.,Clinical Management of Vitamin D Deficiency in Adults,2018,"Italian Association of Clinical Endocrinologists, Italian Chapter of the American Association of Clinical Endocrinologists",Other: Italy,Fractures & Osteoporosis,GRADE,4,4,2,We recommend to maintain 25(OH)D levels above 30 ng/mL (75 nmol/L) in older adults with history of falls or non-traumatic fractures.,Moderate,3,Strong,2,,0.75,"Cesareo R, Attanasio R, Caputo M, Castello R, Chiodini I, Falchetti A, et al. Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Nutrients. 2018 Apr 27;10(5):546.",6
464,7113,Cesareo 2018,Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults.,Clinical Management of Vitamin D Deficiency in Adults,2018,"Italian Association of Clinical Endocrinologists, Italian Chapter of the American Association of Clinical Endocrinologists",Other: Italy,Fractures & Osteoporosis,GRADE,4,4,2,We recommend screening for Vitamin D deficiency in older adults with history of falls or non-traumatic fractures.,Moderate,3,Strong,2,,0.75,"Cesareo R, Attanasio R, Caputo M, Castello R, Chiodini I, Falchetti A, et al. Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Nutrients. 2018 Apr 27;10(5):546.",14
465,7307,Hawkey 2018,Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.,Treatment of infections caused by multidrug-resistant Gram-negative bacteria,2018,"British Society for Antimicrobial Chemotherapy, Healthcare Infection Society, British Infection Association",UK,UTI & Asymptomatic Bacturia,SIGN,5,8,3,Do not prescribe antibiotics in asymptomatic bacteriuria in the elderly with or without an indwelling catheter.,1+,7,Strong,3,,0.875,"Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†. Journal of Antimicrobial Chemotherapy. 2018 Mar 1;73(suppl_3):iii2–78.",18
466,7307,Hawkey 2018,Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.,Treatment of infections caused by multidrug-resistant Gram-negative bacteria,2018,"British Society for Antimicrobial Chemotherapy, Healthcare Infection Society, British Infection Association",UK,UTI & Asymptomatic Bacturia,SIGN,5,8,3,"For an elderly patient, do NOT send urine for culture or start empirical antibiotics unless there are specific symptoms or signs of urinary tract infection and none elsewhere. Use the algorithm in Figure 5 (Decision tiered by symptoms and presence of a catheter) to decide whether to do this in elderly patients, especially in those with dementia.",3,2,Conditional,2,,0.25,"Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†. Journal of Antimicrobial Chemotherapy. 2018 Mar 1;73(suppl_3):iii2–78.",18
467,7474,Bjerre 2018,Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.,Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia,2018,"College of Family Physicians of Canada, Canadian Pharmacists Association, Canadian Society of Consultant Pharmacists",Canada,ADR & Deprescribing,GRADE,6,4,2,"For adults with behavioural and psychological symptoms of dementia treated for at least 3 months (symptoms stabilized or no response to adequate trial), we recommend the following: Taper and stop antipsychotics slowly in collaboration with the patient and caregivers: eg, 25%-50 % dose reduction every 1-2 weeks.",Moderate,3,Strong,2,,0.75,"Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician. 2018 Jan;64(1):17–27.",21
468,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients with mild cognitive impairment (MCI), clinicians should assess for the presence of functional impairment related to cognition before giving a diagnosis of dementia.",Moderate,3,B,3,,0.75,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
469,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients diagnosed with mild cognitive impairment (MCI), clinicians should wean patients from medications that can contribute to cognitive impairment (where feasible and medically appropriate) and treat modifiable risk factors that may be contributing.",Moderate,3,B,3,,0.75,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
470,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"If clinicians choose to offer cholinesterase inhibitors, they must first discuss with patients the fact that this is an off-label prescription not currently backed by empirical evidence.",High,4,A,4,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,25
471,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients diagnosed with mild cognitive impairment (MCI), clinicians should recommend regular exercise (twice/week) as part of an overall approach to management.",High,4,B,3,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
472,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients diagnosed with mild cognitive impairment (MCI), clinicians should discuss diagnosis and uncertainties regarding prognosis. Clinicians should counsel patients and families to discuss long-term planning topics such as advance directives, driving safety, finances, and estate planning.",Moderate,3,B,3,,0.75,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
473,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients and families asking about biomarkers in mild cognitive impairment (MCI), clinicians should counsel that there are no accepted biomarkers available at this time.",High,4,B,3,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
474,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For interested patients, clinicians may discuss the option of biomarker research or refer patients, or both, if feasible, to centers or organizations that can connect patients to this research.",High,4,C,2,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
475,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients diagnosed with mild cognitive impairment (MCI), clinicians should perform serial assessments over time to monitor for changes in cognitive status.",Moderate,3,B,3,,0.75,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
476,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"In patients with mild cognitive impairment (MCI), clinicians may recommend cognitive interventions.",High,4,C,2,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
477,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients for whom the patient or a close contact voices concern about memory or impaired cognition, clinicians should assess for mild cognitive impairment (MCI) and not assume the concerns are related to normal aging.",High,4,B,3,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
478,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients diagnosed with mild cognitive impairment (MCI), clinicians may choose not to offer cholinesterase inhibitors.",High,4,B,3,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
479,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients who test positive for mild cognitive impairment (MCI), clinicians should perform a more formal clinical assessment for diagnosis of MCI.",Moderate,3,B,3,,0.75,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
480,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,Clinicians should assess for behavioral and neuropsychiatric symptoms in mild cognitive impairment (MCI) and treat with both pharmacologic and nonpharmacologic approaches when indicated.,High,4,B,3,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
481,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients diagnosed with mild cognitive impairment (MCI), clinicians should perform a medical evaluation for MCI risk factors that are potentially modifiable.",Moderate,3,B,3,,0.75,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
482,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients diagnosed with mild cognitive impairment (MCI), clinicians should counsel the patients and families that there are no pharmacologic or dietary agents currently shown to have symptomatic cognitive benefit in MCI and that no medications are FDA-approved for this purpose.",Moderate,3,B,3,,0.75,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
483,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients suspected to have mild cognitive impairment (MCI), clinicians who lack the necessary experience should refer these patients to a specialist with experience in cognition.",High,4,B,3,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
484,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients for whom screening or assessing for mild cognitive impairment (MCI) is appropriate, clinicians should use validated assessment tools to assess for cognitive impairment.",Moderate,3,B,3,,0.75,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
485,7564,Petersen 2018,"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.",Mild cognitive impairment,2017,American Academy of Neurology,United States,Delirium & Dementia,Other: AAN classification of evidence,5,4,4,"For patients diagnosed with mild cognitive impairment (MCI) who are interested in pharmacologic  treatment,  clinicians  may  inform  these patients of centers or organizations that can connect patients to clinical trials.",High,4,C,2,,1,American Academy of Neurology. Practice guideline update: mild cognitive impairment. AAN website: https://www aan com/Guidelines/home/GetGuidelineContent/882 Published. 2017;,19
486,7895,Qaseem 2017,Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.,Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women,2017,American College of Physicians,United States,Fractures & Osteoporosis,Other: modified GRADE,4,3,2,"The American College of Physicians (ACB) recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications.",Low,1,Weak,1,,0.333333333333333,"Qaseem A, Forciea MA, McLean RM, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017 Jun 6;166(11):818.",7
487,7897,Qaseem 2017,Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians.,Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets,2017,"American College of Physicians, American Academy of Family Physicians",United States,Hypertension,Other: modified GRADE,5,3,2,"The American College of Physicians (ACB) and American Academy of Family Physicians (AAFP) recommend that clinicians consider initiating or intensifying pharmacologic treatment in some adults aged 60 years or older at high cardiovascular risk, based on individualized assessment, to achieve a target systolic blood pressure of less than 140 mmHg to reduce the risk for stroke or cardiac events.",Low,1,Weak,1,,0.333333333333333,"Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA, et al. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017 Mar 21;166(6):430.",15
488,7897,Qaseem 2017,Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians.,Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets,2017,"American College of Physicians, American Academy of Family Physicians",United States,Hypertension,Other: modified GRADE,5,3,2,The American College of Physicians (ACB) and American Academy of Family Physicians (AAFP) recommend that clinicians consider initiating or intensifying pharmacologic treatment in adults aged 60 years or older with a history of stroke or  transient ischemic attack to achieve a target systolic blood pressure of less than 140 mmHg to reduce the risk for recurrent stroke.,Moderate,2,Weak,1,,0.666666666666667,"Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA, et al. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017 Mar 21;166(6):430.",15
489,7897,Qaseem 2017,Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians.,Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets,2017,"American College of Physicians, American Academy of Family Physicians",United States,Hypertension,Other: modified GRADE,5,3,2,"The American College of Physicians (ACB) and American Academy of Family Physicians (AAFP) recommend that clinicians initiate treatment in adults aged 60 years or older with systolic blood pressure persistently at or above 150 mmHg to achieve a target systolic blood pressure of less than 150 mmHg to reduce the risk for mortality, stroke, and cardiac events.",High,3,Strong,2,,1,"Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA, et al. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline From the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017 Mar 21;166(6):430.",6
490,7920,Jellinger 2017,AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.,Management of dyslipidemia and prevention of cardiovascular disease,2017,"American Association of Clinical Endocrinologists, American College of Endocrinology",United States,Dyslipidemia,Other: custom,4,4,4,"Screening for older adults is based on age and risk, but not sex; therefore, older women should be screened in the same way as older men.",1,4,A,4,,1,"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice. 2017 Apr;23:1–87.",14
491,7920,Jellinger 2017,AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.,Management of dyslipidemia and prevention of cardiovascular disease,2017,"American Association of Clinical Endocrinologists, American College of Endocrinology",United States,Dyslipidemia,Other: custom,4,4,4,Annually screen older adults with 0 to 1 atherosclerotic cardiovascular disease risk factor for dyslipidemia.,1,4,A,4,,1,"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice. 2017 Apr;23:1–87.",23
492,7945,Compston 2017,UK clinical guideline for the prevention and treatment of osteoporosis.,Prevention and treatment of osteoporosis,2017,UK National Osteoporosis Guideline Group,UK,Fractures & Osteoporosis,Other: custom ,4,6,3,Age-dependent intervention thresholds up to 70 years and fixed thresholds thereafter provide clinically appropriate and equitable access to treatment.,Ib,5,B,2,,0.833333333333333,"The National Osteoporosis Guideline Group (NOGG), Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017 Dec;12(1):43.",20
493,7945,Compston 2017,UK clinical guideline for the prevention and treatment of osteoporosis.,Prevention and treatment of osteoporosis,2017,UK National Osteoporosis Guideline Group,UK,Fractures & Osteoporosis,Other: custom ,4,6,3,"Treatment review should be performed after 3 years of zoledronic acid therapy and 5 years of oral bisphosphonate treatment. Continuation of bisphosphonate treatment beyond 3-5 years an generally be recommended in individuals age ≥ 75 years, those with a history of hip or vertebral fracture, those who sustain a fracture while on treatment, and those taking oral glucocorticoids.",IIb,3,B,2,,0.5,"The National Osteoporosis Guideline Group (NOGG), Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017 Dec;12(1):43.",7
494,8070,Ezekowitz 2017,2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure.,Management of Heart Failure,2017,Canadian Cardiovascular Society,Canada,Heart Failure,GRADE,4,4,2,"We suggest, in ambulatory patients with heart failure with reduced ejection fraction (HFrEF), measurement of BNP or NT-proBNP to guide management should be considered to decrease heart failure  related hospitalizations and potentially reduce mortality. The benefit is uncertain in individuals older than 75 years of age.",Moderate,3,Weak,1,,0.75,"Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology. 2017 Nov;33(11):1342–433.",15
495,8875,Shen 2017,2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.,Evaluation and Management of Patients With Syncope,2017,"American College of Cardiology, American Heart Association, Heart Rhythm Society",United States,Syncope,Other: custom,5,5,3,"Evaluation of the cause and assessment for the short- and long-term morbidity and mortality risk of syncope are recommended (among others: age > 60, high CHADS2 score).",B-NR,3,I,3,,0.6,"Shen WK, Sheldon RS, Benditt DG, Cohen MI, Forman DE, Goldberger ZD, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. Journal of the American College of Cardiology. 2017 Aug;70(5):e39–110.",15
496,8875,Shen 2017,2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.,Evaluation and Management of Patients With Syncope,2017,"American College of Cardiology, American Heart Association, Heart Rhythm Society",United States,Syncope,Other: custom,5,5,3,It is reasonable to consider syncope as a cause of nonaccidental falls in older adults.,B-NR,3,IIa,2,,0.6,"Shen WK, Sheldon RS, Benditt DG, Cohen MI, Forman DE, Goldberger ZD, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. Journal of the American College of Cardiology. 2017 Aug;70(5):e39–110.",11
497,9187,Lems 2017,EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures.,Management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures,2016,"European League Against Rheumatism, European Federation of National Associations of Orthopaedics and Traumatology ",Other: Europe,Fractures & Osteoporosis,Other: modified Oxford,4,6,4,"To improve functional outcome, and to reduce length of hospital stay and mortality, orthogeriatric comanagement should be provided, especially in elderly patients with hip fracture.",IA,6,A,4,,1,"Lems WF, Dreinhöfer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, Da Silva J, et al. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis. 2017 May;76(5):802–10.",7
498,9187,Lems 2017,EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures.,Management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures,2016,"European League Against Rheumatism, European Federation of National Associations of Orthopaedics and Traumatology ",Other: Europe,Fractures & Osteoporosis,Other: modified Oxford,4,6,4,"Appropriate treatment of the fractures in these, often elderly and multimorbid, patients with frail bones requires a balanced approach with regard to operative vs non-operative treatment and careful selection of fixation devices and techniques.",III,2,C,2,,0.333333333333333,"Lems WF, Dreinhöfer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, Da Silva J, et al. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis. 2017 May;76(5):802–10.",7
499,9255,Duceppe 2017,Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery.,Perioperative Cardiac Risk Assessment and Managementfor Patients Who Undergo Noncardiac Surgery,2016,Canadian Cardiovascular Society,Canada,Perioperative Management,GRADE,4,4,2,"We suggest performing a postoperative electrocardiography in the postanesthetic care unit in patients with an elevated NT-proBNP/BNP measurement before surgery or, if there is no NT-proBNP/BNP measurement before surgery, in those who have an revised cardiac risk index (RCRI) score ≥ 1, age 45-64 years with significant cardiovascular disease, or age 65 years or older.",Low,2,Conditional,1,,0.5,"Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Canadian Journal of Cardiology. 2017 Jan;33(1):17–32.",15
500,9255,Duceppe 2017,Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery.,Perioperative Cardiac Risk Assessment and Managementfor Patients Who Undergo Noncardiac Surgery,2016,Canadian Cardiovascular Society,Canada,Perioperative Management,GRADE,4,4,2,"We recommend obtaining daily troponin measurements for 48-72 hours after noncardiac surgery in patients with a baseline risk > 5 % for cardiovascular death or nonfatal myocardial infarction at 30 days after surgery (i.e., patients with an elevated NT-proBNP/BNP measurement before surgery or, if there is no NT-proBNP/BNP measurement before surgery, in those who have an revised cardiac risk index (RCRI) score ≥ 1, age 45-64 years with significant cardiovascular disease, or age 65 years or older).",Moderate,3,Strong,2,,0.75,"Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Canadian Journal of Cardiology. 2017 Jan;33(1):17–32.",15
501,9255,Duceppe 2017,Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery.,Perioperative Cardiac Risk Assessment and Managementfor Patients Who Undergo Noncardiac Surgery,2016,Canadian Cardiovascular Society,Canada,Perioperative Management,GRADE,4,4,2,"We suggest shared-care management of patients with an elevated NT-proBNP/BNP measurement before surgery or if there is no NT-proBNP/BNP measurement before surgery, in those who have an revised cardiac risk index (RCRI) score ≥ 1, age 45-64 years with significant cardiovascular disease, or age 65 years or older.",Low,2,Conditional,1,,0.5,"Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Canadian Journal of Cardiology. 2017 Jan;33(1):17–32.",15
502,9255,Duceppe 2017,Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery.,Perioperative Cardiac Risk Assessment and Managementfor Patients Who Undergo Noncardiac Surgery,2016,Canadian Cardiovascular Society,Canada,Perioperative Management,GRADE,4,4,2,"We recommend measuring NT-proBNP or BNP before noncardiac surgery to enhance perioperative cardiac risk estimation in patients who are 65 years of age or older, are 45-64 years of age with significant cardiovascular disease, or have an revised cardiac risk index (RCRI) score ≥ 1.",Moderate,3,Strong,2,,0.75,"Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Canadian Journal of Cardiology. 2017 Jan;33(1):17–32.",15
503,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that in the absence of delirium, if nonemergency antipsychotic medication treatment is indicated, haloperidol should not be used as a first-line agent.",B,2,1,2,,0.666666666666667,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,3
504,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that in patients with dementia whose antipsychotic medication is being tapered, assessment of symptoms should occur at least monthly during the taper and for at least 4 months after medication discontinuation to identify signs of recurrence and trigger a reassessment  of  the  benefits  and  risks  of  antipsychotic treatment.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
505,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that nonemergency antipsychotic medication should only be used for the treatment of agitation or psychosis in patients with dementia when symptoms are severe, are dangerous, and/or cause significant distress to the patient.",B,2,1,2,,0.666666666666667,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
506,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,The American Psychiatric Association (APA) recommends reviewing the clinical response to nonpharmacological interventions prior to non-emergency  use  of  an  antipsychotic  medication  to  treat agitation or psychosis in patients with dementia.,C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
507,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that in patients with dementia with agitation or psychosis, if there is no clinically significant response after a 4-week trial of an adequate dose of an antipsychotic drug, the medication should be tapered and withdrawn.",B,2,1,2,,0.666666666666667,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
508,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that in patients with dementia with agitation or psychosis, a long-acting injectable antipsychotic medication should not be utilized unless it is otherwise indicated for a co-occurring chronic psychotic disorder.",B,2,1,2,,0.666666666666667,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
509,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that in a patient who has shown a positive response to treatment, decision making about possible tapering of antipsychotic medication should be accompanied by a discussion with the patient (if clinically feasible) as well as with the patient’s surrogate decision maker (if relevant) with input from family or others involved with the patient. The aim of such a discussion is to elicit their preferences and concerns and to review the initial goals, observed benefits and side effects of antipsychotic treatment, and potential risks of continued exposure to antipsychotics,  as  well  as  past  experience  with  antipsychotic medication trials and tapering attempts.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
510,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that before nonemergency treatment with an antipsychotic is initiated in patients with dementia, the potential risks and benefits from antipsychotic medication be assessed by the clinician and discussed with the patient (if clinically feasible) as well as with the patient’s surrogate decision maker (if relevant) with input from family or others involved with the patient.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
511,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that in patients with dementia with agitation or psychosis, response to treatment be assessed with a quantitative measure.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,2
512,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that in patients with dementia who show adequate response of behavioral/psychological symptoms to treatment with an antipsychotic drug, an attempt to taper and withdraw the drug should be made within 4 months of initiation, unless the patient experienced a recurrence of symptoms with prior attempts at tapering of antipsychotic medication.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
513,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that if a patient with dementia experiences a clinically significant side effect of antipsychotic treatment, the potential risks and benefits of antipsychotic medication should be reviewed by the clinician to determine if tapering and discontinuing of the medication is indicated.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
514,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that if a risk/benefit assessment favors the use of an antipsychotic for behavioral/psychological symptoms in patients with dementia, treatment should be initiated at a low dose to be titrated up to the minimum effective dose as tolerated.",B,2,1,2,,0.666666666666667,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,21
515,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that patients with dementia be assessed for pain and other potentially modifiable contributors to symptoms as well as for factors, such as the subtype of dementia, that may influence choices of treatment.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,2
516,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that patients with dementia have a documented comprehensive treatment plan that includes  appropriate  person-centered  nonpharmacological and pharmacological interventions, as indicated.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,2
517,9812,Reus 2017,The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.,Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia,2016,American Psychiatric Association,United States,Delirium & Dementia,Other: modified GRADE,5,3,2,"The American Psychiatric Association (APA) recommends that patients with dementia be assessed for the type, frequency, severity, pattern, and timing of symptoms.",C,1,1,2,,0.333333333333333,American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia [Internet]. American Psychiatric Association; 2016 [cited 2024 Feb 20]. Available from: http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807,2
518,9859,Kim 2017,Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.,Diagnosis and Management of Chronic Heart Failure,2017,Korean Society of Cardiology,Korea,Heart Failure,Other: custom,4,3,3,Administration of nebivolol can be useful in patients with HFrEF aged over 70 years.,B,2,IIa,2,,0.666666666666667,"Kim MS, Lee JH, Kim EJ, Park DG, Park SJ, Park JJ, et al. Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J. 2017;47(5):555.",23
519,9859,Kim 2017,Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.,Diagnosis and Management of Chronic Heart Failure,2017,Korean Society of Cardiology,Korea,Heart Failure,Other: custom,4,3,3,"The CHA2DS2-VASc scoring system is the recommended tool for estimating the risk of stroke, and should be used in the decision of the treatment modalities in patients with heart failure  and AF.",B,2,I,3,,0.666666666666667,"Kim MS, Lee JH, Kim EJ, Park DG, Park SJ, Park JJ, et al. Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J. 2017;47(5):555.",15
520,10146,Anderson 2016,2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.,Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult,2016,Canadian Cardiovascular Society,Canada,Dyslipidemia,GRADE,4,4,2,We recommend management that includes statin therapy for individuals at intermediate risk (modified Framingham Risk Score 10-19 %) with LDL-C 3.5 mmol/L to decrease the risk of cardiovascular events. Statin therapy should also be considered for intermediate risk persons with LDL-C < 3.5 mmol/L but with apoB 1.2 g/L or non-HDL-C 4.3 mmol/L or in men 50 years of age and older and women 60 years of age and older with 1 cardiovascular risk factor.,High,4,Strong,2,women,1,"Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 2016 Nov;32(11):1263–82.",23
521,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"People with dementia and severe behavioural and psychological symptoms of dementia (i.e., psychosis and/or agitation/aggression) causing significant distress to themselves or others, may be offered treatment with an antipsychotic medication. Risperidone has the strongest evidence for treating psychosis. Risperidone and olanzapine have the strongest evidence for treating agitation/aggression, with weaker evidence for aripiprazole. The following conditions should also be met:
- There should be a full discussion with the person with dementia and their carers and family about the possible benefits and risks of treatment. In particular, cerebrovascular risk factors should be assessed and the possible increased risk of stroke/transient ischaemic attack and possible adverse effects on cognition discussed
- Target symptoms should be identified, quantified and documented
- The effect of comorbid conditions, such as depression, should be considered
- The choice of antipsychotic should be made after an individual risk-benefit analysis
- The dose should be initially low and titrated upwards if necessary
- Monitoring for adverse effects including the metabolic syndrome should occur.
- If there is no efficacy observed within a relatively short timeframe (usually one to two weeks), treatment should be discontinued. Treatment should be reviewed every four to 12 weeks, considering the need for antipsychotics and possible cessation of medication. Review should include regular assessment and recording of changes in cognition and target symptoms",Moderate,3,may,1,,0.75,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",21
522,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"To assist the carer(s) and family help the person with dementia who is experiencing behavioural and psychological symptoms of dementia, carer(s) and family should be offered interventions which involve:
- carer skills training in managing symptoms and communicating effectively with the person with dementia
- meaningful activity planning
- environmental redesign and modification to improve safety and enjoyment
- problem solving and management planning",Low,2,should,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",8
523,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"People with Alzheimer’s disease, vascular dementia or mixed dementias with mild-to-moderate behavioural and psychological symptoms of dementia should not usually be prescribed antipsychotic medications because of the increased risk of cerebrovascular adverse events and death.",Moderate,3,should not,2,,0.75,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",21
524,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,Health and aged care staff should attempt to minimise the impact of behavioural and psychological symptoms of dementia by providing person-centred care (care that is consistent with the 10 Principles of Dignity in Care).,Low,2,should,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",8
525,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"People with dementia who experience agitation should be offered a trial of selective serotonin reuptake inhibitor (SSRI) antidepressants (the strongest evidence for effectiveness exists for citalopram) if non-pharmacological treatments are inappropriate or have failed. Review with evaluation of efficacy and consideration of de-prescribing should occur after two months. The need for adherence, time to onset of action and risk of withdrawal effects and possible side effects should be explained at the start of treatment.",Moderate,3,should,2,,0.75,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",21
526,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"For people with dementia who also have depression and/or anxiety or agitation, interventions should be tailored to the person's preferences, skills and abilities. The response to each modality should be monitored and the care plan adapted accordingly. Multicomponent interventions that involve engagement in activities that are enjoyable for the person with dementia plus individualised support should be offered where available. Where multicomponent interventions are not available, the following individual therapies should be considered:
For depression and or/anxiety:
- therapeutic use of music and/or dancing
- support and counselling
- reminiscence therapy.
For agitation:
- behavioural management interventions
- therapeutic use of music and/or dancing
- massage
- reminiscence therapy",Low,2,should,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",8
527,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"If a person with dementia is suspected to be in pain due to their distress or behaviour, as indicated by responses on an observational pain assessment tool, analgesic medication should be trialled using a stepped approach. The trial should be for a defined time period, particularly if opioids are used.",Low,2,should,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",2
528,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,Memantine is recommended as an option for people with moderate-to-severe Alzheimer's disease who are intolerant of or have a contraindication to acetylcholinesterase inhibitors. For people with severe renal impairment (creatinine clearance < 30ml/min) the dose of memantine should be halved.,Moderate,3,is recommended,2,,0.75,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",25
529,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,People with a possible diagnosis of dementia should be offered referral to memory assessment specialists or services for a comprehensive assessment.,Low,2,should,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",2
530,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"People with a diagnosis of dementia, particularly those living alone, should be provided with information about how to join a social support group.",Very Low,1,should,2,,0.25,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",8
531,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,The combination of an acetylcholinesterase inhibitor plus memantine could be considered for managing the symptoms of moderate-to-severe Alzheimer’s disease.,Low,2,could be considered,1,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",25
532,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,Acetylcholinesterase inhibitors should not be prescribed for people with mild cognitive impairment.,Low,2,should not,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",9
533,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,The Rowland Universal Dementia Assessment Scale (RUDAS) should be considered for assessing cognition in culturally and linguistically diverse populations.,Very Low,1,should,2,,0.25,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",2
534,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,The Kimberley Indigenous Cognitive Assessment (KICA-Cog) or KICA-Screen tool is recommended for use with remote living Indigenous Australians for whom the use if alternative cognitive assessment tools is not considered appropriate.,Low,2,is recommended,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",19
535,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"Any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine) are recommended as options for managing the symptoms of mild to moderately severe Alzheimer's disease. Any one of the three acetylcholinesterase inhibitors could be considered for managing the symptoms of severe Alzheimer’s disease. Prior to initiation of treatment medical practitioners should consider performing an electrocardiogram (ECG), recording weight and undertaking a falls risk assessment. Concomitant administration of medications with anticholinergic effects should be avoided.",Low,2,are recommended,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",25
536,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"The modified Kimberley Indigenous Cognitive Assessment (mKICA) is recommended as an alternative to the Mini Mental State Exam (MMSE) in urban and rural Indigenous Australian populations when illiteracy, language or cultural considerations deem it appropriate.",Low,2,is recommended,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",19
537,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"A number of nutritional drinks are currently being investigated to reduce the symptoms of mild cognitive impairment or dementia, of which one (Souvenaid®) is marketed in Australia. There is currently insufficient evidence to recommend the routine use of Souvenaid® in people with mild Alzheimer's disease. Souvenaid® should not be recommended for people with moderate or severe Alzheimer's disease.",Moderate,3,should not,2,,0.75,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",13
538,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"Medical and nurse practitioners should be aware that the acetylcholinesterase inhibitors are associated with a number of adverse reactions that have a risk of harm. These include (but are not limited to) nausea, vomiting, diarrhoea, dizziness, increased urinary incontinence and frequency, falls, muscle cramps, weight loss, anorexia, headache and insomnia. Heart block is a rare, but serious potential adverse event.",Moderate,3,should,2,,0.75,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",21
539,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,"Any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine) could be considered for managing the symptoms of Dementia with Lewy  Bodies, Parkinson’s Disease dementia, vascular dementia or mixed dementia.",Low,2,could be considered,1,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",25
540,10843,Laver 2016,Clinical practice guidelines for dementia in Australia.,Principles of Care for People with Dementia,2016,National Health and Medical Research Council,Australia,Delirium & Dementia,GRADE,6,4,2,People with dementia should be strongly encouraged to exercise. Assessment and advice from a physiotherapist or exercise physiologist may be indicated.,Low,2,should,2,,0.5,"Laver K, Cumming R, Dyer S, Agar M, Beattie E, Brodaty H, et al. Clinical practice guidelines for dementia in Australia. 2016;",26
541,10866,Crandall 2016,Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline.,Prevention of fall-related injuries in the elderly,2016,Eastern Association for the Surgery of Trauma,United States,Fall Prevention,GRADE,4,4,2,We conditionally recommend frailty screening for the elderly.,Moderate,3,Weak,1,,0.75,"Crandall M, Duncan T, Mallat A, Greene W, Violano P, Christmas AB, et al. Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline. Journal of Trauma and Acute Care Surgery. 2016 Jul;81(1):196–206.",14
542,10866,Crandall 2016,Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline.,Prevention of fall-related injuries in the elderly,2016,Eastern Association for the Surgery of Trauma,United States,Fall Prevention,GRADE,4,4,2,We conditionally recommend hip protectors for frail elderly individuals in the appropriate environment.,High,4,Weak,1,,1,"Crandall M, Duncan T, Mallat A, Greene W, Violano P, Christmas AB, et al. Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline. Journal of Trauma and Acute Care Surgery. 2016 Jul;81(1):196–206.",7
543,10866,Crandall 2016,Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline.,Prevention of fall-related injuries in the elderly,2016,Eastern Association for the Surgery of Trauma,United States,Fall Prevention,GRADE,4,4,2,We conditionally recommend evidence-based exercise programs for frail elderly individuals.,Moderate,3,Weak,1,,0.75,"Crandall M, Duncan T, Mallat A, Greene W, Violano P, Christmas AB, et al. Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline. Journal of Trauma and Acute Care Surgery. 2016 Jul;81(1):196–206.",14
544,10866,Crandall 2016,Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline.,Prevention of fall-related injuries in the elderly,2016,Eastern Association for the Surgery of Trauma,United States,Fall Prevention,GRADE,4,4,2,We conditionally recommend physical environment modification for frail elderly people.,Moderate,3,Weak,1,,0.75,"Crandall M, Duncan T, Mallat A, Greene W, Violano P, Christmas AB, et al. Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline. Journal of Trauma and Acute Care Surgery. 2016 Jul;81(1):196–206.",14
545,10866,Crandall 2016,Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline.,Prevention of fall-related injuries in the elderly,2016,Eastern Association for the Surgery of Trauma,United States,Fall Prevention,GRADE,4,4,2,We conditionally recommend Vitamin D and calcium supplementation for frail elderly individuals.,High,4,Weak,1,,1,"Crandall M, Duncan T, Mallat A, Greene W, Violano P, Christmas AB, et al. Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline. Journal of Trauma and Acute Care Surgery. 2016 Jul;81(1):196–206.",14
546,10866,Crandall 2016,Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline.,Prevention of fall-related injuries in the elderly,2016,Eastern Association for the Surgery of Trauma,United States,Fall Prevention,GRADE,4,4,2,"We strongly recommend risk stratification with targeted, comprehensive risk-reduction strategies tailored to particular high-risk groups.",Moderate,3,Strong,2,,0.75,"Crandall M, Duncan T, Mallat A, Greene W, Violano P, Christmas AB, et al. Prevention of fall-related injuries in the elderly: An Eastern Association for the Surgery of Trauma practice management guideline. Journal of Trauma and Acute Care Surgery. 2016 Jul;81(1):196–206.",5
547,11743,Snook 2021,British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults.,Management of iron deficiency anaemia in adults,2021,British Society of Gastroenterology,UK,Anemia,GRADE,4,4,2,"Iron deficiency is common in the elderly, and is often multifactorial in aetiology.",High,4,Strong,2,,1,"Snook J, Bhala N, Beales IL, Cannings D, Kightley C, Logan RP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70(11):2030–51.",1
548,11743,Snook 2021,British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults.,Management of iron deficiency anaemia in adults,2021,British Society of Gastroenterology,UK,Anemia,GRADE,4,4,2,We recommend that the risks and benefits of invasive endoscopic and alternative investigation(s) are carefully considered in those with major comorbidities and/or limited performance status.,Medium,3,Strong,2,,0.75,"Snook J, Bhala N, Beales IL, Cannings D, Kightley C, Logan RP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut. 2021;70(11):2030–51.",11
549,11824,Maski 2021,Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.,Treatment of central disorders of hypersomnolence,2021,American Academy of Sleep Medicine,United States,Delirium & Dementia,GRADE,4,4,2,We suggest that clinicians use armodafinil (vs no treatment) for the treatment of hypersomnia secondary to dementia with Lewy bodies in adults.,Very Low,1,Conditional,1,,0.25,"Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine. 2021 Sep;17(9):1881–93.",25
550,11929,George 2021,Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021.,Interventions for the Management of Acute and Chronic Low Back Pain,2021," Academy of Orthopaedic Physical Therapy, American Physical Therapy Association",United States,Pain Management,Other: modified Oxford,5,5,4,Physical therapists should use general exercise training to reduce pain and disability in older adults with chronic lower back pain.,I,5,A,4,,1,"George SZ, Fritz JM, Silfies SP, Schneider MJ, Beneciuk JM, Lentz TA, et al. Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021: Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability and Health From the Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association. J Orthop Sports Phys Ther. 2021 Nov;51(11):CPG1–60.",26
551,12020,Crea 2021,The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors.,Cardiovascular disease prevention in clinical practice,2021,European Society of Cardiology,Other: Europe,Hypertension,Other: custom,5,3,3,"In apparently healthy people ≥ 70 years without established atherosclerotic cardiovascular disease, diabetes mellitus, chronic kidney disease, genetic/rarer lipid or blood pressure disorders, estimation of 10-year fatal and non-fatal cardiovaskular disease risk with SCORE2-OP (Systematic Coronary Risk Estimation 2-Older Persons) is recommended.",B,2,I,3,,0.666666666666667,"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021 Sep 7;42(34):3227–337.",15
552,12020,Crea 2021,The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors.,Cardiovascular disease prevention in clinical practice,2021,European Society of Cardiology,Other: Europe,Hypertension,Other: custom,5,3,3,"It is recommended to initiate antihypertensive treatment with a two-drug combination in most patients, preferably as a single-pill combination. Exceptions are frail older patients and those with low-risk, grade 1 hypertension (particularly if systolic blood pressure < 150 mmHg).",B,2,I,3,,0.666666666666667,"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021 Sep 7;42(34):3227–337.",6
553,12020,Crea 2021,The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors.,Cardiovascular disease prevention in clinical practice,2021,European Society of Cardiology,Other: Europe,Dyslipidemia,Other: custom,5,3,3,Treatment with statins is recommended for older people (≥ 70 years) with atherosclerotic cardiovascular disease in the same way as for younger patients.,A,3,I,3,,1,"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021 Sep 7;42(34):3227–337.",23
554,12020,Crea 2021,The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors.,Cardiovascular disease prevention in clinical practice,2021,European Society of Cardiology,Other: Europe,Hypertension,Other: custom,5,3,3,"A stepwise treatment-intensification approach aiming at intensive risk factor treatment is recommended for apparently healthy people at high or very high CVD risk, as well as patients with established atherosclerotic cardiovascular disease and/or diabetes mellitus, with consideration of CVD risk, treatment benefit of risk factors, risk modifiers, comorbidities, and patient preferences.",B,2,I,3,,0.666666666666667,"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021 Sep 7;42(34):3227–337.",23
555,12020,Crea 2021,The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors.,Cardiovascular disease prevention in clinical practice,2021,European Society of Cardiology,Other: Europe,Dyslipidemia,Other: custom,5,3,3,"Initiation of statin treatment for primary prevention in older people aged ≥ 70 may be considered, if at high risk or above.",B,2,IIb,1,,0.666666666666667,"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021 Sep 7;42(34):3227–337.",23
556,12020,Crea 2021,The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors.,Cardiovascular disease prevention in clinical practice,2021,European Society of Cardiology,Other: Europe,Diabetes Mellitus,Other: custom,5,3,3,"For patients with a long duration of diabetes mellitus and in old or frail adults, a relaxing of the HbA1c targets (i.e. less stringent) should be considered.",B,2,IIa,2,,0.666666666666667,"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021 Sep 7;42(34):3227–337.",16
557,12020,Crea 2021,The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors.,Cardiovascular disease prevention in clinical practice,2021,European Society of Cardiology,Other: Europe,Hypertension,Other: custom,5,3,3,"In treated patients aged ≥ 70 years, it is recommended that systolic blood pressure should generally be targeted to < 140 and down to 130 mmHg if tolerated.",A,3,I,3,,1,"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021 Sep 7;42(34):3227–337.",6
558,12020,Crea 2021,The ESC Guidelines on cardiovascular prevention and a focus on old and new risk factors.,Cardiovascular disease prevention in clinical practice,2021,European Society of Cardiology,Other: Europe,Diabetes Mellitus,Other: custom,5,3,3,"In patients with diabetes mellitus at high or very high CVD risk, low-dose aspirin may be considered for primary prevention in the absence of clear contraindications.",A,3,IIb,1,DM,1,"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021 Sep 7;42(34):3227–337.",12
559,12145,,Management of Rotator Cuff Injuries,Management of Rotator Cuff Injuries ,2019,American Academy of Orthopaedic Surgeons,United States,Other: Orthopaedic Surgery,GRADE,5,4,4,Strong evidence supports that older age is associated with higher failure rates and poorer patient reported outcomes after rotator cuff repair.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Rotator Cuff Injuries Evidence Based Clinical Practice Guideline. Published March. 2019;11.,7
560,12167,,Management of Osteoarthritis of the Hip,Management of Osteoarthritis of the Hip,2017,American Academy of Orthopaedic Surgeons,United States,Osteoarthritis,GRADE,5,4,4,Limited strength evidence supports that increased age may be associated with a higher risk of mortality in patients with symptomatic osteoarthritis of the hip undergoing total hip arthroplasty.,Low,2,Limited,2,,0.5,American Academy of Orthopaedic Surgeons. Management of Rotator Cuff Injuries Evidence Based Clinical Practice Guideline. Published March. 2019;11.,7
561,12167,,Management of Osteoarthritis of the Hip,Management of Osteoarthritis of the Hip,2017,American Academy of Orthopaedic Surgeons,United States,Osteoarthritis,GRADE,5,4,4,Moderate strength evidence supports that increased age is associated with lower functional and quality of life outcomes in patients with symptomatic osteoarthritis of the hip undergoing total hip arthroplasty.,Moderate,3,Moderate,3,,0.75,American Academy of Orthopaedic Surgeons. Management of Rotator Cuff Injuries Evidence Based Clinical Practice Guideline. Published March. 2019;11.,7
562,12205,,ECRI Guidelines Trust® - Clinical practice guideline non-invasive blood pressure measurement,Non-invasive blood pressure measurement,2019,Emergency Nurses Association,United States,Hypertension,Other: Melnyk & Fineout-Overholt,4,7,4,Older adults may be more susceptible to variances in blood pressure associated with the effect of clothing.,II,6,B,3,,0.857142857142857,Emergency Nurses Association (ENA). Clinical practice guideline: Non-invasive blood pressure measurement. Emergency Nurses Association (ENA).; 2019.,6
563,12205,,ECRI Guidelines Trust® - Clinical practice guideline non-invasive blood pressure measurement,Non-invasive blood pressure measurement,2019,Emergency Nurses Association,United States,Hypertension,Other: Melnyk & Fineout-Overholt,4,7,4,Measuring BP of adults over 65 requires no special technique.,I,7,B,3,,1,Emergency Nurses Association (ENA). Clinical practice guideline: Non-invasive blood pressure measurement. Emergency Nurses Association (ENA).; 2019.,6
564,12209,,ECRI Guidelines Trust® - BTS_ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults,Ventilatory management of acute hypercapnic respiratory failure in adults,2016,"British Thoracic Society (BTS), Intensive Care Society (ICS)",UK,Pneumonia & COPD,SIGN,5,8,5,Advanced age alone should not preclude a trial of non-invasive ventilation (NIV).,1+,7,A,5,,0.875,"Davidson AC, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax. 2016 Apr;71(Suppl 2):ii1–35.",20
565,12213,,EAU-Guidelines on Urinary Incontinence,Urinary Incontinence in Adults,2020,European Association of Urology,Other: Europe,Incontinence,Oxford,5,6,2,"Offer supervised intensive PFMT, lasting at least 3 months, as a first-line therapy to all women with stress urinary incontinence or mixed urinary incontinence (including the elderly and post-natal).",1b,5,Strong,2,Women,0.833333333333333,"Burkhard F, Bosch J, Cruz F, Lemack G, Nambiar A, Thiruchelvam N, et al. EAU guidelines on urinary incontinence in adults. Arnhem: European Association of Urology. 2018;",18
566,12213,,EAU-Guidelines on Urinary Incontinence,Urinary Incontinence in Adults,2020,European Association of Urology,Other: Europe,Incontinence,Oxford,5,6,2,Do not routinely treat asymptomatic bacteriuria in elderly patients to improve urinary incontinence.,2,3,Strong,2,,0.5,"Burkhard F, Bosch J, Cruz F, Lemack G, Nambiar A, Thiruchelvam N, et al. EAU guidelines on urinary incontinence in adults. Arnhem: European Association of Urology. 2018;",18
567,12213,,EAU-Guidelines on Urinary Incontinence,Urinary Incontinence in Adults,2020,European Association of Urology,Other: Europe,Incontinence,Oxford,5,6,2,"Inform older women with urinary incontinence about the increased risks associated with surgery (including onabotA injection), together with the lower probability of benefit.",2,3,Weak,1,Women,0.5,"Burkhard F, Bosch J, Cruz F, Lemack G, Nambiar A, Thiruchelvam N, et al. EAU guidelines on urinary incontinence in adults. Arnhem: European Association of Urology. 2018;",18
568,12213,,EAU-Guidelines on Urinary Incontinence,Urinary Incontinence in Adults,2020,European Association of Urology,Other: Europe,Incontinence,Oxford,5,6,2,"Long-term antimuscarinic treatment should be used with caution in elderly patients especially those who are at risk of, or have, cognitive dysfunction.",2,3,Strong,2,,0.5,"Burkhard F, Bosch J, Cruz F, Lemack G, Nambiar A, Thiruchelvam N, et al. EAU guidelines on urinary incontinence in adults. Arnhem: European Association of Urology. 2018;",20
569,12213,,EAU-Guidelines on Urinary Incontinence,Urinary Incontinence in Adults,2020,European Association of Urology,Other: Europe,Incontinence,Oxford,5,6,2,"Inform older women with stress urinary incontinence about the increased risks associated with surgery, including the lower probability of success.",2,3,Weak,1,Women,0.5,"Burkhard F, Bosch J, Cruz F, Lemack G, Nambiar A, Thiruchelvam N, et al. EAU guidelines on urinary incontinence in adults. Arnhem: European Association of Urology. 2018;",18
570,12216,,Management of Distal Radius Fractures,Management of Distal Radius Fractures  ,2020,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,5,4,4,Strong evidence suggests that operative treatment for geriatric patients (most commonly defined in studies as 65 years of age and older) does not lead to improved long term patient reported outcomes copared to non-operative treatment.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Distal Radius Fractures Evidence-Based Clinical Practice Guideline [Internet]. American Academy of Orthopaedic Surgeons; 2020. Available from: http://www.aaos.org/drfcpg,20
571,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Employ communication strategies and techniques that demonstrate compassion, validate emotions, support dignity, and promote comprehension when caring for people with dementia.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",8
572,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Develop a tailored, non-pharmacological, multi-component delirium prevention plan for persons at risk for delirium in collaboration with the person, his/her family/care partners, and the interprofessional team.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",11
573,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"For older adults whose assessments indicate delirium, identify the underlying causes and contributing factors using clinical assessments and collaboration with the interprofessional team.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",11
574,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Implement the delirium prevention plan in collaboration with the person, his/her family/care partners, and the interprofessional team.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",11
575,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Promote strategies for people living with dementia that will preserve their abilities and optimize their quality of life, including but not limited to:
- exercise
- interventions that support cognitive function
- advanced care planning",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",8
576,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,Continue to employ prevention strategies when caring for older adults at risk for delirium who have not been identified as having delirium.,Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",11
577,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Refer older adults suspected of delirium, dementia, and/or depression to the appropriate clinicians, teams, or services for further assessment, diagnosis, and/or follow-up care.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",2
578,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,Provide education and psychosocial support to family members and care partners of people with dementia that align with the person’s unique needs and the stage of dementia.,Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",8
579,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Monitor older adults with dementia for pain, and implement pain-reduction measures to help manage behavioural and psychological symptoms of dementia.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",2
580,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Exercise caution in prescribing and administering medication to older adults (within the health-care provider’s scope of practice), and diligently monitor and document medication use and effects, paying particular attention to medications with increased risk for older adults and polypharmacy.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",20
581,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Use clinical assessments and validated tools to assess older adults at risk for delirium at least daily (where appropriate) and whenever changes in the person’s cognitive function, perception, physical function, or social behaviour are observed or reported.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",11
582,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Assess older adults for possible dementia when changes in cognition, behaviour, mood, or function are observed or reported Use validated, context-specific screening or assessment tools, and collaborate with the person, his/her family/care partners, and the interprofessional team for a comprehensive assessment.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",2
583,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,Assess older adults with dementia for pain using a population-specific pain assessment tool.,Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",2
584,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Develop an individualized plan of care that addresses the behavioural and psychological symptoms of dementia (BPSD) and/or the person’s personal care needs Incorporate a range of non-pharmacological approaches, selected according to:
- the person’s preferences
- the assessment of the behavioral and psychological symptoms of dementia
- the stage of dementia
- the person’s needs during personal care and bathing
- consultations with the person’s family/care partners and the interprofessional team
- ongoing observations of the person",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",8
585,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Implement tailored, multi-component interventions to actively manage the person’s delirium in collaboration with the person, the person’s family/care partners, and the interprofessional team. These interventions should include:
- treatment of the underlying causes
- appropriate use of medications to alleviate the symptoms of delirium and/or manage pain",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",11
586,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,Refer the person for further assessment/diagnosis if dementia is suspected.,Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",2
587,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Systematically explore the underlying causes of any behavioural and psychological symptoms of dementia that are present, including identifying the person’s unmet needs and potential “triggers ” Use an appropriate tool and collaborate with the person, his/her family/care partners, and the interprofessional team.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",2
588,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,Assess older adults for delirium risk factors on initial contact and if there is a change in the person’s condition.,Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",11
589,12221,,"Delirium, Dementia, and Depression in Older Adults: Assessment and Care","Delirium, Dementia, and Depression in Older Adults: Assessment and Care",2016,Registered Nureses' Association of Ontario,Canada,Delirium & Dementia,SIGN,5,7,0,"Establish therapeutic relationships and provide culturally sensitive person- and family-centred care when caring for and providing education to people with delirium, dementia, and depression and their families and care partners.",Ia,7,Recommendation,1,,1,"Grinspun D. Delirium, dementia, and depression in older adults: assessment and care. Registered Nurses’ Association of Ontario; 2016.",8
590,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,Preoperative traction should not routinely be used for patients with a hip fracture.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
591,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"In patients with pertrochanteric femur fractures, short or long cephalomedullary nail may be considered.",Limited,2,Limited,2,,0.5,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
592,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"Following surgical treatment of hip fractures, immediate, full weight bearing to tolerance may be considered.",Limited,2,Limited,2,,0.5,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
593,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"In properly selected patients with unstable (displaced) femoral neck fractures, there may be a functional benefit to total hip arthroplasty over hemi arthroplasty at the risk of increasing complications.",Strong,4,Moderate,3,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
594,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"In patients undergoing arthroplasty for femoral neck fractures, the use of cemented femoral stems is recommended.",Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
595,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,Hip fracture surgery within 24-48 hours of admission may be associated with better outcomes.,Limited,2,Moderate,3,,0.5,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
596,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"In patients with unstable (displaced) femoral neck fractures, unipolar or bipolar hemiarthroplasty can be equally beneficial.",Moderate,3,Moderate,3,,0.75,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
597,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"In patients with unstable (displaced) femoral neck fractures, arthroplasty is recommended over fixation.",Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
598,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,A blood transfusion threshold of no higher than 8g/dl is suggested in asymptomatic postoperative hip fracture patients.,Moderate,3,Moderate,3,,0.75,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
599,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,Tranexamic acid should be administered to reduce blood loss and blood transfusion in patients with hip fractures.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
600,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,Interdisciplinary care programs should be used in the care of hip fracture patients to decrease complications and improve outcomes.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
601,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"In patients with stable intertrochanteric fractures, use of either a sliding hip screw or a cephalomedullary device is recommended.",Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
602,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,Venous thromboembolism (VTE) prophylaxis should be used in hip fracture patients.,Moderatie,3,Strong,4,,0.75,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
603,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,Patients with unstable intertrochanteric fractures should be treated with a cephalomedullary device.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
604,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,Multimodal analgesia incorporating preoperative nerve block is recommended to treat pain after hip fracture.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
605,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,In patients with subtrochanteric or reverse obliquity fractures a cephalomedullary device is recommended.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
606,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"In patients undergoing treatment of femoral neck fractures with hip arthroplasty, evidence does not show a favored surgical approach.",Moderate,3,Moderate,3,,0.75,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
607,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,Either spinal or general anesthesia is appropriate for patients with a hip fracture.,Strong,4,Strong,4,,1,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
608,12264,,Management of Hip Fractures in Older Adults,Management of Hip Fractures in Older Adults,2021,American Academy of Orthopaedic Surgeons,United States,Fractures & Osteoporosis,GRADE,6,4,4,"In patients with stable (impacted/non-displaced) femoral neck fractures, hemiarthroplasty, internal fixation or non-operative care may be considered.",Moderate,3,Limited,2,,0.75,American Academy of Orthopaedic Surgeons. Management of Hip Fractures in Older Adults [Internet]. American Academy of Orthopaedic Surgeons; 2021. Available from: https://www.aaos.org/hipfxcpg,7
609,12271,,SIGN 160 - Management of suspected bacterial lower urinary tract infection in adult women,Management of suspected bacterial lower urinary tract infection in adult women,2020,Scottish Intercollegiate Guidelines Network ,UK,UTI & Asymptomatic Bacturia,SIGN,5,8,3,Be aware that functional deterioration and/or changes to performance of activities of daily living may be indicators of infection in frail older people.,2++,5,Strong,3,Women,0.625,Management of suspected bacterial lower urinary tract infection in adult women: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2020.,1
610,12271,,SIGN 160 - Management of suspected bacterial lower urinary tract infection in adult women,Management of suspected bacterial lower urinary tract infection in adult women,2020,Scottish Intercollegiate Guidelines Network ,UK,UTI & Asymptomatic Bacturia,SIGN,5,8,3,"Be aware that women aged 65 years and over, especially those in long-term care facilities, may not display the usual symptoms and signs of urinary tract infection that are seen in younger women.",2++,5,Strong,3,Women,0.625,Management of suspected bacterial lower urinary tract infection in adult women: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2020.,18
611,12271,,SIGN 160 - Management of suspected bacterial lower urinary tract infection in adult women,Management of suspected bacterial lower urinary tract infection in adult women,2020,Scottish Intercollegiate Guidelines Network ,UK,UTI & Asymptomatic Bacturia,SIGN,5,8,3,Do not treat asymptomatic bacteriuria in non-pregnant women of any age.,1++,8,Strong,3,Women,1,Management of suspected bacterial lower urinary tract infection in adult women: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2020.,18
612,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,10,3,"Es soll ein regelmäßiges, aktives Screening für Delir insbesondere bei älteren Patient:innen, erfolgen, da Alter ein starker Prädiktor für ein hypoaktives Delir bei Intensivmedizinisch behandelten Patient:innen ist.",2b,6,A,3,,0.6,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
613,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,"Validierte Scoringsysteme sollen zur Therapiesteuerung und Überwachung der Analgesie, der Sedierung, der Angst und des Delirs eingesetzt werden.",+++,4,A,3,,0.8,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
614,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,10,3,Die Faces Pain Scale (FPS) und die Numeric Rating Skala (NRS) sind reliabel und valide und sollen bei älteren Patient:innen zur Erfassung der Schmerz-Intensität eingesetzt werden.,1b,9,A,3,,0.9,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",26
615,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,Eine kontinuierliche Alpha-2-Agonist-Gabe soll zur Therapie eines Delirs verwendet werden.,++++,5,A,3,,1,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",3
616,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,Eine symptomorientierte Therapie des Delirs soll zeitnah durchgeführt werden.,+++,4,A,3,,0.8,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
617,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,"Während der intensivstationären Behandlung soll auf folgende Risikofaktoren geachtet werden:
- Basisfaktoren (Komorbiditäten[5], höherer ASA-Status, höheres Lebensalter, vorbestehendes kognitives Defizit, chronische Schmerzen, Schwere der Erkrankung / höherer APACHE-Score, vorbestehende Immobilität)
- Behandlungsassoziierte Faktoren (operativer Eingriff, anticholinerge Medikation, Einsatz von Benzodiazepinen, Tiefe und Dauer einer Sedierung, maschinelle Beatmung / Intubation, Fixierung, Transfusion)
- Psychologische und soziale Faktoren, Umwelteinflüsse und iatrogene Faktoren",+++,4,A,3,,0.8,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",5
618,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,10,3,Die nicht-pharmakologische Prävention und Therapie eines Delirs soll auch bei älteren Patient:innen vorrangig sein.,1a,10,A,3,,1,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
619,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,Zur Reduktion von Schmerzen und Angst und zur Therapie des Delirs sollen nicht-pharmakologische Maßnahmen eingesetzt werden. Diese können Einzelmaßnahmen oder ein Bündel von Maßnahmen umfassen.,++++,5,A,3,,1,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
620,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,10,3,Anticholinerge Medikamente sollen auf Grund Ihres hohen Delir-Risikos bei älteren Patient:innen gemieden werden.,1a,10,A,3,,1,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",3
621,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,"Wenn nicht-pharmakologische Maßnahmen nicht erfolgreich sind, sollte die Behandlung produktiv-psychotischer Symptome eines Delirs niedrig dosiert titriert mit Haloperidol, Risperidon, Olanzapin oder Quetiapin erfolgen.",+++,4,B,2,,0.8,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",3
622,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,Das Ergebnis des Delirmonitorings soll mindestens einmal pro Schicht (in der Regel 8-stündlich) dokumentiert werden.,++++,5,A,3,,1,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
623,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,Bei Patient:innen mit unklaren Bewusstseinsstörungen (zum Beispiel hypoaktivem Delir) soll der Ausschluss eines non-konvulsiven Status mittels Elektroencephalographie (EEG) erfolgen.,++,3,A,3,,0.6,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
624,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,10,3,Benzodiazepine sollen bei älteren Patient:innen nur nach strenger Indikationsprüfung zur Sedierung verwendet und auch nur titriert nach Ziel-RASS (Richmond Agitation-Sedation Scale) verwendet werden. Problem: Abschätzung hypoaktive Delirien.,1b,9,A,3,,0.9,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",17
625,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,"Das Behandlungsziel und der aktuelle Grad von Analgesie, Sedierung, Angst und Delir sollen standardisiert mindestens einmal pro Schicht (in der Regel 8-stündlich) dokumentiert werden.",++,3,A,3,,0.6,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
626,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,10,3,"Bei Patient:innen mit fortgeschrittener Demenz kann die ""BESD"" (Beurteilung von Schmerzen bei Demenz) zur Schmerzeinschätzung eingesetzt werden; auch andere validierte Scores stehen zur Verfügung.",2a,7,0,1,,0.7,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",2
627,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,Eine nicht-pharmakologische Prävention des Delirs soll bei allen intensivmedizinisch-behandelten Patient:innen durchgeführt werden: Tagsüber sollen aktivierende Maßnahmen durchgeführt werden. Nachts sollen schlaffördernde Maßnahmen durchgeführt werden.,++++,5,A,3,,1,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
628,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,Es soll ein regelmäßiges gezieltes Screening auf delirante Symptome mit einem validen und reliablen Delir-Score durchgeführt werden.,+++,4,A,3,,0.8,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",11
629,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,"Eine pharmakologische Delirprävention sollte bei erwachsenen, intensivmedizinisch-behandelten Patient:innen nicht durchgeführt werden.",+++,4,B,2,,0.8,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",3
630,12273,,S3- Leitlinie Analgesie Sedierung Delirmanagement in der Intensivmedizin,"Analgesie, Sedierung und Delirmanagement in der Intensivmedizin ",2020,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin, Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin",Germany,Delirium & Dementia,Other: modified GRADE | Oxford,6,5,3,"Die Behandlung von psychotischen Symptomen (unabhängig ob im Delir, beginnendem Delir oder isoliert vorkommend) soll mit Neuroleptika erfolgen.",++++,5,A,3,,1,"Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI). S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie 2020). 2021 Mar [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-012",3
631,12278,ArzneimittelkommissionDerDeutschenApotheker(AMK) 2019,"NVL Chronische Herzinsuffizienz – Langfassung, 3. Auflage",Chronische Herzinsuffizienz,2019,"Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften",Germany,Heart Failure,Oxford,6,5,3,"Allen klinisch stabilen (1-2 Wochen konstantes Körpergewicht unter Diuretikatherapie, keine Zeichen einer Dekompensation) symptomatischen Patienten (NYHA II-IV) mit nachgewiesener Herzinsuffizienz mit reduzierter Ejektionsfraktion und Fehlen von Kontraindikationen sollen Betarezeptorenblocker (Bisoprolol, Carvedilol oder Metoprololsuccinat) empfohlen werden, Patienten über 70 Jahren alternativ auch Nebivolol.",2,4,++,3,,0.8,"Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale Versorgungs Leitlinie Chronische Herzinsuffizienz – Langfassung, 3. Auflage. Version 3. 2019 [cited 2021 Dec 18]; Available from: https://www.leitlinien.de/herzinsuffizienz",15
632,12278,ArzneimittelkommissionDerDeutschenApotheker(AMK) 2019,"NVL Chronische Herzinsuffizienz – Langfassung, 3. Auflage",Chronische Herzinsuffizienz,2019,"Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften",Germany,Heart Failure,Oxford,6,5,3,"Patienten mit Herzinsuffizienz sollten auf Anzeichen von Funktionsverlusten untersucht werden, insbesondere bei Veränderungen im Krankheitsverlauf (z. B. Dekompensationen). Dafür können geriatrische Assessmentverfahren angewendet werden. Bei Hinweisen auf drohende oder manifeste Funktionsverluste sollten unterstützende Maßnahmen (z. B. Physiotherapie, Ernährungstherapie) eingeleitet werden.",1,5,+,2,,1,"Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale Versorgungs Leitlinie Chronische Herzinsuffizienz – Langfassung, 3. Auflage. Version 3. 2019 [cited 2021 Dec 18]; Available from: https://www.leitlinien.de/herzinsuffizienz",1
633,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Die Empfehlung einer Gewichtsreduktion kann bei stark übergewichtigen, eher jüngeren Frauen mit Harninkontinenz in Erwägung gezogen werden.",I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",24
634,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,DDAVP (Desmopressin) ist auch bei Erwachsenen wirksam in der Reduktion der nächtlichen Diurese und damit auch der Nykturie.,III,2,C,1,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",3
635,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Die 180-Watt-LTB-Greenlight-Laserung (Lithium-Tri-Borat-Laserung; Laserablation der Prostata) ist besonders bei kardiovaskulären Risikopatienten und solchen unter Blutverdünnung empfehlenswert.,I,5,C,1,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",5
636,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Anticholinergika (syn. Antimuskarinika) können eine wirksame Therapieform zur Verbesserung von Symptomen bei überaktiver Blase mit oder ohne Inkontinenz sein.,I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
637,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Eine Laserablation der Prostata kann momentan für solche Patienten in Erwägung gezogen werden, bei denen einerseits eine konservative Therapie der benigne Prostatahyperplasie fehlgeschlagen ist, andererseits jedoch Bedenken hinsichtlich der OP-Fähigkeit für eine klassische TUR-P bestehen.",IIb,3,B,2,,0.5,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
638,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Damit können Alpha-1-Rezeptoren-Blocker unter den Bedingungen des off-label-uses auch bei der Blasenauslassobstruktion der Frau flankierend zu anderen Maßnahmen angewendet werden.,I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
639,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,In der Geriatrie ist die Empfehlung einer Flüssigkeitsrestriktion wegen der veränderten Verteilungsvolumina und der häufig vorhandenen Multimorbidität und Polymedikation problematisch und sollte individuell unter engmaschiger Kontrolle ausgesprochen werden.,III,2,C,1,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
640,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Der Einsatz einer spezialisierten Pflegekraft ist mit nichtpharmakologischen Interventionen wirksam in der Reduktion von Inkontinenzereignissen und des Vorlagenverbrauches bei geriatrischen Patienten.,I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
641,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Zur Vermeidung nosokomialer Infektionen sollten grundsätzlich geschlossene Urindrainagesysteme mit einer kontinuierlichen Urindrainage Verwendung finden.,I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
642,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Die Injektion von Botulinum Toxin A in den Detrusor stellt eine operative, hochwirksame Maßnahme mit limitierter Invasivität in Fällen einer therapierefraktären überaktiven Blase dar.",I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
643,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Nach einer Harnverhaltung besteht eine höhere Chance der Restitution der Spontanmiktion im Sinne eines Katheterauslassversuches, wenn parallel eine Senkung des Blasenauslasswiderstandes eingeleitet wurde.",I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
644,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Die offen-operative Entfernung des Prostataadenoms (transvesikale Prostataadenomektomie) bietet die Möglichkeit einer raschen Entfernung eines großen Adenomvolumens (in aller Regel > 70 ml) in kurzer Operationszeit auf Kosten einer längeren Katheterliegezeit und längerer Immobilität. Damit bleibt das Verfahren der operativen Sanierung großer Prostataadenome unter gründlicher Risiko-Nutzen-Analyse Einzelfällen reserviert.,III,2,B,2,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
645,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Zusätzlich zur strukturierten Anamneseerhebung bietet ein validiertes Assessment den Vorteil der Vollständigkeit, standardisierten Terminologie, Vergleichbarkeit im zeitlichen Verlauf und Unabhängigkeit vom Untersucher.Es wird empfohlen, symptom- bzw. krankheitsspezifische Lebensqualitätsfragebögen zusätzlich zur Inkontinenzanamnese einzusetzen.",III,2,C,1,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",26
646,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Diuretika sollten deswegen, wenn möglich unter Vermeidung von schnell wirksamen Substanzen in retardierter Form und an das individuelle Miktionsmuster im Tagesverlauf, angeglichen verabreicht werden.",III,2,B,2,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
647,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Ein Elektro-Biofeedbacktraining ist genauso effektiv wie ein Biofeedbacktraining, bei dem mit vag. Palpation angeleitet wird, und wie eine Verhaltensintervention mittels eines Blasentagebuches.",I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",26
648,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Falls vorhanden, sollte eine Obstipation im Rahmen der Inkontinenzbehandlung flankierend reguliert werden.",III,2,B,2,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
649,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Ein physiotherapeutisch geleitetes Beckenbodentraining ist Therapie der ersten Wahl bei der Behandlung von Belastungs- und/oder gemischter Inkontinenz, besonders, weil von keinen unerwünschten Wirkungen berichtet wird. Erforderlich sind die Fähigkeit und der Wille zur Kooperation auf der Seite des Patienten.",I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
650,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Unretardiertes Oxybutynin ist mit dem höchsten Risiko von kognitiven Nebenwirkungen verbunden.,III,2,B,2,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",21
651,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Im Einzelfall sollte der mögliche Zusammenhang zwischen Rauchen und einer Harninkontinenz mit dem Patienten besprochen werden.,III,2,B,2,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",0
652,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Eine unter Therapie auftretende Harnretention kann bei geriatrischen Patienten mit der evtl. erforderlichen Harnableitung (z. B. Dauerkatheter, suprapubischer Katheter) und den daraus resultierenden Sekundärproblemen besonders schwerwiegend sein. Da diese Nebenwirkung bei Hochbetagten, multimorbiden Patienten und Frauen mit mehrfachen vag. Entbindungen häufiger auftritt, sollten bei Hochbetagten eher niedrigerere Dosierungen auch unter Inkaufnahme einer geringeren Wirksamkeit Anwendung finden.",III,2,B,2,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
653,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Mirabegron ist eine wirksame und zugelassene Substanz in der Therapie der überaktiven Blase mit einem nicht anticholinergen Wirkmechanismus.,I,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",10
654,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,"Die beschriebene Gruppe der Anticholinergika Darifenacin, Fesoterodin, Oxybutynin, Propiverin, Solifenacin, Tolterodin und Trospiumchlorid stellt unter Beachtung der Kontraindikationen und Nebenwirkungen eine wirksame Therapie der überaktiven Blase dar.",Ia,6,A,3,,1,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",10
655,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Screeningfragebögen und Symptomfragebögen (Questionnaire for urinary incontinence diagnosis QUID und andere) können dabei Hinweise auf die vorliegende Harninkontinenzform liefern.,III,2,B,2,,0.333333333333333,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
656,12306,,"Federführende Gesellschaft: Deutsche Gesellschaft für Geriatrie - S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie","Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie",2019,Deutsche Gesellschaft für Geriatrie,Germany,Incontinence,Other: custom,4,6,3,Die Präferenz einer Vorlagenversorgung ist bei den Betroffenen höher als eine Katheterversorgung und ähnlich hoch wie eine medikamentöse Therapie oder Verhaltenstherapie.,II,4,B,2,,0.666666666666667,"Deutsche Gesellschaft für Geriatrie e.V. (DGG). S2e-Leitlinie Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. 2019 Jan 2 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/084-001",18
657,12616,,Deprescribing antihyperglycemic agents in older persons,Deprescribing antihyperglycemic agents in older persons ,2017,College of Family Physicians of Canada,Canada,ADR & Deprescribing,GRADE,4,4,2,"We recommend deprescribing antihyperglycemic agents that are known to contribute to gypoglycemia in elderly (> 65 y) adults taking ≥ 1 antihyperglycemic medications to treat type 2 diabetes and meeting ≥ 1 of the following criteria:
- at risk of hypoglycemia (e.g., owing to advancing age, overly intense glycemic control, multiple comorbidities, drug interactions, hypoglycemia history or lack of awareness, impaired renal function, or taking a sulfonylurea or insulin);
- at risk of other antihyperglycemic adverse effects; or
- in whom benefit is uncertain owing to frailty, dementia, or limited life expectancy",very low,1,Strong,2,,0.25,"Farrell B, Black C, Thompson W, McCarthy L, Rojas-Fernandez C, Lochnan H, et al. Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline. Can Fam Physician. 2017 Nov;63(11):832–43.",16
658,12616,,Deprescribing antihyperglycemic agents in older persons,Deprescribing antihyperglycemic agents in older persons ,2017,College of Family Physicians of Canada,Canada,ADR & Deprescribing,GRADE,4,4,2,"We recommend individualizing glycemic targets to goals of care and time to benefit according to the Canadian Diabetes Association guidelines and other guidelines that specifically address deprescribing for elderly (> 65 y) adults taking ≥ 1 antihyperglycemic medications to treat type 2 diabetes and meeting ≥ 1 of the following criteria:
- at risk of hypoglycemia (e.g., owing to advancing age, overly intense glycemic control, multiple comorbidities, drug interactions, hypoglycemia history or lack of awareness, impaired renal function, or taking a sulfonylurea or insulin);
- at risk of other antihyperglycemic adverse effects; or
- in whom benefit is uncertain owing to frailty, dementia, or limited life expectancy",very low,1,Strong,2,,0.25,"Farrell B, Black C, Thompson W, McCarthy L, Rojas-Fernandez C, Lochnan H, et al. Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline. Can Fam Physician. 2017 Nov;63(11):832–43.",16
659,12623,,Deprescribing benzodiazepine receptor agonists,Deprescribing benzodiazepine receptor agonists,2018,College of Family Physicians of Canada,Canada,ADR & Deprescribing,GRADE,6,4,2,"For elderly adults (≥ 65 y) who use BZRAs, we recommend the following: Taper the benzodiazepine receptor agonist dose slowly.",low,2,Strong,2,,0.5,"Farrell B, Black C, Thompson W, McCarthy L, Rojas-Fernandez C, Lochnan H, et al. Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline. Can Fam Physician. 2017 Nov;63(11):832–43.",17
660,12697,Grundy 2019,2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol,Management of Blood Cholesterol,2018,"American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association",United States,Dyslipidemia,"Other: custom (AHA, ACC)",5,5,3,"In adults older than 75 years of age with diabetes mellitus and who are already on statin therapy, it is reasonable to continue statin therapy.",B-NR,3,Moderate,2,,0.6,"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019 Jun;73(24):e285–350.",23
661,12697,Grundy 2019,2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol,Management of Blood Cholesterol,2018,"American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association",United States,Dyslipidemia,"Other: custom (AHA, ACC)",5,5,3,"In adults 76 to 80 years of age with an LDL-C level of 70 to 189 mg/dL (1.7 to 4.8 mmol/L), it may be nreasonable to measure coronary artery calcium to reclassify those with a CAC score of zero to avoid statin therapy.",B-R,4,Weak,1,,0.8,"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019 Jun;73(24):e285–350.",23
662,12697,Grundy 2019,2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol,Management of Blood Cholesterol,2018,"American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association",United States,Dyslipidemia,"Other: custom (AHA, ACC)",5,5,3,"In adults older than 75 years with diabetes mellitus, it may be reasonable to initiate statin therapy after a
clinician-patient discussion of potential benefits and risks.",C-LD,2,Weak,1,,0.4,"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019 Jun;73(24):e285–350.",23
663,12697,Grundy 2019,2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol,Management of Blood Cholesterol,2018,"American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association",United States,Dyslipidemia,"Other: custom (AHA, ACC)",5,5,3,"In patients older than 75 years of age who are tolerating high-intensity statin therapy, it is reasonable to
continue high-intensity statin therapy after evaluation of the potential for atherosclerotic cardiovascular disease risk reduction, adverse
effects, and drug-drug interactions, as well as patient frailty and patient preferences.",C-LD,2,Moderate,2,,0.4,"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019 Jun;73(24):e285–350.",23
664,12697,Grundy 2019,2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol,Management of Blood Cholesterol,2018,"American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association",United States,Dyslipidemia,"Other: custom (AHA, ACC)",5,5,3,"In patients older than 75 years of age with clinical atherosclerotic cardiovascular disease (ASCVD), it is reasonable to initiate moderate- or high-intensity statin therapy after evaluation of the potential for ASCVD risk reduction, adverse effects, and drug–drug interactions, as well as patient frailty and patient preferences.",B-R,4,Moderate,2,,0.8,"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019 Jun;73(24):e285–350.",23
665,12697,Grundy 2019,2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol,Management of Blood Cholesterol,2018,"American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association",United States,Dyslipidemia,"Other: custom (AHA, ACC)",5,5,3,"In adults 75 years of age or older with an LDL-C level of 70 to 189 mg/dL (1.7 to 4.8 mmol/L), initiating a moderate-intensity statin may be reasonable.",B-R,4,Weak,1,,0.8,"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019 Jun;73(24):e285–350.",23
666,12697,Grundy 2019,2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol,Management of Blood Cholesterol,2018,"American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Physician Assistants, Association of Black Cardiologists, American College of Preventive Medicine, American Diabetes Association, American Geriatrics Society, American Pharmacists Association, American Society for Preventive Cardiology, National Lipid Association, and Preventive Cardiovascular Nurses Association",United States,Dyslipidemia,"Other: custom (AHA, ACC)",5,5,3,"In adults 75 years of age or older, it may be reasonable to stop statin therapy when functional decline (physical or cognitive), multimorbidity, frailty, or reduced life-expectancy limits the potential benefits of statin therapy.",B-R,4,Weak,1,,0.8,"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019 Jun;73(24):e285–350.",23
667,12712,,Hypertension in adults: diagnosis and management,Hypertension in adults: diagnosis and management,2019,National Institute for Health and Care Excellence,UK,Hypertension,GRADE,6,4,3,Consider antihypertensive drug treatment in addition to lifestyle advice for people aged over 80 with stage 1 hypertension if their clinic blood pressure is over 150/90 mmHg. Use clinical judgement for people with frailty or multimorbidity.,Moderate,2,Consider,3,,0.5,National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management [Internet]. London: National Institute for Health and Care Excellence; 2019 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng136,6
668,12712,,Hypertension in adults: diagnosis and management,Hypertension in adults: diagnosis and management,2019,National Institute for Health and Care Excellence,UK,Hypertension,GRADE,6,4,3,Reduce and maintain blood pressure at the following levels: below 145/85 mmHg for adults aged 80 and over. Use clinical judgement for people with frailty or multimorbidity.,Very Low - High,4,Should,2,,1,National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management [Internet]. London: National Institute for Health and Care Excellence; 2019 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng136,6
669,12712,,Hypertension in adults: diagnosis and management,Hypertension in adults: diagnosis and management,2019,National Institute for Health and Care Excellence,UK,Hypertension,GRADE,6,4,3,Reduce clinic blood pressure to below 150/90 mmHg and maintain that level in adults with hypertension aged 80 and over. Use clinical judgement for people with frailty or multimorbidity.,Very Low - High,4,Should,2,,1,National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management [Internet]. London: National Institute for Health and Care Excellence; 2019 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng136,6
670,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend that the 4-variable Kidney Failure Risk Equation performs sufficiently well for use in older patients with advanced chronic kidney disease and estimated glomerual filtration rate (eGFR) < 45 ml/min/1.73m².,B,3,Strong,2,,0.75,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
671,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend that there is insufficient evidence to prefer one estimating equation over another since all perform equally and substantial misclassification can occur with any of these equations when used in older patients with differing body composition.,B,3,Strong,2,,0.75,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",20
672,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,"For formal measurement of kidney function, use of CKD-EPICr-Cys may be an acceptable alternative.",C,2,Weak,1,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
673,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend the Subjective Global Assessment (SGA) as the gold standard to assess nutritional status of older patients with chronic kidney disease stage 3b or higher (estimated glomerual filtration rate (eGFR) < 45 ml/min).,C,2,Strong,2,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
674,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend that exercise has a positive impact on the functional status of older patients with chronic kidney disease stage 3b or higher.,C,2,Strong,2,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
675,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend taking account of kidney function when prescribing drugs whose active forms or metabolites are renally cleared.,A,4,Strong,2,,1,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
676,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We suggest that exercise training be offered in a structured and individualized manner to avoid adverse events.,C,2,Weak,1,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",14
677,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend a simple score be used on a regular basis to assess functional status in older patients with chronic kidney disease stage 3b-5d with the intention to identify those who would benefit from more in depth geriatric assessment and rehabilitation.,C,2,Strong,2,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
678,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,"We suggest that in older patients on haemodialysis, a score including serum albumin, body mass index, serum creatinine/body surface area and normalised Protein Nitrogen Appearance (nPNA) may be used to assess nutritional status.",D,1,Weak,1,,0.25,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",16
679,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We suggest the Renal Epidemiology and Information Network (REIN) score be used to predict the short term/6 month risk for mortality in older patients with chronic kidney disease stage 5.,B,3,Weak,1,,0.75,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
680,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We suggest a trial of structured dietary advice and support with the aim of improving nutritional status.,C,2,Weak,1,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",24
681,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,"We suggest that in patients at low risk on the Bansal score, a formal assessment of frailty be carried out. Frail patients should be managed as high risk.",B,3,Weak,1,,0.75,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
682,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend that the option for conservative management be discussed during the shared decision making process on different management options for end stage renal disease.,D,1,Strong,2,,0.25,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",20
683,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We suggest using the Bansal score to predict individual five year risk of death before end-stage kidney disease in older people with chronic kidney disease stage 3 to 5.,B,3,Weak,1,,0.75,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
684,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend the Renal Epidemiology and Information Network (REIN) score can be useful to stratify short term/6 month mortality risk of patients intending to start renal replacement therapy.,C,2,Strong,2,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
685,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend formal measurement of kidney function if more accurate and precise estimation of glomerual filtration rate (GFR) is required.,B,3,Strong,2,,0.75,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
686,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,"We suggest that for drugs with a narrow toxic/therapeutic range, regular measurement of serum concentrations can provide useful information. Differences in protein binding in relation to uraemia may necessitate use of different target levels of total drug concentration.",C,2,Weak,1,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
687,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,"We recommend that most simple scores, including self report scales and field tests (sit to stand, gait speed or 6 minute walk test) have comparable and sufficient discriminating power to identify patients with decreased functional status.",C,2,Strong,2,,0.5,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",26
688,12729,Farrington 2016,Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ),Management of older patients with chronic kidney disease stage 3b or higher,2016,European Renal Best Practice Group,Other: Europe,Chronic Kidney Disease,GRADE,5,4,2,We recommend using estimating equations which correct for differences in creatinine generation rather than plain serum creatinine measurements to assess kidney function in older patients.,A,4,Strong,2,,1,"Farrington K, Covic A, Aucella F, Clyne N, De Vos L, Findlay A, et al. Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR< 45 mL/min/1.73 m2). Nephrology Dialysis Transplantation. 2016;31(suppl_2):ii1–66.",1
689,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,"We suggest evaluating the following preoperative risk factors for post-operative delirium: Comorbidities (e.g. cerebrovascular including stroke, cardiovascular, peripheral vascular diseases, diabetes, anaemia, Parkinson’s disease, depression, chronic pain and anxiety disorders).",1b,9,B,1,,0.9,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
690,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We suggest evaluating the following preoperative risk factors for post-operative delirium: The results of comorbidity scores such as the American Society of Anesthesiologists’ physical status classification system (ASA-PS) or the Charlson Comorbidity Index (CCI) or the Clinical Impairment Assessment Score (CIAS) before surgery.,2b,6,B,1,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
691,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We suggest considering the following intraoperative risk factors for post-operative delirium: Site of surgery (Abdominal and cardiothoracic).,2b,6,B,1,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
692,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We recommend using a validated delirium score for post-operative delirium screening.,2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
693,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We recommend monitoring depth of anaesthesia.,1b,9,A,2,,0.9,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
694,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,In elderly surgical patients we recommend evaluating the following preoperative risk factors for post-operative delirium: Sensory impairment.,4,2,A,2,,0.2,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
695,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We suggest avoiding routinepremedication with benzodiazepines except forpatients with severe anxiety.,2b,6,B,1,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",3
696,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We suggest considering the following intraoperative risk factors for post-operative delirium: Intraoperative bleeding.,2b,6,B,1,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
697,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,In elderly surgical patients we recommend evaluating the following preoperative risk factors for post-operative delirium: Reduced functional status and/or frailty.,2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
698,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We recommend adequate pain management and treatment.,1b,9,A,2,,0.9,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",26
699,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We recommend considering duration of surgery as a further intraoperative risk factor.,2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
700,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,In elderly surgical patients we recommend evaluating the following preoperative risk factors for post-operative delirium: Malnutrition (low serum albumin).,2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
701,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,In elderly surgical patients we recommend evaluating the following preoperative risk factors for post-operative delirium: Cognitive impairment.,2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
702,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,"We suggest implementing nonpharmacological measures to reduce post-operative delirium: orientation (clock, communication, etc.), visual/hearing aids, noise reduction and maintenance of a day/night rhythm avoidance of unnecessary indwelling catheters, early mobilisation and early nutrition.",4,2,B,1,,0.2,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
703,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We recommend evaluating pain as a postoperative risk factor for post-operative delirium.,2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
704,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We suggest using low-dose haloperidol a or low-dose atypical neuroleptics to treat post-operative delirium.,2b,6,B,1,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",3
705,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We recommend screening for post-operative delirium in all patients starting in the recovery room and in each shift up to postoperative day 5.,2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
706,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We suggest evaluating the following preoperative risk factors for post-operative delirium: Advanced age.,2b,6,B,1,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
707,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We suggest evaluating the following preoperative risk factors for post-operative delirium: Hyponatraemia or hypernatraemia.,1b,9,B,1,,0.9,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
708,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,"We recommend promptly diagnosing post-operative delirium, establishing a differential diagnosis, and instituting treatment.",2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
709,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We recommend evaluating alcohol related disorders (ICD-10)/alcohol use disorders(DSM-5) as a further preoperative riskfactor.,2b,6,A,2,,0.6,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",13
710,12739,Aldecoa 2017,European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium,Postoperative Delirium,2017,European Society of Anaesthesiology,Other: Europe,Delirium & Dementia,Oxford,4,10,2,We suggest implementing fast-track surgery to prevent post-operative delirium.,1b,9,B,1,,0.9,"Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. European Journal of Anaesthesiology| EJA. 2017;34(4):192–214.",11
711,12762,Ak 2018,CLINICAL PRACTICE GUIDELINES - Management of Hypertension,Management of Hypertension,2018,"Malysian Society of Hypertension, Ministry of Health Malaysia, Academy of Medicine  of Malaysia",Other: Malaysia,Hypertension,"Other: US/Canada Preventive Services Task Force, SIGN",4,5,3,Use renin–angiotensin system (RAS) blockers in patients > 75 years old with atrial fibrillation to reduce mortality.,II-2,3,B,2,,0.6,Malaysian Society of Hypertension. Management of Hypertension (5th Edition) [Internet]. Malaysian Society of Hypertension; 2018. Available from: https://www.msh.org.my/,12
712,12762,Ak 2018,CLINICAL PRACTICE GUIDELINES - Management of Hypertension,Management of Hypertension,2018,"Malysian Society of Hypertension, Ministry of Health Malaysia, Academy of Medicine  of Malaysia",Other: Malaysia,Hypertension,"Other: US/Canada Preventive Services Task Force, SIGN",4,5,3,Consider systolic blood pressure < 130 mmHg in fit 65-80 year olds.,I,5,A,3,,1,Malaysian Society of Hypertension. Management of Hypertension (5th Edition) [Internet]. Malaysian Society of Hypertension; 2018. Available from: https://www.msh.org.my/,6
713,12762,Ak 2018,CLINICAL PRACTICE GUIDELINES - Management of Hypertension,Management of Hypertension,2018,"Malysian Society of Hypertension, Ministry of Health Malaysia, Academy of Medicine  of Malaysia",Other: Malaysia,Hypertension,"Other: US/Canada Preventive Services Task Force, SIGN",4,5,3,Target systolic blood pressure < 150 mmHg for > 80 year olds.,I,5,A,3,,1,Malaysian Society of Hypertension. Management of Hypertension (5th Edition) [Internet]. Malaysian Society of Hypertension; 2018. Available from: https://www.msh.org.my/,6
714,12762,Ak 2018,CLINICAL PRACTICE GUIDELINES - Management of Hypertension,Management of Hypertension,2018,"Malysian Society of Hypertension, Ministry of Health Malaysia, Academy of Medicine  of Malaysia",Other: Malaysia,Hypertension,"Other: US/Canada Preventive Services Task Force, SIGN",4,5,3,Target systolic blood pressure < 140 mmHg for 65-80 year olds.,II-2,3,B,2,,0.6,Malaysian Society of Hypertension. Management of Hypertension (5th Edition) [Internet]. Malaysian Society of Hypertension; 2018. Available from: https://www.msh.org.my/,6
715,12763,,Cough (acute): antimicrobial prescribing,Cough (acute): antimicrobial prescribing ,2019,National Institute for Health and Care Excellence,UK,Pneumonia & COPD,GRADE,5,4,3,"For people with an acute cough who are identified as at higher risk of complications (ideally at a face-to-face clinical examination), consider: 
- an immediate antibiotic prescription 
- a back-up antibiotic prescription",limited,1,Consider,1,,0.25,National Institute for Health and Care Excellence. Cough (acute): antimicrobial prescribing [Internet]. London: National Institutefor Health and Care Excellence; 2019 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng120,5
716,12763,,Cough (acute): antimicrobial prescribing,Cough (acute): antimicrobial prescribing ,2019,National Institute for Health and Care Excellence,UK,Pneumonia & COPD,GRADE,5,4,3,"Be aware that people with an acute cough may be at higher risk of complications if they are older than 65 years with 2 or more of the following criteria, or older than 80 years with 1 or more of the following criteria: 
- hospitalisation in previous year 
- type 1 or type 2 diabetes 
- history of congestive heart failure 
- current use of oral corticosteroids",limited,1,Should,2,,0.25,National Institute for Health and Care Excellence. Cough (acute): antimicrobial prescribing [Internet]. London: National Institutefor Health and Care Excellence; 2019 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng120,5
717,12777,,Chronic obstructive pulmonary disease in over 16s: diagnosis and management,Chronic obstructive pulmonary disease in over 16s: diagnosis and management ,2019,National Institute for Health and Care Excellence,UK,Pneumonia & COPD,GRADE,5,4,3,"From diagnosis onwards, when discussing prognosis and treatment decisions with people with stable COPD, think about the following factors that are individually associated with prognosis:
- FEV1
- smoking status
- breathlessness (MRC scale) chronic hypoxia and/or cor pulmonale
- low BMI
- severity and frequency of exacerbations
- hospital admissions
- symptom burden (for example, COPD Assessment Test [CAT] score)
- exercise capacity (for example, 6-minute walk test)
- Transfer Factor for Carbon Monoxide
- whether the person meets the criteria for long-term oxygen therapy and/or home non-invasive ventilation
- multimorbidity
- frailty",High,4,Should,2,,1,National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management [Internet]. London: National Institutefor Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng115,5
718,12779,,Chronic heart failure in adults: diagnosis and management,Chronic heart failure in adults: diagnosis and management ,2018,National Institute for Health and Care Excellence,UK,Heart Failure,GRADE,6,4,3,"Be aware that high levels of serum natriuretic peptides can have causes other than heart failure (for example, age over 70 years, left ventricular hypertrophy, ischaemia, tachycardia, right ventricular overload, hypoxaemia [including pulmonary embolism], renal dysfunction [estimated glomerual filtration rate (eGFR) less than 60 ml/minute/1.73m²], sepsis, chronic obstructive pulmonary disease, diabetes, or cirrhosis of the liver).",very low,1,Should,2,,0.25,National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management [Internet]. Final. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng106,12
719,12779,,Chronic heart failure in adults: diagnosis and management,Chronic heart failure in adults: diagnosis and management ,2018,National Institute for Health and Care Excellence,UK,Heart Failure,GRADE,6,4,3,"The specialist heart failure multidisciplinary team should directly involve, or refer people to,
other services, including rehabilitation, services for older people and palliative care services, as needed.",moderate,3,Should,2,,0.75,National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management [Internet]. Final. London: National Institute for Health and Care Excellence; 2018 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng106,14
720,12781,,Chinese Guideline on the Primary Prevention of Cardiovascular Disease,Primary Prevention of Cardiovascular Diseases,2021,"Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention andRehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committeeof Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee ofChinese Medical Doctor Association",China,Hypertension,Other: Newcastle Ottawa scale,4,3,4,"A blood pressure target of < 140/90 mmHg should be
considered for older hypertensive patients (the target should be individualized based on the tolerability of the individual patient).",B,2,IIb,2,,0.666666666666667,Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Cardiology Discovery. 2021 Jun;1(2):70–104.,6
721,12781,,Chinese Guideline on the Primary Prevention of Cardiovascular Disease,Primary Prevention of Cardiovascular Diseases,2021,"Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention andRehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committeeof Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee ofChinese Medical Doctor Association",China,Hypertension,Other: Newcastle Ottawa scale,4,3,4,Low-dose aspirin (75-100 mg/d) is not recommended for primary prevention of atherosclerotic cardiovascular disease in patients aged below 40 years or over 70 years.,B,2,III,1,,0.666666666666667,Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Cardiology Discovery. 2021 Jun;1(2):70–104.,12
722,12810,,Type 2 diabetes in adults: management,Type 2 diabetes in adults: management ,2020,National Institute for Health and Care Excellence,UK,Diabetes Mellitus,GRADE,6,4,3,"Consider relaxing the target HbA1c level [6.5-7.5 %]. on a case-by case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes:
- who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy
- for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job
- for whom intensive management would not be appropriate, for example, people with significant comorbidities",High,4,Consider,1,,1,National Institute for Health and Care Excellence. Type 2 diabetes in adults: management [Internet]. London: National Institutefor Health and Care Excellence; 2015 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng28,16
723,12828,,Parkinson’s disease in adults,Parkinson’s disease in adults ,2017,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,3,Consider a cholinesterase inhibitor for people with severe Parkinson's disease dementia.,High,4,Consider,1,,1,National Institute for Health and Care Excellence. Parkinson’s disease in adults [Internet]. London: National Institutefor Health and Care Excellence; [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng71,25
724,12828,,Parkinson’s disease in adults,Parkinson’s disease in adults ,2017,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,3,Offer a cholinesterase inhibitor for people with mild or moderate Parkinson's disease dementia.,High,4,Should,2,,1,National Institute for Health and Care Excellence. Parkinson’s disease in adults [Internet]. London: National Institutefor Health and Care Excellence; [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng71,25
725,12828,,Parkinson’s disease in adults,Parkinson’s disease in adults ,2017,National Institute for Health and Care Excellence,UK,Delirium & Dementia,GRADE,6,4,3,"Consider memantine for people with Parkinson's disease dementia, only if cholinesterase inhibitors are not tolerated or are contraindicated.",Moderate,3,Consider,1,,0.75,National Institute for Health and Care Excellence. Parkinson’s disease in adults [Internet]. London: National Institutefor Health and Care Excellence; [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng71,25
726,12830,,Osteoporosis: assessing the risk of fragility fracture,Osteoporosis: assessing the risk of fragility fracture ,2017,National Institute for Health and Care Excellence,UK,Fractures & Osteoporosis,Other: Modified Version of QUADAS II,5,3,3,Consider assessment of fracture risk in all women aged 65 years and over and all men aged 75 years and over.,Risk of Bias: High,2,Consider,1,,0.666666666666667,National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture [Internet]. London: National Institute for Health and Care Excellence; 2012 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/cg146,7
727,12844,,Intravenous fluid therapy in adults in hospital,Intravenous fluid therapy in adults in hospital ,2017,National Institute for Health and Care Excellence,UK,"Hydration, Nutrition & Sarcopenia",GRADE,6,4,3,"Consider prescribing less fluid (for example, 20-25 ml/kg/day fluid) for patients who are older or frail.",Low,2,Consider,1,,0.5,National Institute for Health and Care Excellence. Intravenous fluid therapy in adults in hospital [Internet]. London: National Institutefor Health and Care Excellence; 2013 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/cg174,6
728,12848,,Hip fracture: management,Hip fracture: management ,2017,National Institute for Health and Care Excellence,UK,Fractures & Osteoporosis,GRADE,6,4,3,"From admission, offer patients a formal, acute, orthogeriatric or orthopaedic ward-based Hip Fracture Programme that includes all of the following:
- orthogeriatric assessment
- rapid optimisation of fitness for surgery
- early identification of individual goals for multidisciplinary rehabilitation to recover mobility and independence, and to facilitate return to pre fracture residence and longterm wellbeing
- continued, coordinated, orthogeriatric and multidisciplinary review
- liaison or integration with related services, particularly mental health, falls prevention, bone health, primary care and social services
- clinical and service governance responsibility for all stages of the pathway of care and rehabilitation, including those delivered in the community",high,4,should,2,,1,National Institute for Health and Care Excellence. Hip fracture: management [Internet]. London: National Institute for Health and Care Excellence; 2011 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/cg124,7
729,12848,,Hip fracture: management,Hip fracture: management ,2017,National Institute for Health and Care Excellence,UK,Fractures & Osteoporosis,GRADE,6,4,3,"Healthcare professionals should deliver care that minimises the patient's risk of delirium and maximises their independence, by:
- actively looking for cognitive impairment when patients first present with hip fracture
- reassessing patients to identify delirium that may arise during their admission",moderate,3,should,2,,0.75,National Institute for Health and Care Excellence. Hip fracture: management [Internet]. London: National Institute for Health and Care Excellence; 2011 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/cg124,11
730,12896,,VA/DoD Clinical Practice Guideline for Diagnosis and Treatment of Low Back Pain,Diagnosis and Treatment of Low Back Pain,2017,"Department of Veterans Affairs, Department of Defense",United States,Pain Management,GRADE,5,4,3,"For patients with low back pain, we recommend diagnostic imaging (fractures in age > 75 years) and appropriate laboratory testing when neurologic deficits areserious or progressive or when red flag symptoms are present.",moderate,3,Strong,3,,0.75,"Pangarkar SS, Kang DG, Sandbrink F, Bevevino A, Tillisch K, Konitzer L, et al. VA/DoD Clinical Practice Guideline: Diagnosis and Treatment of Low Back Pain. J GEN INTERN MED. 2019 Nov;34(11):2620–9.",26
731,12896,,VA/DoD Clinical Practice Guideline for Diagnosis and Treatment of Low Back Pain,Diagnosis and Treatment of Low Back Pain,2017,"Department of Veterans Affairs, Department of Defense",United States,Pain Management,GRADE,5,4,3,"For patients with low back pain, we recommend that clinicians conduct a history and physical examination, that should include identifying and evaluating neurologic deficits (e.g., radiculopathy, neurogenic claudication), red flag symptoms associated with serious underlying pathology (fracture in age > 75 years), andpsychosocial factors.",moderate,3,Strong,3,,0.75,"Pangarkar SS, Kang DG, Sandbrink F, Bevevino A, Tillisch K, Konitzer L, et al. VA/DoD Clinical Practice Guideline: Diagnosis and Treatment of Low Back Pain. J GEN INTERN MED. 2019 Nov;34(11):2620–9.",26
732,12941,Olson 2020,Diagnosis and Treatment of Adults With Community-Acquired Pneumonia,Diagnosis and Treatment of Adults with Community-acquired Pneumonia,2019,"American Thoracic Society, Infectious Diseases Society of America",United States,Pneumonia & COPD,GRADE,4,4,2,"In addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) to determine the need for hospitalization in adults diagnosed with community-acquired penumonia.",Moderate,3,Strong,2,,0.75,"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45–67.",5
733,12941,Olson 2020,Diagnosis and Treatment of Adults With Community-Acquired Pneumonia,Diagnosis and Treatment of Adults with Community-acquired Pneumonia,2019,"American Thoracic Society, Infectious Diseases Society of America",United States,Pneumonia & COPD,GRADE,4,4,2,"As an alternative to the Pneumonia Severity Index (PSI) the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age > 65) can be considered to determine the need for hospitalization in adults diagnosed with community-acquired penumonia.",Low,2,Conditional,1,,0.5,"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45–67.",5
734,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,"We suggest taking known risk factors such as older age or obesity, into consideration to identify patients at risk of postoperative acute kidney injury (AKI). Additional caution is warranted when administering potentially nephrotoxic medication, adjusting the volume status and controlling blood pressure in this group.",C,1,2,1,,0.333333333333333,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",5
735,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,"Frailty is a state of extreme vulnerability. It predicts morbidity and mortality. We recommend the assessment of frailty in a structured, multimodal way such as Fried Score or Edmonton Frailty Scale, avoiding surrogate single measures.",B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",14
736,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,"Comorbidity and multiple morbidity become more frequent with ageing and are related to increased morbidity and mortality. We recommend the assessment of comorbidities by age adjusted scores, such as the Charlson Comorbidity Index.",B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",20
737,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,"Malnutrition is frequent, often underevaluated and predicts complications. Obesity is associated with increased risk for kidney injury. We recommend the assessment of nutritional status (preferably by Nutritional Risk Screening), to implement appropriate interventions in patients at risk and to minimise pre-operative fasting.",B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",24
738,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,Levels of independence may be impaired which predicts complications. We recommended scoring the level of independence using validated tools such as the Basal and Instrumental Activities of Daily Life.,B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",26
739,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,We recommend the evaluation and management of risk factors for postoperative delirium in accordance with the European Society of Anaesthesiology (ESA) evidence-based and consensus-based guidelines on postoperative delirium.,B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",11
740,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,"Cognitive impairment is frequent and often underevaluated. It may affect comprehension, hampering appropriate informed consent. Cognitive impairment predicts complications and mortality. We recommend the evaluation of cognitive function based on validated tools.",B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",19
741,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,"Functional status can be impaired in the elderly and predicts functional outcome. We recommend the evaluation of functional status, preferably through comprehensive geriatric assessment to identify patients at risk and/or to predict complications.",B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",14
742,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,"Poly-medication and inappropriate medication (mostly anticholinergic or sedative-hypnotic drugs) are common and predict complications and mortality. We recommend the consideration of appropriate peri-operative medication adjustments. We recommend the evaluation of medication in a structured way, such as the Beers criteria.",B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",11
743,12953,DeHert 2018,Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology,Pre-operative evaluation of adults undergoing elective noncardiac surgery,2018,European Society of Anaesthesiology,Other: Europe,Perioperative Management,Other: Modified GRADE,4,3,2,Sensory impairment weakens communication and is associated with postoperative delirium. We recommend the assessment of sensory impairment and that time without sensory aids in the peri-operative setting is minimised.,B,2,1,2,,0.666666666666667,"De Hert S, Staender S, Fritsch G, Hinkelbein J, Afshari A, Bettelli G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. European Journal of Anaesthesiology. 2018 Jun;35(6):407–65.",11
744,12957,,Pneumonia (community-acquired): antimicrobial prescribing,Pneumonia (community-acquired): antimicrobial prescribing ,2019,National Institute for Health and Care Excellence,UK,Pneumonia & COPD,GRADE,5,4,3,"First-choice oral antibiotics if moderate severity (based on clinical judgement and guided by a CRB65 score 1 or 2, or a CURB65 score 2 when these scores can be calculated; guided by microbiological results when available): 
- Amoxicillin
- With (if atypical pathogens suspected) Clarithromycin or Erythromycin",Moderate,3,Should,2,,0.75,National Institute for Health and Care Excellence. Pneumonia (community-acquired): antimicrobial prescribing [Internet]. London: National Institutefor Health and Care Excellence; 2019 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng138,5
745,12957,,Pneumonia (community-acquired): antimicrobial prescribing,Pneumonia (community-acquired): antimicrobial prescribing ,2019,National Institute for Health and Care Excellence,UK,Pneumonia & COPD,GRADE,5,4,3,First-choice oral antibiotic if low severity (based on clinical judgement and guided by a CRB65 score 0 or a CURB65 score 0 or 1 when these scores can be calculated): Amoxicillin.,Moderate,3,Should,2,,0.75,National Institute for Health and Care Excellence. Pneumonia (community-acquired): antimicrobial prescribing [Internet]. London: National Institutefor Health and Care Excellence; 2019 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng138,5
746,12957,,Pneumonia (community-acquired): antimicrobial prescribing,Pneumonia (community-acquired): antimicrobial prescribing ,2019,National Institute for Health and Care Excellence,UK,Pneumonia & COPD,GRADE,5,4,3,"First-choice antibiotics if high severity (based on clinical judgement and guided by a CRB65 score 3 or 4, or a CURB65 score 3 to 5 when these scores can be calculated; guided by microbiological results when available): Co-amoxiclav with Clarithromycin or Erythromycin.",Low,2,Should,2,,0.5,National Institute for Health and Care Excellence. Pneumonia (community-acquired): antimicrobial prescribing [Internet]. London: National Institutefor Health and Care Excellence; 2019 [cited 2021 Dec 18]. Available from: https://www.nice.org.uk/guidance/ng138,5
747,13039,,S2e Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,2020,"Deutsche Gesellschaft für Neurologie, Gesellschaft für Neuropsychologie",Germany,Delirium & Dementia,Other: custom,4,4,3,Die Wirksamkeit des spezifischen funktions- oder strategieorientierten kognitiven Trainings hängt von der Trainingshäufigkeit ab (mindestens 10 Sitzungen gelten als gute klinische Praxis).,Ib,3,C,1,,0.75,"Deutschen Gesellschaft für Neurologie e.V. (DGN), Gesellschaft für Neuropsychologie  e.V. (GNP). S2e-Leitlinie Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen. 2020 Feb 26 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-124",8
748,13039,,S2e Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,2020,"Deutsche Gesellschaft für Neurologie, Gesellschaft für Neuropsychologie",Germany,Delirium & Dementia,Other: custom,4,4,3,Aerobes Konditionstraining kann zur unspezifischen Förderung der kognitiven Leistungsfähigkeit empfohlen werden.,III,1,C,1,,0.25,"Deutschen Gesellschaft für Neurologie e.V. (DGN), Gesellschaft für Neuropsychologie  e.V. (GNP). S2e-Leitlinie Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen. 2020 Feb 26 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-124",26
749,13039,,S2e Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,2020,"Deutsche Gesellschaft für Neurologie, Gesellschaft für Neuropsychologie",Germany,Delirium & Dementia,Other: custom,4,4,3,Die Ergebnisse zum Errorless Learning sind widersprüchlich. Der Einsatz kann bei Patienten mit schwerer Amnesie zum Erlernen von domänenspezifischem Wissen oder von festen Abläufen empfohlen werden.,II,2,C,1,,0.5,"Deutschen Gesellschaft für Neurologie e.V. (DGN), Gesellschaft für Neuropsychologie  e.V. (GNP). S2e-Leitlinie Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen. 2020 Feb 26 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-124",8
750,13039,,S2e Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,2020,"Deutsche Gesellschaft für Neurologie, Gesellschaft für Neuropsychologie",Germany,Delirium & Dementia,Other: custom,4,4,3,"Für Patienten mit schweren Gedächtnisstörungen sollte die Trainingssituation so gestaltet werden, dass die Patienten die zu lernende Information selbst abrufen und der Abruf durch sehr eindeutige Hinweisreize mit hoher Wahrscheinlichkeit erfolgreich ist (fehlerarmes Lernen). Dabei sollte das Abrufintervall zunächst kurz, im weiteren Verlauf länger gestaltet werden (Spaced Retrieval).",II,2,B,2,,0.5,"Deutschen Gesellschaft für Neurologie e.V. (DGN), Gesellschaft für Neuropsychologie  e.V. (GNP). S2e-Leitlinie Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen. 2020 Feb 26 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-124",8
751,13039,,S2e Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,2020,"Deutsche Gesellschaft für Neurologie, Gesellschaft für Neuropsychologie",Germany,Delirium & Dementia,Other: custom,4,4,3,"Elektronische Erinnerungshilfen (z.B. Smartphone-Kalender) sollen unabhängig vom Schweregrad der Gedächtnisstörung als Kompensationsstrategie in die Therapie einbezogen werden, sofern die Patienten dazu bereit und interessiert sind.",II,2,A,3,,0.5,"Deutschen Gesellschaft für Neurologie e.V. (DGN), Gesellschaft für Neuropsychologie  e.V. (GNP). S2e-Leitlinie Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen. 2020 Feb 26 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-124",8
752,13039,,S2e Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,2020,"Deutsche Gesellschaft für Neurologie, Gesellschaft für Neuropsychologie",Germany,Delirium & Dementia,Other: custom,4,4,3,"Bei auffälligem Screening-Befund soll eine eingehende 
neuropsychologische Untersuchung durch einen entsprechend qualifizierten Neuropsychologen erfolgen.",I,4,A,3,,1,"Deutschen Gesellschaft für Neurologie e.V. (DGN), Gesellschaft für Neuropsychologie  e.V. (GNP). S2e-Leitlinie Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen. 2020 Feb 26 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-124",19
753,13039,,S2e Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,2020,"Deutsche Gesellschaft für Neurologie, Gesellschaft für Neuropsychologie",Germany,Delirium & Dementia,Other: custom,4,4,3,Patienten mit Gedächtnisstörungen sollen ein spezifisches funktions- oder strategieorientiertes kognitives Training erhalten (z.B. bildhafte Vorstellung).,Ib,3,A,3,,0.75,"Deutschen Gesellschaft für Neurologie e.V. (DGN), Gesellschaft für Neuropsychologie  e.V. (GNP). S2e-Leitlinie Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen. 2020 Feb 26 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-124",8
754,13039,,S2e Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen,2020,"Deutsche Gesellschaft für Neurologie, Gesellschaft für Neuropsychologie",Germany,Delirium & Dementia,Other: custom,4,4,3,"Screening-Verfahren, die für den Ausschluss einer Demenz entwickelt wurden, sind für die Identifikation leichter bis mittelschwerer Gedächtnisstörungen nicht geeignet.",I,4,A,3,,1,"Deutschen Gesellschaft für Neurologie e.V. (DGN), Gesellschaft für Neuropsychologie  e.V. (GNP). S2e-Leitlinie Diagnostik und Therapie von Gedächtnisstörungen bei neurologischen Erkrankungen. 2020 Feb 26 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-124",9
755,13223,,S3 Ideopathisches Parkinson Syndrome,Idiopathisches Parkinson-Syndrom,2016,Deutsche Gesellschaft für Neurologie,Germany,Delirium & Dementia,SIGN,5,8,4,Donepezil kann bei der Behandlung kognitiver Symptome von Patienten mit PDD genutzt werden. Dabei handelt es sich um einen „off-label-use“.,1++,8,0,2,,1,Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Idiopathisches Parkinson-Syndrom. 2016 Apr 5 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-010,21
756,13223,,S3 Ideopathisches Parkinson Syndrome,Idiopathisches Parkinson-Syndrom,2016,Deutsche Gesellschaft für Neurologie,Germany,Delirium & Dementia,SIGN,5,8,4,Rivastigmin sollte bei der Behandlung kognitiver Symptome von Patienten mit Parkinson's Disease Dementia (PDD) genutzt werden.,1++,8,B,3,,1,Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Idiopathisches Parkinson-Syndrom. 2016 Apr 5 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/030-010,25
757,13296,,"S3 Screening, Diagnose und Behandlung alkoholbezogene Störungen","Screening, Diagnose und Behandlung alkoholbezogener Störungen",2020,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V.",Germany,Alcohol & Drug Abuse,Oxford,5,10,4,"Antipsychotika wie Haloperidol werden beim akuten Alkoholdelir mit Wahn- oder Halluzinationen empfohlen, sollen aber aufgrund der fehlenden eigenen Wirkung auf vegetative Entzugssymptome mit z.B. Benzodiazepinen oder Clomethiazol kombiniert werden.",2,6,B,3,,0.6,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT). S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener Störungen. 2021 Jan 1 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/076-001",3
758,13296,,"S3 Screening, Diagnose und Behandlung alkoholbezogene Störungen","Screening, Diagnose und Behandlung alkoholbezogener Störungen",2020,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V.",Germany,Alcohol & Drug Abuse,Oxford,5,10,4,"Für die Behandlung deliranter Syndrome mit Halluzinationen, Wahnsymptome und Agitation sollte Clomethiazol mit Antipsychotika (insbesondere Butyrophenone, wie Haloperidol) kombiniert werden.",1,9,B,3,,0.9,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT). S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener Störungen. 2021 Jan 1 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/076-001",3
759,13296,,"S3 Screening, Diagnose und Behandlung alkoholbezogene Störungen","Screening, Diagnose und Behandlung alkoholbezogener Störungen",2020,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V.",Germany,Alcohol & Drug Abuse,Oxford,5,10,4,"Kurzinterventionen sollen auch bei älteren Menschen (> 65 Jahre) mit problematischem oder
riskantem Alkoholkonsum angeboten werden.",1a,10,A,4,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT). S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener Störungen. 2021 Jan 1 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/076-001",13
760,13296,,"S3 Screening, Diagnose und Behandlung alkoholbezogene Störungen","Screening, Diagnose und Behandlung alkoholbezogener Störungen",2020,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V.",Germany,Alcohol & Drug Abuse,Oxford,5,10,4,Clomethiazol reduziert effektiv die Schwere und Häufigkeit von Alkoholentzugssymptomen sowie die Häufigkeit schwerer Entzugskomplikationen wie Delirien und Entzugskrampfanfälle. Clomethiazol sollte unter stationären Bedingungen zur Behandlung des Alkoholentzugssyndroms eingesetzt werden.,1,9,B,3,,0.9,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT). S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener Störungen. 2021 Jan 1 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/076-001",17
761,13296,,"S3 Screening, Diagnose und Behandlung alkoholbezogene Störungen","Screening, Diagnose und Behandlung alkoholbezogener Störungen",2020,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V.",Germany,Alcohol & Drug Abuse,Oxford,5,10,4,"Für die Behandlung  deliranter Syndrome mit Halluzinationen, Wahn oder Agitation sollten Benzodiazepine mit Antipsychotika (insbesondere Butyrophenone, wie Haloperidol) kombiniert werden.",4,2,B,3,,0.2,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT). S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener Störungen. 2021 Jan 1 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/076-001",3
762,13296,,"S3 Screening, Diagnose und Behandlung alkoholbezogene Störungen","Screening, Diagnose und Behandlung alkoholbezogener Störungen",2020,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V.",Germany,Alcohol & Drug Abuse,Oxford,5,10,4,"Eine stationäre Behandlung in Form einer körperlichen Entgiftung oder qualifizierten Entzugsbehandlung soll angeboten werden
1. bei einem Risiko eines alkoholbedingten Entzugsanfalles und/ oder Entzugsdelirs und/ oder
2. bei Vorliegen von gesundheitlichen bzw. psychosozialen Rahmenbedingungen, unter denen Alkoholabstinenz im ambulanten Setting nicht erreichbar erscheint.",2,6,A,4,,0.6,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT). S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener Störungen. 2021 Jan 1 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/076-001",13
763,13296,,"S3 Screening, Diagnose und Behandlung alkoholbezogene Störungen","Screening, Diagnose und Behandlung alkoholbezogener Störungen",2020,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V.",Germany,Alcohol & Drug Abuse,Oxford,5,10,4,Benzodiazepine reduzieren effektiv die Schwere und Häufigkeit von Alkoholentzugssymptomen sowie die Häufigkeit schwerer Entzugskomplikationen wie Delirien und Entzugskrampfanfälle. Benzodiazepine sollen zur Behandlung des akuten Alkoholentzugssyndroms zeitlich limitiert eingesetzt werden.,1a,10,A,4,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT). S3-Leitlinie Screening, Diagnostik und Behandlung alkoholbezogener Störungen. 2021 Jan 1 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/076-001",13
764,13357,,S3 Harnwegsinfektionen,"Epidemiolgoie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten",2017,Deutsche Gesellschaft für Urologie,Germany,UTI & Asymptomatic Bacturia,Oxford,5,10,3,"Für folgende Personengruppen hat eine asymptomatische Bakteriurie offenbar keine nachteiligen Folgen.  Deshalb  wird weder  ein  Screening noch  eine  Therapie  der asymptomatischen Bakteriurie empfohlen.
-ältere Personen, die zu Hause leben
-ältere Personen, die in Heimen leben.",1a,10,A,3,,1,"Deutsche Gesellschaft für Urologie e.V. (DGU). S3-Leitlinie Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. 2017 Apr 30 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/043-044",18
765,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Wenn Zweifel an einem günstigen Verhältnis von Nutzen zu Nebenwirkungen eines Acetylcholinesterase-Hemmers auftreten, kann das Umsetzen auf einen anderen Acetylcholinesterase-Hemmer erwogen werden.",IIb,3,B,4,,0.5,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",3
766,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Es soll die höchste verträgliche Dosis von Acetylcholinesterase-Hemmern angestrebt werden.,1a,6,A,4,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",10
767,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Bei leichtgradiger Alzheimer-Demenz ist eine Wirksamkeit von Memantin nicht belegt. Memantin soll zur Behandlung von Patienten mit leichter Alzheimer-Demenz nicht eingesetzt werden.,Ib,5,A,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
768,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Es gibt keine Evidenz für eine wirksame Pharmakotherapie zur Risikoreduktion des Übergangs von mild cognitive impairment (MCI) zu einer Demenz.,1b,5,,,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
769,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Bei schwerer psychomotorischer Unruhe, die zu deutlicher Beeinträchtigung des Betroffenen und/oder der Pflegenden führt, kann ein zeitlich begrenzter Therapieversuch mit Risperidon empfohlen werden.",II,3,0,2,,0.5,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
770,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Es gibt Hinweise für die Wirksamkeit von Citalopram bei agitiertem Verhalten von Demenzkranken. Ein Behandlungsversuch kann erwogen werden.,Ib,5,0,2,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
771,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Eine Behandlung von Agitation und Aggression mit Valproat wird nicht empfohlen.,Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
772,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Es gibt Hinweise auf eine günstige Wirkung von Carbamazepin auf Agitation und Aggression. Carbamazepin kann nach fehlendem Ansprechen anderer Therapien empfohlen werden. Es ist auf Medikamenteninteraktionen zu achten.,Ib,5,0,2,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",3
773,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Aripiprazol kann aufgrund seiner Wirksamkeit gegen Agitation und Aggression als alternative Substanz empfohlen werden.,Ia,6,0,2,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",3
774,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Die Datenlage zu einer Add-on-Behandlung mit Memantin bei Patienten mit schwerer Alzheimer-Demenz, die Donepezil erhalten, ist widersprüchlich. Eine Add-on-Behandlung kann erwogen werden.",Ib,5,0,4,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
775,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Olanzapin soll aufgrund des anticholinergen Nebenwirkungsprofils und heterogener Datenlage bezüglich Wirksamkeit nicht zur Behandlung von agitiertem und aggressivem Verhalten bei Patienten mit Demenz eingesetzt werden.,Ia,6,A,4,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
776,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Wenn zur Behandlung von agitiertem und aggressivem Verhalten Antipsychotika erforderlich werden, dann sollte Risperidon bevorzugt werden.",Ia,6,B,3,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
777,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Für eine Add-on-Behandlung mit Memantin bei Patienten mit einer Alzheimer-Demenz im leichten bis oberen mittelschweren Bereich (Mini-Mental-Status-Test (MMST): 15-22 Punkte), die bereits einen Acetylcholinesterase-Hemmer erhalten, wurde keine Überlegenheit gegenüber einer Monotherapie mit einem Acetylcholinesterase-Hemmer gezeigt. Sie wird daher nicht empfohlen.",Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
778,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Haloperidol wird aufgrund fehlender Evidenz für Wirksamkeit nicht zur Behandlung von Agitation empfohlen. Es gibt Hinweise auf Wirksamkeit von Haloperidol auf aggressives Verhalten mit geringer Effektstärke. Unter Beachtung der Risiken (extrapyramidale Nebenwirkungen, zerebrovaskuläre Ereignisse, erhöhte Mortalität) kann der Einsatz bei diesem Zielsymptom erwogen werden.",Ia,6,A,4,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",3
779,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Für eine Add-on-Behandlung mit Memantin bei Patienten mit mittelschwerer Alzheimer-Demenz (Mini-Mental-Status-Test (MMST): 10-14 Punkte), die bereits einen Acetylcholinesterase-Hemmer erhalten, liegt keine überzeugende Evidenz vor. Es kann keine Empfehlung gegeben werden.",Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
780,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Es gibt Hinweise für die Wirksamkeit einer medikamentösen antidepressiven Therapie bei Patienten mit Demenz und Depression. Bei der Ersteinstellung und Umstellung sollten trizyklische Antidepressiva aufgrund des Nebenwirkungsprofils nicht eingesetzt werden.,Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
781,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Es gibt Hinweise für die Wirksamkeit von Ginkgo Biloba EGb 761 auf Kognition bei Patienten mit leichter bis mittelgradiger Alzheimer-Demenz oder vaskulärer Demenz und nicht-psychotischen Verhaltenssymptomen. Eine Behandlung kann erwogen werden.,Ia,6,0,3,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
782,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Die Gabe von Antipsychotika bei Patienten mit Demenz ist wahrscheinlich mit einem erhöhten Risiko für Mortalität und für zerebrovaskuläre Ereignisse assoziiert. Es besteht wahrscheinlich ein differenzielles Risiko, wobei Haloperidol das höchste und Quetiapin das geringste Risiko hat. Das Risiko ist in den ersten Behandlungswochen am höchsten, besteht aber wahrscheinlich auch in der Langzeitbehandlung. Es besteht ferner wahrscheinlich das Risiko für beschleunigte kognitive Verschlechterung durch die Gabe von Antipsychotika bei Demenz. Patienten und rechtliche Vertreter müssen über dieses Risiko aufgeklärt werden. Die Behandlung soll mit der geringstmöglichen Dosis und über einen möglichst kurzen Zeitraum erfolgen. Der Behandlungsverlauf muss engmaschig kontrolliert werden.",Ia,6,A,4,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
783,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Eine Therapie der Alzheimer-Demenz mit Vitamin E wird wegen mangelnder Evidenz für Wirksamkeit und auf Grund des Nebenwirkungsrisikos nicht empfohlen.,Ib,5,A,2,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
784,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Für die antidementive Behandlung der Lewy-Körperchen-Demenz existiert keine zugelassene oder ausreichend belegte Medikation. Es gibt Hinweise für eine Wirksamkeit von Rivastigmin auf Verhaltenssymptome und von Donepezil auf Kognition, den klinischen Gesamteindruck und Verhaltenssymptome. Es gibt ferner Hinweise für die Wirksamkeit von Memantin auf den klinischen Gesamteindruck und Verhaltenssymptome, nicht aber auf Kognition. Entsprechende Behandlungsversuche können erwogen werden.",Ia,6,0,2,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
785,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Es gibt keine überzeugende Evidenz für eine Wirksamkeit von nichtsteroidalen Antiphlogistika (Rofecoxib, Naproxen, Diclofenac, Indomethacin) auf die Symptomatik der Alzheimer-Demenz. Eine Behandlung der Alzheimer-Demenz mit diesen Substanzen wird nicht empfohlen.",Ia,6,A,4,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
786,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Die Evidenz für eine Wirksamkeit von Piracetam, Nicergolin, Hydergin, Phosphatidylcholin (Lecithin), Nimodipin, Cerebrolysin und Selegilin bei Alzheimer-Demenz ist unzureichend. Eine Behandlung wird nicht empfohlen.",Ia,6,A,4,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
787,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Rivastigmin (Kapseln) ist zur antidementiven Behandlung der Demenz bei M. Parkinson im leichten und mittleren Stadium wirksam im Hinblick auf kognitive Störung und Alltagsfunktion und sollte eingesetzt werden. Es gibt Hinweise für die Wirksamkeit von Donepezil auf Kognition und klinischen Gesamteindruck bei der Demenz bei M. Parkinson.,Ia,6,B,3,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
788,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Es existiert keine zugelassene oder durch ausreichende Evidenz belegte medikamentöse symptomatische Therapie für vaskuläre Demenzformen, die einen regelhaften Einsatz rechtfertigen. Es gibt Hinweise für eine Wirksamkeit von Acetylcholinesterase-Hemmern und Memantin, insbesondere auf exekutive Funktionen bei Patienten mit subkortikaler vaskulärer Demenz. Im Einzelfall kann eine Therapie erwogen werden.",Ib,5,0,4,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
789,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Es existiert keine überzeugende Evidenz zur Behandlung kognitiver Symptome oder Verhaltenssymptome bei Patienten mit frontotemporaler Demenz. Es kann keine Behandlungsempfehlung gegeben werden.,IIb,3,B,3,,0.5,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
790,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Ginkgo Biloba wird nicht zur Prävention von Demenz empfohlen.,Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
791,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Die günstige Wirkung von Risperidon auf psychotische Symptome bei Demenz ist belegt. Falls eine Behandlung mit Antipsychotika bei psychotischen Symptomen (Wahn, Halluzinationen) notwendig ist, wird eine Behandlung mit Risperidon (0,5-2 mg) empfohlen.",Ia,6,B,3,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
792,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Memantin ist wirksam auf die Kognition, Alltagsfunktion und den klinischen Gesamteindruck bei Patienten mit moderater bis schwerer Alzheimer-Demenz und sollte eingesetzt werden.",Ia,6,B,3,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
793,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Multisensorische Verfahren (Snoezelen) mit individualisierten, biographiebezogenen Stimuli im 24-Stunden-Ansatz können geringe Effekte auf Freude und Aktivität bei Patienten mit moderater bis schwerer Demenz haben. Sie können empfohlen werden.",Ib,5,0,2,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
794,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Zur Prävention von Erkrankungen, die durch die Pflege und Betreuung hervorgerufen werden, und zur Reduktion von Belastung der pflegenden Angehörigen sollten strukturierte Angebote für Bezugspersonen von Demenzerkrankten vorgesehen werden. Inhaltlich sollten neben der allgemeinen Wissensvermittlung zur Erkrankung das Management in Bezug auf Patientenverhalten, Bewältigungsstrategien und Entlastungsmöglichkeiten für die Angehörigen sowie die Integration in die Behandlung des Demenzkranken im Vordergrund stehen. Hierbei können auch kognitiv-verhaltenstherapeutische Verfahren eingesetzt werden.",Ia,6,B,3,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
795,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Angemessene strukturierte soziale Aktivierung während des Tages kann zu einer Besserung des Tag-Nacht-Schlafverhältnisses führen und sollte eingesetzt werden.,Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
796,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Familienähnliche Esssituationen, verbale Unterstützung und positive Verstärkung können das Essverhalten von Menschen mit Demenz verbessern und können empfohlen werden.",Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
797,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Zur Behandlung depressiver Symptome bei Demenzerkrankten sind Edukations- und Unterstützungsprogramme von Pflegenden und Betreuenden wirksam und sollten eingesetzt werden.,Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
798,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Angehörigentraining zum Umgang mit psychischen und Verhaltenssymptomen bei Demenz können geringe Effekte auf diese Symptome beim Erkrankten haben. Sie sollten angeboten werden.,Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
799,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Es gibt keine ausreichenden Hinweise für einen therapeutischen Effekt von Licht, die eine spezielle Empfehlung in der Anwendung bei Menschen mit Demenz erlauben.",1b,5,,,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
800,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Für die Wirksamkeit von Aripiprazol 10 mg bei psychotischen Symptomen bei Patienten mit Demenz gibt es Hinweise. Die Datenlage ist jedoch heterogen.,Ib,5,0,2,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
801,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Die Anwendung von Aromastoffen kann geringe Effekte auf agitiertes Verhalten und allgemeine Verhaltenssymptome bei Patienten mit mittel- bis schwergradiger Demenz haben. Sie kann empfohlen werden.,Ib,5,0,2,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",21
802,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Spezifische Behandlungsprogramme bewirken bei leicht- bis mittelgradig betroffenen Demenzkranken ähnliche, bis nur mäßig geringfügigere Therapieerfolge hinsichtlich Mobilität und Selbstversorgungsfähigkeit wie bei kognitiv Gesunden.",IIb,3,B,3,,0.5,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
803,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Rezeptive Musiktherapie, insbesondere das Vorspielen von Musik mit biographischem Bezug (""preferred music"") kann geringe Effekte auf agitiertes und aggressives Verhalten haben. Sie kann empfohlen werden.",III,2,0,2,,0.333333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
804,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Es gibt Hinweise, dass körperliche Aktivierung positive Wirksamkeit auf kognitive Funktionen, Alltagsfunktionen, psychische und Verhaltenssymptome, Beweglichkeit und Balance hat. Körperliche Aktivität sollte empfohlen werden. Es existiert jedoch keine ausreichende Evidenz für die systematische Anwendung bestimmter körperlicher Aktivierungsverfahren.",Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",26
805,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Es gibt Evidenz, dass ergotherapeutische, individuell angepasste Maßnahmen bei Patienten mit leichter bis mittelschwerer Demenz unter Einbeziehung der Bezugspersonen zum Erhalt der Alltagsfunktionen beitragen. Der Einsatz sollte angeboten werden.",Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
806,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Reminiszenzverfahren können in allen Krankheitsstadien aufgrund von Effekten auf die kognitive Leistung, Depression und lebensqualitätsbezogene Faktoren zur Anwendung kommen.",IIb,3,B,3,,0.5,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
807,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Es gibt Hinweise für eine Wirksamkeit von Donepezil bei Alzheimer-Demenz im schweren Krankheitsstadium auf Kognition, Alltagsfunktionen und klinischen Gesamteindruck und für Galantamin auf die Kognition. Die Weiterbehandlung von vorbehandelten Patienten, die in das schwere Stadium eintreten, oder die erstmalige Behandlung von Patienten im schweren Stadium kann empfohlen werden.",Ib,5,B,3,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",25
808,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Es gibt Evidenz für die Wirksamkeit von kognitiver Stimulation auf die kognitive Leistung bei Patienten mit leichter bis moderater Demenz. Kognitive Stimulation sollte empfohlen werden.,IIb,3,B,3,,0.5,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
809,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,Melatonin ist in der Behandlung von Schlafstörungen bei Demenz nicht wirksam. Eine Anwendung wird nicht empfohlen.,Ib,5,A,4,,0.833333333333333,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
810,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Für andere atypische Antipsychotika gibt es keine Evidenz für Wirksamkeit bei psychotischen Symptomen bei Demenz, daher wird der Einsatz nicht empfohlen.",Ia,6,B,3,,1,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",9
811,13367,,S3 Demenzen,Demenzen,2016,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, Deutsche Gesellschaft für Neurologie",Germany,Delirium & Dementia,Other: modified NICE-SCIE,5,6,4,"Es gibt Hinweise, dass aktive Musiktherapie günstige Effekte auf psychische und Verhaltenssymptome bei Menschen mit Demenz hat, insbesondere auf Angst. Musiktherapie kann bei psychischen und Verhaltenssymptomen bei Alzheimer-Demenz angeboten werden.",IIa,4,0,2,,0.666666666666667,"Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft für Neurologie e.V. (DGN). S3-Leitlinie Demenzen. 2016 Jan [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/038-013",8
812,13413,,S3 Osteoporose Prophylaxe Diagnostik Therapie,"Prophylaxe, Diagnostik und Therapie der Osteoporose",2017,Dachverband der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V.,Germany,Fractures & Osteoporosis,SIGN,5,8,3,"NSAR, Paracetamol, Metamizol und Opiate sind zur Behandlung von Frakturschmerzen wirksam. Vom WHO-Stufenschema muss in vielen Fällen wegen Kontraindikationen oder nicht tolerabler Nebenwirkungen abgewichen werden. Da meist ältere Menschen behandelt werden, sind die Regeln der “Schmerztherapie beim älteren Menschen” anzuwenden mit Berücksichtigung von Komorbiditäten, Nebenwirkungen und Komedikationen.",1++,8,,,,1,"Dachverband Osteologie e.V. S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern ab dem 50. Lebensjahr. 2017 Dec [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/183-001",20
813,13413,,S3 Osteoporose Prophylaxe Diagnostik Therapie,"Prophylaxe, Diagnostik und Therapie der Osteoporose",2017,Dachverband der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V.,Germany,Fractures & Osteoporosis,SIGN,5,8,3,"Ab einem Lebensalter von 70 Jahren sollte regelmäßig eine Sturzanamnese zur Feststellung des Sturzrisikos erhoben werden, z.B. im Rahmen eines „Geriatrischen Assessments“.",2+,4,B,2,,0.5,"Dachverband Osteologie e.V. S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern ab dem 50. Lebensjahr. 2017 Dec [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/183-001",14
814,13413,,S3 Osteoporose Prophylaxe Diagnostik Therapie,"Prophylaxe, Diagnostik und Therapie der Osteoporose",2017,Dachverband der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V.,Germany,Fractures & Osteoporosis,SIGN,5,8,3,"Alten Menschen in institutioneller Pflege sollten Hüftprotektoren zur Verfügung gestellt werden, um hüftnahe Frakturen zu reduzieren.",1++,8,B,2,,1,"Dachverband Osteologie e.V. S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern ab dem 50. Lebensjahr. 2017 Dec [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/183-001",7
815,13446,,S3 Intravasale Volumentherapie bei Erwachsenen,Intravasale Volumentherapie bei Erwachsenen,2020,Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin,Germany,"Hydration, Nutrition & Sarcopenia",Oxford,5,10,3,"Zur Steuerung der Volumentherapie bei Patienten mit hohem Risiko* in der perioperativen Phase können Überwachungsverfahren zum Einsatz kommen, die eine Optimierung des Volumenstatus anhand flussbasierter (Schlagvolumen) und/oder dynamischer Vorlastparameter (SVV, PP-VAR.) erlauben.
* Patienten mit vorbestehend eingeschränkter kardiovaskulärer Reserve (z.B. hochbetagte Patienten mit hüftnaher Fraktur) oder Eingriffe mit großen Volumenverschiebungen (z.B. ausgedehnte abdominalchirurgische Eingriffe).",III,3,0,1,,0.3,Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI). S3-Leitlinie Intravasale Volumentherapie beim Erwachsenen. 2020 Jul 21 [cited 2021 Dec 18]; Available from: https://register.awmf.org/de/leitlinien/detail/001-020,5
816,13466,WHO 2021,RISK REDUCTION OF COGNITIVE DECLINE AND DEMENTIA,Risk Reduction of Cognitive Decline and Dementia,2019,World Health Organisation,Other: International,Delirium & Dementia,GRADE,5,4,2,Physical activity may be recommended to adults with mild cognitive impairment to reduce the risk of cognitive decline.,Low,2,Conditional,1,,0.5,World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines [Internet]. Geneva: World Health Organization; 2019 [cited 2024 Feb 20]. Available from: https://iris.who.int/handle/10665/312180,8
817,13466,WHO 2021,RISK REDUCTION OF COGNITIVE DECLINE AND DEMENTIA,Risk Reduction of Cognitive Decline and Dementia,2019,World Health Organisation,Other: International,Delirium & Dementia,GRADE,5,4,2,Cognitive training may be offered to older adults with normal cognition and with mild cognitive impairment to reduce the risk of cognitive decline and/or dementia.,Low,2,Conditional,1,,0.5,World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines [Internet]. Geneva: World Health Organization; 2019 [cited 2024 Feb 20]. Available from: https://iris.who.int/handle/10665/312180,8
818,13466,WHO 2021,RISK REDUCTION OF COGNITIVE DECLINE AND DEMENTIA,Risk Reduction of Cognitive Decline and Dementia,2019,World Health Organisation,Other: International,Delirium & Dementia,GRADE,5,4,2,Interventions aimed at reducing or ceasing hazardous and harmful drinking should be offered to adults with normal cognition and mild cognitive impairment to reduce the risk of cognitive decline and/or dementia in addition to other health benefits.,Moderate,3,Conditional,1,,0.75,World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines [Internet]. Geneva: World Health Organization; 2019 [cited 2024 Feb 20]. Available from: https://iris.who.int/handle/10665/312180,13
819,13466,WHO 2021,RISK REDUCTION OF COGNITIVE DECLINE AND DEMENTIA,Risk Reduction of Cognitive Decline and Dementia,2019,World Health Organisation,Other: International,Delirium & Dementia,GRADE,5,4,2,The Mediterranean-like diet may be recommended to adults with normal cognition and mild cognitive impairment to reduce the risk of cognitive decline and/or dementia.,Moderate,3,Conditional,1,,0.75,World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines [Internet]. Geneva: World Health Organization; 2019 [cited 2024 Feb 20]. Available from: https://iris.who.int/handle/10665/312180,8
820,13472,Arnett 2019,2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,Primary Prevention of Cardiovascular Disease,2019,"American College of Cardiology, American Heart Association",United States,Hypertension,Other: custom (ACC/AHA),5,5,3,Low-dose aspirin (75-100 mg orally daily) should not be administered on a routine basis for the primary prevention of atherosclerotic cardiovascular disease among adults > 70 years of age.,B-R,4,III,3,,0.8,"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation [Internet]. 2019 Sep 10 [cited 2024 Feb 20];140(11). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678",12
